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Abstract
The work presented in this thesis explores possible physiological and pathogenic roles 
for human xanthine oxidoreductase (XOR) and its subcellular localisation. The human 
mammary epithelial cell line (HB4a) was used, together with the buffalo rat liver 
epithelial cell line (BRLE), as systems for investigating the regulation of XOR.
XOR in HB4a cells was shown to have a low true specific activity similar to that seen in 
most other human tissues. Specific enzymic activity in both cell lines varied with cell 
density. Activity in HB4a cells was increased two fold in response to the inflammatory 
cytokines, TNFa and IL-lp, whereas IFNy elicited an increase of 8 fold. This latter 
increase in activity corresponded to only a two to three fold increase in XOR protein, 
indicating a post-translational regulation. Combinations of cytokines gave additive 
increases in XOR activity. Regulation of XOR activity by inflammatory mediators 
suggests a role for the enzyme in the immune response.
Subcellular localisation of XOR was determined by indirect immunofluorescence using 
confocal microscopy. XOR was diffusely distributed throughout the cytoplasm, but with 
higher intensity in the perinuclear region. Non-permeabilised cells displayed 
asymmetrical localisation of XOR on the outer plasma membrane, possibly indicating a 
function for the enzyme in cell-cell signalling.
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1.1 Introduction to Xanthine oxidoreductase
Xanthine oxidoreductase (XOR) is a complex metalloflavoprotein, which has been 
studied for almost a hundred years (Massey & Harris, 1997). The abundance and 
stability of XOR in bovine milk were important factors in allowing examination of the 
enzyme's characteristics.
It can exist in both a dehydrogenase form, Type D (EC 1.1.1 204) and an oxidase form, 
Type O (EC 1.1.3.22), both of which are capable of catalysing the hydroxylation of 
xanthine and hypoxanthine to uric acid (Fig.l), in the course of routine purine 
catabolism.
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Type O 0 2 +  H2O2 O2
Hypoxanthine * Urate> Xanthine
Type D NAD+ + H+ NADH NAD+ + H* NADH
Fig. 1.1 Type D and Type O XOR-catalysed hydroxylation o f hypoxanthine and
xanthine
The ability of XOR to produce the reactive oxygen species (ROS), superoxide and 
hydrogen peroxide, has generated much interest in alternative physiological and 
pathogenic roles for XOR, and this thesis explores some of these possibilities in the case 
of the human enzyme.
1.2 Enzymology
XOR is a homodimer with a molecular weight of approximately 300 kDa. Each 
monomer of 150 kDa contains three different redox centres, a molybdenum centre (Mo), 
which is thought to have a pterin cofactor that contributes to its catalytic properties, a 
flavine adenine dinucleotide centre (FAD), and two iron-sulphur (2Fe-2S) centres. 
These redox centres are located within the protein domains of 85 kDa, 40 kDa, and 20 
kDa respectively (Massey et a l , 1969; Hart et al.9 1970; Fried & Fried, 1974; 
Rajagopalan & Johnson, 1992).
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Electrons are rapidly cycled around the three centres, entering and leaving the enzyme at 
separate locations (Fig. 1.2). It has been found by spectrophotometric and EPR studies 





0 2/NAD4 -> Ferricyanide 
Methylene blue
Fig. 1.2 Electron transport between the redox centres o f XOR.
The molybdenum centre is the site where xanthine and all reducing substrates, apart 
from NADH, are oxidised. NADH reacts directly with the FAD centre (Bray, 1975). 
Oxygen and NAD+ accept electrons from the FAD centre of the enzyme, depending 
upon the type of XOR. The [Fe-S] centres maintain the other centres in the optimum 
redox state, molybdenum for reducing substrates and FAD for oxidising substrates, by 
acting as an electron reservoir (Olson et al, 1974). They are also able to reduce directly 
artificial substrates such as methylene blue and ferricyanide (Fried & Fried, 1974). 
Oxygen, as a substrate for the enzyme, can be univalently or divalently reduced, to yield 
superoxide or hydrogen peroxide respectively (Bray, 1975) (Fig 1.3). The very reactive
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hydroxyl radical (OH) can also be produced from H2O2  via the Fenton and iron- 
mediated Haber-Weiss reactions (Fig. 1.4).
O2 + e- —► O2 
O2 + 2e- + 2H+—► H2O2
Fig. 1.3 Univalent and divalent reduction o f oxygen.
Fe2+ + H20 2 ----► OH + OH + Fe3*
O2 H2O2 — O2 + OH’ + OH 
Fig. 1.4 Production o f hydroxyl radical via the Fenton reaction and iron-mediated
Haber-Weiss reaction
Inhibitors of XOR include substrate analogues such as allopurinol, which is widely used 
clinically to treat hyperuricemia (Krenitsky et al., 1986), and oxypurinol, the oxidised 
derivative of allopurinol, which binds tightly to the reduced form of Mo. A number of 
other nitrogen heterocyclics also inhibit the enzyme by binding at or near the Mo active 
site. None of these inhibitors however, affects the NADH oxidase activity of the 
enzyme, which depends primarily on the FAD site. Other, structurally unrelated 
inhibitors are cyanide, arsenite, formaldehyde and methanol (Bray, 1975; Parks & 
Granger, 1986).
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1.3 Inactive forms of XOR
In vivo, XOR occurs as two inactive forms, demolybdo and desulpho. Both forms are 
inactive towards substrates interacting directly with the Mo centre, such as xanthine or 
hypoxanthine, but are still able to catalyse the oxidation of NADH.
The desulpho isoform has an essential Mo=S grouping replaced by Mo=0. This form 
accounts for 30-40% of XOR in bovine milk (Godber, 1998). It can be purified from 
enzyme preparations by affinity chromatography using AH Sepharose 4B folate columns 
(Nishino etal., 1981).
The demolybdo form of the enzyme lacks the molybdenum atom and, to some extent, its 
associated pterin cofactor. In the case of bovine milk XOR, demolybdo enzyme makes 
up some 40% of the total. It has been proposed that dietary intake of Mo is an important 
factor in Mo incorporation into XOR, which is one of the last stages in the enzyme’s 
biosynthesis (Hart et al, 1970; Ventom et al, 1988). The human milk enzyme has an 
extremely low specific activity towards conventional reducing substrates such as 
purines; a fact that has been attributed (Godber et a l, 1997) to its very low Mo and 
molybdopterin content, which is in the order of 5% theoretical.
The desulpho and demolybdo forms of XOR are commonly found in enzyme 
preparations of bovine milk, where about 60% of the protein is usually inactive (Nishino 
et al, 1981; Ventom et al, 1988). In human milk the figure can be as high as 98% 
(Abadeh et al., 1992).
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A third inactive form of XOR has been produced in vitro, by incubation with CaCh or 
KI. This deflavo form lacks the FAD centre and is incapable of oxidising hypoxanthine, 
xanthine or NADH when NAD+ or O2 are electron acceptors.
Desulpho-sulpho conversion can be effected in vitro, by treatment of the reduced 
enzyme with sulphide (Wahl & Rajagopolan, 1982), and a similar mechanism has been 
proposed as the basis of activation of the enzyme in vivo (Coughlan, 1981; Nishino et 
al, 1983; Furth-Walker & Amy, 1987). Demolybdo-molybdo conversion has also been 
implicated in activation of XOR in vitro, but only in the particular case of the L929 
mouse fibroblast cell line, in which Mo (IV) salts were shown to activate non-functional 
XOR (Falciani et al, 1994). Post-translational activation, by unspecified mechanisms, of 
XOR has been reported in a mouse endothelial cell line in response to EFNy (Falciani et 
al, 1994). Likewise, Poss et a l (1996) described upregulation of XOR activity in 
bovine aortic endothelial cells in response to hypoxia, without concomitant increases in 
XOR mRNA or protein concentration. Apparent post-translational activation of XOR 
has been observed in in vivo systems. For example, high enzymic activity of XOR in 
human milk during the first two weeks of lactation was shown to decline during 
subsequent weeks; a trend which was not paralleled by concentrations of the enzyme 
protein, suggesting hormone-driven post-translational control (Brown et al, 1995). 
Lactating mammary tissue in mice has also been shown to have higher XOR activities 
than non-lactating mammary tissue, despite having similar XOR protein concentrations 
(Kurosaki e ta l, 1996).
The presence of high concentrations of inactive forms of XOR, which are capable of 
post-translational activation in response to patho/physiological stimuli is intriguing, 
particularly in view of the enzyme’s capacity to generate ROS.
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1.4 Type D and Type O forms of XOR
XOR, as mentioned previously, exists in two forms, Type D and Type O. They are 
derived from the same gene product with indistinguishable absorption spectra and no 
significant difference in their Km values for xanthine (Waud & Rajagopalan, 1976a). In 
vivo, the enzyme occurs predominantly as Type D, an NAD+-dependant dehydrogenase 
(Waud & Rajagopalan, 1976b). This can be converted to Type O, the oxygen-dependant 
oxidase form, by heating at 37°C, freezing at -20°C, proteolysis, anaerobosis, sulphydryl 
reagents, some organic solvents and incubation with subcellular fractions (Stirpe & Della 
Corte, 1969; Batteli et al, 1973; Parks & Granger, 1986). Some reagents, such as 
oxygen, 4,4-dithiodipyridine and p-hydroxymercuribenzoate, are thought to sequentially 
oxidise some of the fourteen free sulphydryl groups on the D isoform of the enzyme 
molecule, to disulphides, thereby changing the conformation and catalytic properties of 
the enzyme gradually to those of the reversible Type O form (Waud & Rajagopalan, 
1976a). This change is reversible by reduction using thiol reagents, such as 
dithioerythritol and dithiothreitol (Batteli et al, 1973; 1980; Saksela & Raivio, 1996). 
Proteolysis results in irreversible conversion to Type O by cleavage of a 20 kDa 
polypeptide from the enzyme, which is thought to contain 10 free sulphydryls 
responsible for the stabilisation of Type D activity (Waud & Rajagapolan, 1976b; 















Fig. 1.5 Interconversion o f oxidase and dehydrogenase forms o f XOR. Solid lines 
indicate known conversions, dashed lines indicated hypothesised conversions.
Conversion of Type D to Type 0  has been reported by Friedl et al. (1989) to be initiated 
by inflammatory mediators. However, this has been disputed by Terao et al. (1992). It 
has also been claimed that hypoxia promotes D to O conversion (Granger et al., 1986) 
but this has been contested by Kooij et al. (1992) and Hassoun et al. (1994), although 
increases in total XOR have been described (Terada et al 1992; Poss et al., 1996). Both 
types of the enzyme have low specificity’s for their alternative oxidising substrates and 
are able to catalyse the oxidation of NADH by molecular oxygen via the FAD centre. 
The reaction results in the production of superoxide, which occurs faster in the D form 
(Sanders et al., 1997). This oxidation is inhibited by NAD+, as is the reduction of
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NAD+ by NADH (Della Corte & Stirpe, 1970; Nishino & Tamura, 1991). A major 
problem in the detection of NADH oxidase activity of XOR is the lack of a specific 
inhibitor.
1.5 Tissue and cellular distribution of XOR
XOR is found in a wide range of species, from mammals and birds to bacteria and plants 
(Parks & Granger, 1986). Within mammals, XOR is found to have activities and 
concentrations that are tissue specific; the highest XOR activities being found in the liver 
and in small intestinal mucosa. XOR activities in humans are much lower than in other 
mammals. Immunolocalisation techniques and sensitive radioimmunoassays on bovine 
tissue have revealed XOR in lactating mammary tissue, in liver and lung endothelial cells 
and in tissue macrophages. The lowest levels were found in the brain, testis and cornea 
(Bruder et a l , 1983). Histochemical studies carried out on human tissue by Kooij et al 
(1992) detected XOR activity only in liver sinusoidal cells and the small intestine. On the 
other hand, Moriwaki et a l (1996), using immunolocalisation methods in human tissues, 
found XOR in the epithelium of tongue, oesophagus, trachea and mammary gland, with 
weaker reactivity in small and large intestine, skeletal muscle and lymphocytes. Stevens 
et a l (1991) also found XOR activity in human synovium. Immunolocalisation 
techniques revealed XOR associated with the mammary epithelial cells and capillary 
endothelial cells of most organs (Jarasch et al.t 1981; Bruder et al, 1983). Bruder et a l 
(1982) reported XOR in high concentration associated with lipid particles and 
membranes, possibly derived from plasma membrane of mammary epithelial cells, in 
bovine milk. The XOR gene has been detected in all human tissues studied, by northern 
blotting techniques (Xu et al, 1994).
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The wide range of techniques used to detect XOR, together with the low specific 
activity of human XOR compared with other mammals, has led to contradictory results. 
It is, however, generally accepted that XOR occurs in the liver, small intestine and 
mammary epithelium and in the capillary endothelium of most tissues. The detection of 
XOR in several immune cells (Bruder et al, 1983; Hellsten-Westing, 1993; Moriwaki et 
al, 1996), might suggest an immunological role for the enzyme.
At a subcellular level, the enzyme is generally accepted to be localised to the cytoplasm. 
Jarasch et a l (1981) used both light and electron microscopic immunohistochemical 
procedures to show that XOR is present throughout the cytoplasm of bovine capillary 
endothelial, and lactating mammary epithelial cells. This was also found to be the case in 
rat endothelial cells (Angermuller et al, 1987) and human liver cells (Moriwaki et al, 
1996). There have been few published investigations into the enzyme’s precise 
subcellular localisation. However, XOR was found by Angermuller et a l (1987) to be 
localised to the crystalline cores of peroxisomes, but not in other membrane-bound 
organelles. In contrast, Ichikawa et a l (1992), using immunocytochemical techniques, 
found XOR to be exclusively cytosolic with no evidence for localisation to peroxisomes 
or other intracellular organelles.
1.6 Physiological roles of XOR
Xanthine oxidase has a wide substrate specificity. It is able to oxidise purines, pteridines, 
aldehydes and various xenobiotics and to reduce O2 , dyes and methylene blue (Fried & 
Fried, 1974). The wide range of substrates and distribution of the enzyme have made it 
difficult to assign a definitive physiological role for XOR. However, as already briefly
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mentioned, the best characterised function is that of the rate limiting enzyme in purine 














Fig. 1.6 The hydroxylation o f hypoxanthine and xanthine to uric acid
That XOR is physiologically important in this role is evidenced by the inherited disorder 
xanthinuria, which is caused by an absence of functional XOR resulting in accumulation 
of extracellular xanthine. Moreover, the painful disorder of gout, characterised by excess 
urate in the blood, can be managed with the XOR inhibitor allopurinol (Krenitsky et al., 
1986; Cameron et al., 1993), However, other functions have been proposed based on 
the enzyme’s distribution and varying activities within tissues. There is evidence that 
XOR may play a role in iron absorption and mobilisation in the small intestine and liver 
(Topham et al, 1982a; b; 1989). Its ability to oxidise an extensive range of substrates,
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including the prodrug, 6-deoxyacycolvir, into the active compound acyclovir, indicates 
involvement in general detoxification of polar compounds in the liver (Krenitsky et al, 
1986). Bruder et a l (1983) cite the high levels of XOR in mammary glands, where lipids 
and lipoproteins are cleared from the blood, and the low activity in brain endothelium, 
which forms a barrier to lipidic compounds, as possible evidence for a role for XOR in 
lipid metabolism or transport. Also, the waste product uric acid, produced from the 
hydroxylation of purines, could be important in providing protection against oxidant 
stress (Pfeffer et al, 1994; Stryer, 1996). Uric acid is thought to act as a classic suicide 
antioxidant, particularly of water soluble radicals such as hypocholoros acid and singlet 
oxgyen. It is also thought to act by chelating transition metals such as iron and copper 
(Chappie, 1997).
XOR, as a source of ROS, may have a physiological function in antimicrobial defences, 
where it has been implicated as the source of oxidising H2O2 in the lactoperoxidase 
system (Bjork & Claesson, 1979). It may also have a role in cell proliferation, 
differentiation and local changes in membranes (Jarasch et al, 1981; Matsubara & Ziff, 
1986; Hayden et al, 1991). There is mounting evidence that ROS mediate a number of 
cellular processes (Burdon & Rice-Evans, 1989), and this will be discussed in more 
detail in the next section.
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1.6.1 The potential role of XOR in inflammation
The acute inflammatory response is a complex sequence of local events initiated by 
tissue damage or invasion by pathogens, resulting in vasodilation, increased capillary 
permeability and influx of phagocytic cells. It is accompanied by a systemic reaction, the 
acute phase response (APR), which involves the production of several hepatocyte- 
derived proteins, such as C-reactive protein (responsible for complement activation), 
serum amyloid A and fibrinogen. Activated macrophages release cytokines IL-1, TNFa 
and IL-6, which induce many more local and systemic changes, including the induction 
of adhesion molecules and other cytokines. IFNy and TNFa, increase phagocytic 
activity, and chemotactically attract macrophages to the site of damage. Cytokines are 
discussed in more detail in Chapter 5.
IFNy, and in some cases IFNy inducers, have been demonstrated by several groups to 
upregulate XOR expression and activity in various mammalian cell lines (Ghezzi et al, 
1984; Dupont et al, 1992; Falciani et al, 1992; Pfeffer et al, 1994; Powell, 1995), 
although Terada & Arnold (1993) found no such increase in human umbilical vein 
endothelial cells (HUVECs). Other inflammatory cytokines and dexamethasone, have 
been found by Pfeffer et a l (1994) to induce XOR activity in bovine renal epithelial 
cells, and combinations of the cytokines led to an additive increase in activity. The 
pattern of regulation of XOR activity led these authors to suggest that the enzyme has a 
role in the APR. Other indicators of the potential involvement of XOR in inflammation 
are given by reports of lipopolysaccharide (LPS), bacteria and protozoa causing 
increases in XOR activity (Tubaro et al, 1979; 1980; Carpani et al, 1990; Falciani et
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al, 1992; Kurosaki et a l , 1995). Reports of D to O conversion by TNFa, C5a and the 
chemotactic peptide, N-formyl Met Leu Phe (Friedl et al., 1989), also implicate XOR in 
inflammatory events. Characterisation of the human XOR gene has allowed detection of 
an IL-6 site and potential TNF, IFNy and IL-1 response elements (Xu et al, 1996), 
adding weight to the identification of XOR as an immune responsive protein.
ROS production can be induced in different cell types by cytokines such as TNFa and 
IL-1, and by some pathogens (Matsubara & Ziff, 1986; Meier et al, 1989; Schreck & 
Baeuerle, 1991). These ROS are increasingly recognised as intracellular signalling 
molecules (Khan & Wilson, 1995; Palmer & Paulson, 1997); an activity that is clearly 
relevant to the involvement of XOR in inflammation.
1.6.2 ROS within the body
ROS are constantly produced in the body. Cellular sources include the membrane bound 
NADPH oxidase of phagocytic cells, mitochondria, arachidonic acid metabolism and 
XOR. Optimum redox states within tissues are maintained by a variety of antioxidants 
such as vitamins E and C, and uric acid; and enzymes such as glutathione peroxidase, 
superoxide dismutase and catalase; which prevent oxidative damage to molecules. The 
ROS directly produced by XOR are O2 ' and H2O2, and indirectly OH', as discussed 
previously. Superoxide is produced by a one electron reduction of oxygen, occurring for 
example via electron ‘leakage’ from the respiratory chain in mitochondria. It is also 
produced by activated phagocytic cells, as an antibacterial agent. Superoxide is 
comparatively unreactive towards lipids, carbohydrates and nucleic acids, although it 
does react with some proteins (Davies, 1994). It has a short half life and a free diffusion
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distance of less than 40pm (Saran & Bors, 1993). This, combined with the proposed 
inability of the radical to pass through the cell membrane, suggests that it is not 
important as a signalling species. However, superoxide is clearly significant as it is able 
to generate many other ROS, for example H2O2 and singlet oxygen when it 
spontaneously dismutates in aqueous environments, as well as OH and peroxynitrite. 
The hydroxyl radical, in contrast, reacts with most biological molecules, often initiating 
chain reactions, and is therefore considered too reactive to be involved in specific 
signalling (Khan & Wilson, 1995). H2O2 is a small, stable molecule that carries no 
charge, and thus can travel freely across cell membranes. It therefore qualifies well as a 
signalling molecule, because of its stability, ubiquity in cells and tight regulation via 
enzymes catalysing its synthesis and degradation. These properties are held in common 
with those of the better established signalling ROS, nitric oxide (NO ). H2O2 has been 
proposed as a metabolic signal molecule, by virtue of its ability to oxidise protein thiol 
groups thus triggering intracellular events (Chappie, 1997). However, this freedom of 
movement can also result in a high potential to cause damage via production of hydroxyl 
radicals at sites where metal ions are available.
ROS, as signalling molecules, are thought to be involved in inflammatory events, for 
example in the activation of transcription factors such as NF-AB and AP-1. NF-AB is an 
inactive protein complex located in the cytoplasm. Activation requires the dissociation 
of the I-AB inhibitory unit, allowing the translocation of NF-AB into the nucleus. The 
release of I-AB is thought be mediated by phosphorylation, possibly via redox-sensitive 
kinases, allowing proteolytic degradation of the subunit (Khan & Wilson, 1995). The 
active NF-AB then binds to DNA where it regulates genes involved in the production of 
several cytokines and expression of adhesion molecules, as well as in growth,
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differentiation and angiogenesis (Schreck & Baeuerle, 1991; Schreck et ah, 1991; 1992; 
Burdon & Gill, 1993; Singh, 1995). AP-1 transcription factor is found in the nucleus 
where it controls genes such as c-fos and c-jun, which are involved in cell growth and 
differentiation. These immediate early genes, which are important in wound healing, 
have also been shown to be directly induced by some ROS (Schreck & Baeuerle, 1991; 
Schreck et ah, 1992; Winrow et ah, 1993; Burdon & Gill, 1993). Several cell types, 
including fibroblasts and epithelial cells, have been induced to proliferate by low doses 
of hydrogen peroxide or superoxide anion (Murrell et ah, 1990; Burdon & Gill, 1993; 
Molmenti etah, 1993; Burdon, 1995). Although the source of ROS is unclear in most of 
these cases, XOR is often a likely candidate, being an ubiquitous source of ROS, 
because of its potential to be regulated by several cytokines and pathogens, and because 
of its involvement in dysregulated inflammatory events (Tubaro et ah, 1979; 1980; 
Carpani etah, 1990; Schreck & Baeuerle, 1991; Singh, 1995).
These complementary and converging reports of XOR activation and ROS production 
have led to the hypothesis that XOR may be part of a cascade of regulators involved in 
inflammation (Fig. 1.7). Primary factors present during tissue injury, such as IL-1, TNFa 
and LPS, could induce XOR production of ROS, which then activate nuclear 
transcription factors and hence regulate genes involved in inflammation and immune 
response and tissue repair, thereby amplifying the defence mechanisms (Winrow et ah, 
1993; Khan & Wilson, 1995; Powell, 1995).
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Fig. 1.7 Possible activation o f transcription factors by XOR derived ROS
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1.7 Pathological roles of XOR
XOR-derived ROS have been implicated in a variety of pathological disorders, many of 
which are the result of dysregulated inflammation (Granger et al, 1986; Marx, 1987; 
Cameron et al, 1993; Martinez-Cayuela, 1995). Dysregulated or chronic inflammation 
is often the consequence of persistent antigens, and results in significant tissue damage, 
due to inappropriate over-stimulation of activated macrophages. Relevant disorders 
include ischemia-reperfusion injury (IRI), respiratory distress syndrome, endotoxemia, 
rheumatoid arthritis and atherosclerosis (Granger et al, 1986; McCord, 1987; Sussman 
&Bulkley, 1990; Winrow al, 1993; Zweier e ta l, 1994; Burton et al, 1995).
The majority of damage caused in IRI is the result of an acute inflammatory response 
characterised by an influx of neutrophils and increased vascular permeability. During 
ischemia, an increase in the net catabolism of ATP leads to an accumulation of purine 
metabolites such as hypoxanthine within cells. As the energy charge within the cell 
drops, the transmembrane ion gradient is dissipated, resulting in an influx of calcium 
ions. Calcium-mediated proteolysis may irreversibly convert XOR from Type D to Type 
O. On reperfusion, the influx of oxygen allows Type O to catalyse purine metabolism, 
with the concomitant production of ROS (Granger et al, 1986). Recently, there has 
been debate about this theory centering on the extent and time scale of the proteolysis of 
the D form (Parks et al., 1988; Kooij et al, 1992; Hassoun et al., 1994). An alternative, 
or additional, mechanism for IRI has been proposed. During ischemia the amount of 
NADH in the cytoplasm also rises, the NADH oxidase activity of XOR would then be 
able to produce ROS without the need for the D to O conversion (Sanders et al, 1997; 
Zhang e ta l, 1998).
Chapter 1 19
The resultant ROS increase neutrophil attraction to the site by the formation of 
chemotactic lipids and other pro-inflammatory substances, and adherence and activation 
of the neutrophils (Suzuki et al, 1991). Neutrophils also play a major part in cellular 
damage, releasing proteases and other cytotoxic compounds and producing ROS by 
their membrane-bound NADPH oxidase enzyme. ROS damage cells in this and other 
conditions by lipid peroxidation, protein oxidation, and DNA strand breaks, so 
contributing to loss of integrity of the cellular membranes and proteins (Halliwell & 
Gutteridge, 1984; Winrow et al, 1993).
1.8 The role of epithelial cells in inflammation
Epithelial cells are both targets and effectors for inflammatory mediators, and the 
localisation of XOR to several epithelia is therefore of interest (Pfeffer et al, 1994; 
Moriwaki et a l, 1996). Epithelial cells form tightly bound sheets around most cavities 
providing an important interface between the body and external environment. This 
surface is significant both for absorption and defensive purposes. Pulmonary, bronchial 
and intestinal mucosal epithelial cells have been intensively studied, as they are the first 
contact for inhaled or ingested pathogens. These cells have been found to be able to 
synthesis cytokines such as IL-8, a chemotactic cytokine for neutrophils (Standiford et 
al, 1990; Schauer-Maly et a l, 1994), and IL-6 (Cromwell et al, 1992), as well as 
eicosanoids, ROS and platelet-activating factor (PAF) (Alder et al, 1993). Epithelial 
cells also respond to cytokines such as TNFa, IL-1 and IFNy by increasing synthesis of 
defensive agents, such as, surfactant, class 2 MHC molecules and the adhesion 
molecules ICAM=1, CD44 and LFA3 (Bloemann et a l, 1993; Colgan et a l, 1993; 
Pileweski et al, 1993; 1995). Mammary epithelial cells are situated around the lumen of
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an alveolus. They are under the control of several hormones, which dictate growth and 
differentiation of the lobuioductual network, and secretion and expression of milk. 
Mammary epithelial cells secrete cytokines IL- 6  and IL-8 , and milk contains IL-6 , LL- 8  
and IFNy (Basolo et al, 1993a;b) which may provide antimicrobial defence either in situ 
or for the neonate. These cells are able to defend themselves from external pathogens 
and recruit leukocytes to the area of inflammation.
Mammary epithelial cells are of particular interest due to the localisation of XOR to 
human mammaiy epithelium and the expression of XOR as a milk protein.
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2.0 Aims
The aims of this project were to explore possible pathogenic or physiological roles for 
human XOR. It was decided to use a human mammary epithelial cell line (HB4a) as a 
model system in which to investigate the expression, subcellular distribution and 
regulation of the enzyme. A buffalo rat liver epithelial cell line (BRLE) was also used for 
comparison.
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3.0 Materials and Methods
3.1 Materials
3.1.1 Chemicals
Acrylamide stock solution was purchased from Flowgen, Sittingboume, Kent. Bovine 
milk xanthine oxidoreductase was obtained from Biozyme, Blaenavon, Gwent. BIO­
RAD protein assay reagent dye concentrate was obtained from BioRad, Hemel 
Hempstead, Hertfordshire. Nitro-cellulose was obtained from WLS, Aldershot, 
Hampshire. Vectashield fluorescent mounting medium were obtained from VECTOR 
laboratories, Peterborough. DL-dithiothreitol (DTT) was obtained from Alexis 
Corporation. All other chemicals were obtained from Sigma Poole, Dorset.
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3.1.2 Column chromatography matrices
Sephadex G-25, pd-10 prepacked column, was obtained from Pharmacia Biotech, 
Uppsala, Sweden. Heparin-agarose was obtained from Sigma.
3.1.3 Instruments
Centrifugation was carried out in a Beckman TL-100 bench top Ultracentrifuge, and a 
MSE Centaur 2 benchtop centrifuge.
Sonication was done using an MSE 150 Watt Ultrasonic Disintigrator Mk2.
Fluorescent enzyme assays were carried out on a Perkin-Elmer LS-5B Luminescence 
Spectrometer. Absorbance spectra were determined using a CE 272 linear readout 
ultraviolet spectrophotometer. Column chromatography was monitored at 280nm by an 
LKB Uvicord Type 4701A, connected to a Rikademki chart recorder.
Protein assays and ELISAs were read on a Multiskan MCC, Labsystems plate reader. 
SDS-PAGE was performed on a Bio-rad mini protean II electrophoresis cell or Bio-rad 
mini protean II electrophoresis cell, and Western blots were performed using Pharmacia 
biotech nova blot. Confocal laser scanning microscopy was done using a BioRad MRC- 
500 confocal microscope, LSM 510, with either x40 1.30 NA or x63 1.40 NA 
apochromatic objective; Carl Zeiss, Welwyn Garden, UK. The 488 or 468 lines of an 
argon or krypton ion laser were used for excitation of FITC or rhodamine.
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3.1.4 Ceil culture
Dublecco’s Modified Eagle Medium M l99, penicillin 5000 U/ml, streptomycin 5000 
pg/ml, 200mM glutamine and foetal bovine serum were obtained from Life technologies, 
Paisley, Scotland. RPMI 1640 was obtained from ICN, Costa Mesa, USA. Tumour 
necrosis factor alpha, interleukin- 1 beta and interleukin- 6  were obtained from Sigma, 
Poole, Dorset. Interferon gamma was obtained from Calbiochem. Interleukin-13 was 
kindly donated by the pharmacy department of the University of Bath. Plasticware was 
obtained from Falcon, Becton Dickinson, or WLS. Lab-Tek 4 well chamber slide system 
was obtained from Lab-Tek, Nalge Nunc International, Naperville, Illinois, USA.
Cell culture was carried out in a class II microflow culture hood.
3.1.5 Cells
Conditionally immortalised human mammary luminal epithelial cells (HB4a), were the 
kind donation of Dr Kalamati of The Royal Cancer Hospital, Sutton UK. The cells were 
obtained originally from a reduction mammoplastie, and transfected with SV40 (Stamps 
e ta l, 1994).
Buffalo rat liver epithelial cells (BRLEs) were the kind donation of Dr T. Edwards, 
University of Bath. These cells are considered to be immortalised (Coon, 1968).
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3.1.6 Antibodies
Rabbit polyclonal, anti-human XOR antibodies were kindly donated by Dr Benboubetra 
and Richard Bryant, University of Bath.
Fluorescein (FITC)-conjugated anti-rabbit, and anti-mouse IgG were obtained from 
Jackson ImmunoResearch Laboratories Inc. West Grove, PA. USA. Anti-TGN-38 
antibodies was kindly donated by Dr George Banting, Dept, of Biochemistry, Bristol 
University.
Other antibodies used were obtained from Sigma immuno chemicals, Poole, Dorset.
3.2 Methods
3.2.1 Routine maintenance of cell cultures
HB4a cells were grown as a monolayer in 75 cm2 tissue culture flasks. The cells were 
maintained in RMPI 1640 (w/o glutamine), supplemented with 10% foetal bovine serum 
(FBS) (v/v), 3 mM L-glutamine, penicillin (100 IU/ml), streptomycin (100 pg/ml) 
insulin, (5 pg/ml), hydrocortisone (5 pg/ml) and cholera toxin (100 ng/ml). The cells 
were incubated at 37°C humidified with 5% CO2 95% air (v/v).
The BRLE cells grow as a monolayer in 25 cm2 flasks and were maintained in DMEM 
(w/o glutamine), 10% FBS (v/v), 2mM glutamine, penicillin (100 IU/ml) and 
streptomycin ( 1 0 0  pg/ml).
The cells were provided with 0.2ml of media per cm2, this was discarded after 3 to 4 
days, and replaced with fresh prewarmed media.
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3.2.2 Subculturing cells
HB4a and BRLE cells were subcultured at, or shortly after confluence. The monolayers 
were washed twice with sterile phosphate buffered saline (PBS), and detached from the 
flask by trypsinisation, using 0.05% (w/v) trypsin 0.02% (w/v) EDTA solution in PBS. 
The flask was then incubated at 37°C for 5-10 minutes until the cells detached from the 
surface. The reaction was stopped by the addition of an equal volume of medium.
An aliquot of the cell suspension was counted and assessed for viability in a 
haemocytometer using the trypan blue exclusion method. The suspension was diluted 
1:1 with trypan blue [0.04% (w/v)].
New tissue culture flasks were then seeded with 0.3 x 105 cells/ml.
3.2.3 Cryopreservation of cells
Cell stocks were preserved by freezing in liquid nitrogen. One flask of confluent cells 
was trypsinised as detailed above, and a cell pellet obtained by centrifugation at lOOg for 
5 min in a sterile tube. The supernatant was discarded and the pellet resuspended in 50% 
(v/v) FBS. The cells were then transferred to a sterile cryogenic tube with 40% (v/v) 
medium and 10% (v/v) DMSO. The tube was placed in cold N2 vapour for 24 h, then 
transferred to a liquid N2 container.
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Frozen cells were defrosted by immersion in a 37°C water bath. The cell suspension was 
washed by centrifugation (lOOg for 5 min) in fresh medium, and the cell pellet 
resuspended in fresh medium in a new culture flask.
3.2.4 Cell growth and XOR activity curve
The growth activity curve is routinely used to estimate when the cells should be 
harvested for assay (Fig. 3.7.3). Cells seeded at 0.3 xl06/ml are assayed or cytokines 
added after 12 days, to standardise basal activity.
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Figure 3.2.4 Cell growth and XOR activity curve
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3.2.5 Addition of cytokines and hormones
The cells were grown to the required density as assessed by the growth curve. Fresh 
media was given together with an aliquot of the appropriate cytokine or hormone. The 
cells were incubated for 24 h with cytokines, and 48 h with hormones, then harvested 
for assay.
3.2.6 Cell harvesting for pterin assay
Cells were harvested by trypsinisation for the assay, as described in Section 3.7.1. The 
cells were counted and a cell pellet was obtained by centrifugation (lOOg for 5 min). 
This pellet was resuspended in cell buffer ((1.2 ml) 50 mM potassium phosphate, pH 7.4 
containing 0.1 mM EDTA, 0.1 mM PMSF, pepstatin A (lpg/ml), leupeptin (lpg/ml), 
antipain (lpg/ml) and aproteinin (lpg/ml)).
The suspension was then transferred to an eppendorf in a cool box to maintain the 
temperature at 4°C whilst sonication took place using a 3mm probe for 2 0  s on power 
setting 6  microns. The sample was then ultracentrifuged at 500 OOOg for 10 min at 4°C, 
or at 100 OOOg for 25 min, to give a crude cytosolic fraction.
The samples were assayed for XOR activity on the same day as harvesting.
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3.2.7 Pterin assay
The fluorimetric enzyme activity assay was carried out using the method of Beckman et 
al. (1989). The reducing substrate was 10 pM pterin and the oxidising substrate was 
atmospheric oxygen or 10 pM methylene blue. The assay measures the rate of 
production of the fluorescent product isoxanthopterin from the oxidation of pterin, as 
catalysed by XOR at the molybdenum active site. To assess the activity of the oxidase 
form, pterin alone was added to the sample and to measure total activity (dehydrogenase 
and oxidase) both pterin and methylene blue were added.
The fluorimeter was set with an excitation wave length of 345nm and an emission wave 
length of 390nm, with slit width of 5nm. All reactants were brought to room 
temperature, and a stable base line was obtained using buffer, 480pl, (50 mM potassium 
phosphate pH 7.4 containing 0.1 mM EDTA) and cell supernatant, 500pl, in a glass 
cuvette. The reaction rate was measured after addition of methylene blue and pterin 
using x5 scale at 0.5 cm/min. The reaction was inhibited by the addition of 50 pM 
allopurinol.
Sequential additions of 10 pM isoxanthopterin were added to provide calibration and an 
internal standard accounting for variations caused by fluorescence quenching and 
scattering. The reaction rate was then calculated as pmoles isoxanthopterin min' 1 mg' 1 
total protein.
In order to compare Km and values to those obtained using the urate assay, (Section 
3.2.8), the assay was carried out as above, but using lOpl of a 1:100 dilution of purified 
human milk XOR enzyme (2.84 mg/ml), essentially obtained as described by Abadeh et 
a l (1992). The volume was made up to 1 ml using 50 mM potassium phosphate, pH
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7.4, containing O.lmM EDTA. Concentrations of pterin ranging from 0.25pM - 100pM 
were used to establish the Km and Fmax for pterin.
3.2.8 Urate assay
A spectrophotometric method was used to measure the activity of the human milk 
enzyme. The assay mixture consisted of concentrations of xanthine ranging from 2- 
100pM and 500pM NAD+ in 50mM bicine buffer pH 8.3. Purified human milk enzyme 
(10pl, 2.24 mg/ml) was added to a 1ml cuvette and the rate of uric acid production 
measured at 295 nm at room temperature. Specific activities were calculated using an 
extinction coefficient of 9600 M' 1 cm'1, and Km and Vm^for xanthine were established.
3.2.9 NADH oxidase activity assay
A spectrophotometric method was used to determine the NADH oxidase activity of 
XOR. The depletion of NADH was measured at 340 nm at 30°C pH 7.4. Assays were 
carried out in acrylic cuvettes, final volume 1 ml. Specific activities were calculated 
using an extinction coefficient o f6220 NT1 cm'1.
3.2.10 Protein Estimations
Total protein content of the crude cytosolic fraction was estimated using the method of 
Bradford (1976). The standard used was lmg/ml bovine serum albumin, with a standard 
curve ranging from 2-10pg of standard protein diluted with assay buffer to give lOOpl
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total volume. 1ml of BIO-RAD solution was then added and left to develop for 15 min. 
The absorbance of each sample was then measured at 595nm.
3.2.11 Biotinylation of anti-XOR antibodies
1-3 mg of polyclonal rabbit anti-XOR antibodies were transferred into borate buffer 
(0.1M sodium borate, pH 8 .8 ) using a PD10 gel filtration column. The biotin ester (N- 
hydroxysuccinimide biotin, 10 mg/ml in DMSO) was then added at a ratio of 2 0 0 pg per 
mg of antibody, and mixed for 4 h at room temperature. Then 1M NH4CI, 20 pi per 250 
pg of biotin ester was added and incubated for 10 min at room temperature. The 
resulting solution was extensively dialysed with PBS overnight to remove uncoupled 
biotin. The effectiveness of biotinylation was determined using an ELISA as described in 
Section 3.2.12, with standard solutions of XOR and various dilutions of the biotinylated 
antibody. The biotinylated antibodies were then used in the ELISA and as secondary 
antibodies in Western blots.
3.2.12 Enzyme linked immunosorbent assay
The sandwich ELISA was developed to determine concentrations of XOR protein in 
samples. The method used was essentially that of Price & Harrison (1993).
A polystyrene microtitre plate was coated with affinity purified rabbit anti-human XOR 
antibody (6 pg/ml; lOOpl/well) diluted in NaHCOs pH 9.6. The plate was incubated 
overnight at 4°C.
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The plate was washed with PBS, 200pl/well, three times, and blocked using 1% 
BSA/PBS, 200pl/well, and incubated overnight at 4°C. The plate was washed three 
times with PBS containing 0.05% tween 20, (PBS-T, 200pl/well). A duplicated standard 
curve was created using HMXOR, purified as described by Abadeh et al (1992). The 
concentrations ranged from 100 ng/ml to 0.62 ng/ml diluted in 1% BSA/PBS. The 
samples were added to the wells in triplicate dilutions, diluted with 1% BSA/PBS. 
Standard or sample (200 pil) was added to each well. The plate was then incubated at 
37°C for 2 h, after which it was washed three times with PBS-T (200 pi). Biotinylated 
affinity purified rabbit anti-human XOR, (lOOpl, 6 pg/ml diluted with 1 % BSA/PBS), 
was dispensed into each well, and the plate was incubated for 1 h at 37°C. The plate was 
washed again three times with 200pl PBS-T. Extravidin-peroxidase conjugate, (diluted 
1:1000 with 1% B SA/PB S, 1 OOpl/well), was added to the wells and incubated for 20 min 
at 37°C. The plate was washed three times with PBS-T (200pl/well) and once with PBS 
(200pl/well). The reaction was revealed using of 1% tetramethylbenzidine in DMSO 
diluted 1:100 with 0.1 M sodium acetate/citric acid pH 6 , containing O.Olpl H2 0 2 /ml of 
buffer (lOOpl/well). The reaction was terminated using H2 SO4 (50 pl/well). The 
absorbance was then read at 450nm.
3.2.13 SDS-PAGE and Western blotting
Both HB4a and BRLE cells were harvested for SDS-PAGE and Western blotting as 
previously described in Section 3.2.6. The cells were centrifuged at lOOg for 5 min then 
resuspended in cell buffer (50mM potassium phosphate, pH 7.4, containing 0.1 mM 
EDTA) at a concentration of 2 x 107 cells/ml. The cells were then sonicated and
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centrifuged at 500 OOOg for 10 min, or 100 000 g for 25 min at 4°C. The supernatant 
was diluted 1:1 with reducing sample buffer (62 mM Tris pH 6.8, 10% (v/v) glycerol, 
2% (w/v) SDS, 5% (v/v) (3-mercaptoethanol, 1.25% (w/v) bromophenol blue), and 
boiled for 5 min. Molecular weight markers and BXOR, were treated in the same way. 
The separating gel was made up of distilled H20 , 10% (v/v) acrylamide, 2.67% (v/v) 
N’N bis methylene acrylamide, 375 mM Tris pH 8.8, 0.1% (w/v) SDS, 0.05% (w/v) 
APS and 0.05% (v/v) TEMED (NNN’N’-tetramethylethylenediamine). Once the gel had 
set and the gel comb was in place, the stacking gel consisting of distilled H20 , 4% 
acrylamide, 0.9% N’N bis methylene acrylamide, 125mM Tris pH 6.8, 0.1% (w/v) SDS, 
0.05% (w/v) APS and 0.1% (v/v) TEMED was layered onto the gel. The high molecular 
weight markers, 15 pg BXOR, 100 pg BRLE cells and 150 pg HB4a cells were loaded 
into separate wells in the stacking gel. The gel was run at 200 Volts for 1 h in a tank 
containing running buffer, 0.192M glycine, 0.025 M tris, 0.1% (w/v) SDS, pH 8.3, 
diluted 1:10 with distilled H20.
3.2.14 Western transfer
Once run the stacking gel was removed and the separating gel was placed on a layer of 
nitro-cellulose paper soaked in transfer buffer (20mM tris-HCl pH 8.3, 150mM glycine 
and 20% (v/v) methanol), which was then sandwiched between 18 layers of filter paper 
also saturated with transfer buffer. The sandwich was placed onto the graphite anode 
plate soaked with distilled H20 , and the cathode, also soaked with distilled H20 , was 
placed on top. The transfer was run at 0.8mA/cm2 for 2 h. To check whether the
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transfer had been effective the nitro-cellulose was stained with Ponceau Red and the gel 
stained with Coomassie blue, enabling proteins to be visualised.
3.2.15 Western blotting procedure
The nitro-cellulose was washed with distilled H2O to removed Ponceau Red Stain, and 
then washed for 5 min with TBS (10 mM Tris, 0.9 % (w/v) NaCl, in 1L distilled H2O, 
pH 7.4). The nitro-cellulose was incubated at 4°C overnight in 2% BSA/PBS, to block 
non specific binding sites. It was then washed for 5 min with TBST (TBS containing 
0.05% Tween 20). Biotinylated rabbit anti-human XOR, was added (15pg/ml) in TBST 
and 1% (w/v) BSA, and incubated with continual agitation at room temperature for 2 h. 
The membrane was washed twice for 5 min with TBST, then incubated for 20 min at 
room temperature with Extravidin-peroxidase conjugate (stock diluted 1:500 with 
TBST). The final washing procedure was 3 times for 5 min in TBST, then once for 5 
min in TBS. To visualise the XOR bands 4-chloro-2-napthol in methanol (4mls, 
3mg/ml), and H2O2 (20jil) in TBS (20mls) was added.
3.2.16 Immunoprecipitation of XOR from cells using Protein A Sepharose
Polyclonal affinity purified anti-human XOR antibodies were incubated with Protein A 
Sepharose CL-4B gel overnight at 4°C, end over rotation, (100pl of gel : 250pg of 
antibody). The gel was washed three times with PBS and incubated with the cell 
supernatant obtained from the procedure described in Section 3.2.6, overnight at 4°C 
end-over mixing. The supernatant was removed and assessed for XOR activity using the
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pterin assay. The gel was washed three times with PBS. Sample buffer (3.2.13), at half 
the volume of the gel, was then added to the gel, and it was used in SDS-PAGE and 
Western blotting as described in Section 3.2.13.
3.2.17 Gel filtration
A potential source of error when using the pterin assay would be the presence of 
endogenous purines in the cell extract, which could potentially give a smaller than true 
activity. To remove small molecular weight inhibitors such as purines, gel filtration was 
employed. A cell sample treated in the normal way immediately prior to assay, was run 
through a Sephadex G-25 column PD-10. The column was first equilibrated with 
approximately 20 ml phosphate buffer (50 mM potassium phosphate, pH 7.4 containing 
0. ImM EDTA). The sample, and then buffer (1 ml) was added to the top of the column, 
and fractions (500 pi) were collected. Aliquots from each fraction were tested with 
BioRad solution to establish which fractions contained the sample. Fractions containing 
the sample were pooled, protein estimations carried out and assayed as described 
previously. Activities for control samples were 0.95 pmol min"1 mg"1 (+/- 0.17 n=4), and 
for column samples were 1.4 pmol min"1 mg"1 (+/- 0.16 n=4). Results show that there are 
some inhibitors that are removed by gel filtration. However, this method results in an 
unexceptable dilution of the sample and is not practicable due to this, time factors and 
the large number of samples to be assayed, and was not therefore routinely used.
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3.2.18 Column chromatography
To provide controls for confocal cell surface experiments a heparin-agarose column of 
dimensions 3.5cm x 1.5 cm was prepared. The column was washed with approximately 
30 ml of culture media lacking FCS. Complete culture media (100 ml), was then passed 
down the column and collected in a sterile container. The column was then washed with 
25 mM sodium phosphate buffer pH 7.4, until A28o reached a base line level. To elute 
the protein the column was washed with the same buffer containing 1M NaCl. The 
protein containing fraction, as assessed by A28o, was then assayed for XOR activity using 
the pterin assay. Cells were seeded in duplicate slides, as described in Section 3.2.19, 
and grown with either preabsorbed medium or normal medium prior to 
immunolocalisation.
3.2.19 Confocal microscopy
Cells were seeded in chamber slides at the required density (approx. 2 xl05/ml) in 1ml of 
media. After 1 or 2 days growth, the monolayers were washed twice with PBS, then 
fixed by washing for 20 min in 4% (w/v) paraformaldehyde, and washed twice with 
PBS. The cells were then permeabilised using 0.1% (w/v) saponin in PBS for 45 min. 
XOR protein was detected in the cell monolayer by incubation with primary polyclonal 
anti-XOR antibodies (500pl/well, 0.1-0.02 mg/ml), diluted 1:10 using 0.1% (w/v) 
saponin in PBS, 3% (v/v) normal goat serum and 1% BSA (w/v) and incubated for 2 h. 
The monolayer was washed three times with 0.1% (w/v) saponin in PBS then incubated
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with the secondary FITC conjugated antibodies, (500pl/well) diluted 1:100 using the 
same dilutant as for the primary antibodies, for 2 h. The monolayers were washed again 
three times with 0.1% (w/v) saponin in PBS. The chambers were removed leaving the 
cell monolayers attached to the slides. To protect the monolayers and fluorescence, they 
were coated with Vectasheild (20pl) and sealed with a glass slide. The monolayers were 
then visualised using confocal microscopy.
To detect XOR on the surface of the cells, unpermeabilised cells were used. This utilised 
the same method as above, but omitting the saponin incubation and the saponin in the 
antibody dilutant.
To detect transgolgi protein, anti-TGN-38 antibodies were used (500pl/well) diluted 
1:100 using the same dilutant as above, with rhodamine-conjugated secondary 
antibodies (500pl/well), diluted 1:500, using the same dilutant as above.
Co-localisation was carried out by incubating the monolayers with antibodies specific to 
one protein (both primary and secondary), as described above, followed by incubation 
with antibodies specific to the other protein (both primary and secondary).
Detection of ROS was carried out using unpermeabilised cell monolayers, incubated 
with 50pm allopurinol for 24 h prior to the procedure. The cells were incubated with 24 
pM dihydrorhodamine-1,2,3, for 45 min at 37°C before washing 3 times with PBS. Cells 
were then fixed as described previously. Dihydrorhodamine-1,2,3, is oxidised to 
fluorescent rhodamine-1,2,3 on contact with ROS (Rothe et al, 1988; Henderson & 
Chappie, 1993), and this was visualised using confocal microscopy.
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3.2.20 Cell surface XOR activity
Detection of XOR on the cell surface led to the investigation into whether it was active 
protein.
Several methods were employed. The monolayers were incubated with heparin (10 
mg/ml) in PBS for 10 min at 4°C, the supernatant was then removed, and the monolayer 
washed 3 times with PBS. The cells were harvested as described in Section 3.2.6, and 
the total activity was then measured as described in Section 3.2.7, the difference 
between control and heparin incubated cells was assessed.
Cells were also incubated with heparinase 2 units/ml in PBS, for 2 h at 37°C. Total 
activity was then measured as described in Section 3.2.7, after washing the monolayers 3 
times with PBS, and the difference between control and heparinase treated cells 
assessed.
An attempt was made to measure the NADH oxidase activity of the cell surface. Cells 
were grown in 4 well chamber slides as described in Section 3.2.18, the media was 
discarded and the monolayers washed three times with PBS. Then 5mM NADH (lOOpl) 
was added to culture medium (0.9 ml) in each well and incubated at 37°C. Controls used 
were wells containing medium only, NADH only and wells containing medium plus anti- 
XOR antibodies. Measurements of the depletion of NADH were then taken in triplicate 
at intervals as described in Section 3.2.9.
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4.0 XOR Activity in Epithelial Cells
4.1 Introduction
The activity of XOR in epithelial cells was investigated. Human mammary epithelial cells 
were chosen because they are a well documented source of XOR, as discussed in the 
Introduction. The potential involvement of XOR in the inflammatory response could 
also be studied, as epithelial cells are known to be involved in the regulation of the 
immune response by virtue of their production of, and response to, cytokines, and by the 
expression of adhesion molecules (Cromwell et al., 1992; Basolo et al., 1994; Pfeffer et 
al., 1994). The human cell line HB4a was chosen for this study, together with buffalo rat 
liver epithelial cells (BRLE) for purposes of comparison.
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4.2 The relationship between XOR activity and cell growth in HB4a cells
The relationship between XOR activity and cell growth was initially investigated. A 
growth pattern was monitored using HB4a cells at a density of 0.3 x 10s cells/ml. Cell 
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Fig. 4.1 Relationship between cell number and XOR activity for HB4a cells. Initial cell 
density was 0.3x105/ml. Cell number and XOR activities were monitored as described 
in Section 3.2.2 & 3.2.7. Values are quoted as +/- SEM, n=5.
The cells attained confluence around day 9, with a doubling time of approximately 36 h 
and a maximum density of 1.87 x 106 cells/ml. The XOR activity lagged behind cell
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number with no activity detectable for the first three days. The activity then rose sharply, 
attaining plateau values shortly after confluence with a small peak around day 9. A 
second steep rise in activity was observed as the cell number started to decline around 
day 15.
In order to standardise future results the cells were therefore routinely harvested on day 
12, when the average activity was 0.57 +/- 0.09 pmol min'1 mg’1 total protein (+/- SEM 
n=5). DIC images of cells at low and high density are shown in Fig. 4.2.
A B
Figure 4.2 DIC images o f HB4a cells, magnification x 400, bar 20 fjm. ‘A’ low density 
(day 4) and ‘B’ high density (day 9). The images were obtained as described in
Section 3.2.19.
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4.2.1 High density growth curve
HB4a cells were seeded at a higher density in order to establish whether the pattern of 
XOR activity shown in Fig. 4.1 would appear earlier in the growth curve, which might 
indicate that XOR activity is related to cell density. The flasks were seeded at a cell 
density of 4.7x105 cells/ml as apposed to 0.3x105 cells/ml, used previously.
-•— activity —■ - cell number
Figure 4.3 Relationship between cell number and XOR activity for HB4a cells. Initial 
cell density was 4.7xl05 per ml. Cell numbers and XOR activities were determined as 
described in Section 3.2.2 & 3.2.7. Values quoted as +/- SEM, n=4.
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Fig. 4.3 shows that XOR activity follows a similar pattern to that of the original growth 
curve (Fig. 4.1). If the XOR activity were solely a function of cell density, an earlier rise 
in activity might have been expected. The maximum cell density seen was 2 x 106 
cells/ml and the maximum XOR activity was 3.94 +/- 0.58 pmol min1 mg'1 total protein 
(+/- SEM n=4). In both experiments XOR activity appears to rise as cell number is 
declining. However, the high density growth curve has a much higher activity at the end 
of the time course and rises much more steeply than the original growth curve.
Neither growth pattern has detectable XOR activity for the first three days. While a lack 
of sensitivity in the assay could be the explanation in the first growth curve, this is not a 
valid argument in the case of the high cell density growth curve, where the cell number 
at the start of the growth curve is equivalent to that seen on day 7 in the first growth 
curve.
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4.2.2 The relationship between XOR activity and cell growth in BRLE cells
A similar study was carried out using BRLE cells. Flasks were seeded with BRLE cells 
at a density of 0.3x105 cells/ml. Cell number and XOR activity were followed up to and 
past confluence, with the results shown in Fig 4.4.
— activity — * - - cell number
Figure 4.4. Relationship between cell number and XOR activity for BRLE cells. Initial 
cell density was 0.3 xlO5/ml. Cell numbers and XOR activities were determined as 
described in Section 3.2.2 & 3.2.7. Values quoted as +/- SEM, n=3.
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B
Figure 4.5. DIC images o f BRLE cells, magnification x400, bar 20jum. ‘A ’ low 
density (day 3) and B  ’ medium density (day 6). The images were obtained using a 
confocal microscope as described in Section 3.2.19.
Fig. 4.4 shows that the BRLE cells attained confluence around day 12, with a doubling 
time of approximately 28 h and a maximum density of 4.8 x 106 cells/ml. The highest 
activity recorded was 40.5 +/- 2.73 pmol min'1 mg'1 total protein (+/- SEM n=3) which is 
approximately 70 times higher than that seen in the HB4a cells. The graph shows a 
pronounced change in XOR activity in relation to cell number. The XOR activity lagged 
behind cell number with no activity detectable for the first three days, then rose sharply 
at the onset of confluence. XOR activity then appears to decline slightly, tending 
towards plateaux values as the cell number becomes stable. The pattern seen is similar to 
that during the first 8 days of the HB4a growth curve in Fig 4.1. However, no second 
rise in activity was seen in this case. DIC images of BRLE cells at low and medium 
density are shown in Fig.4.5.
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4.2.3 High density BRLE growth curve
The BRLE cells were seeded at the higher initial density of lx 105 cells/ml and a further 
study on the relationship between cell growth and XOR activity was carried out.
♦ — activity —-  - cell number
a 20
Figure 4.6 Relationship between cell number and XOR activity for BRLE cells. Initial 
cell density was lx l 05 /ml. Cell numbers and XOR activities were determined as 
described in Section 3. Values quoted as +/- SEM, n=3.
XOR activity in the high density growth curve follows essentially the same pattern as 
that seen in Fig 4.4 with the XOR activity lagging behind cell number until confluence 
and rising sharply to reach maximum values of 47.4 +/- 4.0 pmol min*1 mg'1 total protein 
(+/- SEM n=3). The maximum cell density recorded was 3.15 x 106 cells/ml. The activity
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falls slightly between days 8 and 11 but then appears to begin rising as cell numbers start 
to decline, possibly following the same pattern as that seen with the HB4a growth 
curves Figs. 4.1 and 4.2.
4.3 Effects of medium on XOR activity
The possibility that resuspending the cells in fresh medium could affect the XOR activity 
was investigated. HB4a cells were given fresh media every 6 h for 48 h before assay on 
day 12 (Fig. 4.1). No difference in activity between cells subjected to frequent medium 
change and those treated as previously was observed (Table 4.5).
Control Wash
0.73 +/- 0.21 0.88+/-0.19
Table 4.1 Table showing XOR activity o f control cultures o f HB4a cells, and cultures 
given fresh medium every 6 h. Activities determined as described in Section 3.2.7. 
Values quoted as pmolmin1 m g1 +/- SEM n=6
A preliminary experiment was also undertaken in which the cultures were subjected to 
washes with fresh medium 1, 4 or 6 h before assay. The results, which are not shown, 
indicate that the time taken between fresh media being supplied and assay does not 
affect the XOR activity.
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4.4 The effects of specific XOR inhibitors on cell growth
The XOR activity pattern seen in the growth curves, led us to speculate that XOR may 
be involved in cell growth, differentiation or even apoptosis. Possible effects of the 
specific XOR inhibitor, allopurinol, on cell growth were investigated.
The allopurinol was dissolved in 0.2M NaOH then diluted using PBS before addition to 
the cultures. 0.2M NaOH diluted with appropriate volumes of PBS, was added to 
separate cultures as a control. To check that the culture conditions did not adversely 
effect the action of allopurinol, this was added to media and kept for three days at 37°C, 
then tested for inhibitory action against BXOR using the urate assay as described in 
Section 3.2.8. It was found that this treatment did not significantly affect the action of 
allopurinol (results not shown).
A concentration of 50|iM allopurinol was chosen, as this concentration is routinely used 
to inhibit XOR activity in the pterin assay. Fig 4.7 illustrates the effects of allopurinol on 
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Fig. 4.7 Influence o f allopurinol on the percentage cell viability and cell number 
xlO4/ml o f HB4a cells, when treated with 50pM allopurinol in NaOH, or NaOH alone 
as a control. Cells were treated approximately every three days, until day 12 when 
cultures were harvested and cell number and viability assessed as described in Section
3.2.2 & 3.2.7.
There appears to be no significant difference between the numbers of cells in controls 
and allopurinol-treated cultures, nor was the cell viability affected.
A higher concentration of allopurinol was then administered to the cultures.
Chapter 4 50
Allopurinolcontrol NaOH
■  cell number ■  Viability
Fig. 4.8 Influence o f allopurinol on the percentage cell viability and cell number 
xlO4/ml when treated with ImM allopurinol in NaOH, or in NaOH alone as a control. 
Additions were made approximately every three days, until day 12 when the cultures 
were harvested and cell number and viability assessed as described in Section 3.2.2 &
3.2.7.
Fig. 4.8 shows that, again, allopurinol treated cultures are not significantly different from 
control cultures.
The experiments shown in Fig. 4.7 and 4.8 were carried out on cells harvested during 
the stationary phase of growth. To assess whether the stage of growth was a factor in 
the potential effects of XOR on cell growth or differentiation, the same experiments 
were carried out on cells that were in the log phase of growth.
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control allopurinol NaOH
■  Cell number ■  viability
Fig. 4.9 Influence o f allopurinol on the percentage cell viability and cell number 
xlO4/ml when treated with 50 pM allopurinol in NaOH' or with NaOH alone as a 
control approximately every three days, until day 7 when the cultures were harvested 
and cell number and viability assessed as described in Section 3.2.2 & 3.2.7.
Fig. 4.9 indicates that allopurinol has little effect on cell growth or viability in the log 
phase of growth.
Allopurinol was also added to cultures that had been in stationary phase for a few days, 
to establish whether the inhibition of XOR extended the life of the cells.
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■  control ■allopurinol DNaOHH control ■allopurinol DNaOH
Figure 4.10 ‘A’ Percentage viability o f cells treated with 50pM  allopurinol
approximately every three days. Cultures were harvested and the cell number and 
viability assessed as described in Section 3.2.2 & 3.2.7. Fig. 4.10. ‘B’ Cell number at 
the same time and under the same conditions as in A \ Values quoted as Average n=2.
Allopurinol does not appear to extend the life of the cells or increase their viability. 
These results indicate that XOR activity is not a significant factor in cell growth or 
viability.
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4.5 The effect of hormones on cell growth and XOR activity
Human mammary epithelial cells are under the influence of several hormones especially 
during pregnancy and lactation. Several of these hormones have actions which include 
inducing cell growth and differentiation to form the fully functional mammary gland 
(Wilson, 1981; Lacock & Wise, 1996). The combination of progesterone and prolactin 
was chosen to mimic physiological events when the cells are stimulated first to 
differentiate with progesterone and then to produce milk with prolactin. The HB4a cells 
were stimulated with prolactin and progesterone at concentrations similar to those found 
in the plasma during the late stages of pregnancy and then harvested in the usual way. 
Progesterone was added initially for 48 h followed by prolactin for a further 48 h. 
Progesterone was dissolved in ethanol, which, at appropriate dilutions, was used as a 




control ethanol prolactin progesterone both
B activity B cell number
Fig. 4.11 HB4a cells (on day 12) incubated with prolactin (0.2 pM) progesterone (5 
pg/ml) and ethanol for 48 h (1% v/v). Ethanol was added as a control. Cultures were 
also incubated with a combination o f prolactin and progesterone at 0.2 pM and 5 pg/ml 
respectively, with progesterone added initially for 48 h followed by prolactin for a 
further 48 h. The cells were then harvested, assayed for XOR activity and counted as 
described in Section 3.2.2 & 3.2.7. n=4 +/- SEM.
Fig.4.11 shows that the highest increase in activity is stimulated by prolactin but there is 
not a corresponding increase in cell number. The combination of progesterone and 
prolactin caused an increase in cell number but no increase in XOR activity.
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4.6 The effect of cytokines on cell growth and XOR activity
The inflammatory cytokine IFNy has pleiotropic effects with relation to immunity, 
including cytostatic effects on various cell types (Chany et al., 1984; Friesel et a l, 1987; 
Vilcek & Oliveria, 1994). IFNy was administered during the stationary phase as assessed 
by the growth curve (see Fig. 4.1), and cells were harvested after 24 h, to establish 
whether IFNy had an effect on cell growth. The results are presented in Table 4.2.
Control IFNy (lOOIU/ml)
XOR activity as % of 
control (+/- SEM n=5)
100 (+/- 0) 776.8 (+/- 26.7)
Cell number xl06/ml (+/- 
SEM n=5)
1.74 (+/- 0.24) 1.42 (+/- 0.31)
Table 4.2 Effects o f IFNy (100 IU/ml) on XOR activity and cell number x l0 6/ml. HB4a 
cells in the stationary phase o f growth (day 12) were incubated with IFNy fo r 24h. Cell 
number and XOR activities were assessed as described in Section 3.2.2 & 3.2.7. Results 
are presented as a percentage o f the control which is normalised to 100% (+/- SEM
n=5)
Table 4.12 shows a dramatic increase in XOR activity when the cells are stimulated by 
IFNy (this is investigated further in Chapter 5). However, this activity is not
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accompanied by a corresponding change in cell number. HB4a cells were then 
stimulated with IFNy during the log phase of growth, to discover whether there would 
be a more pronounced change in cell number. The results are presented in Table 4.3.
Control IFNy (lOOIU/ml)
XOR activity as % of 
control (+/- SEM n=4)
100 (+/- 0) 114.3 (+/-14.3)
Cell number xl05/ml (+/- 
SEM n=4)
4.2 (+/- 0.44) 3.6 (+/- 0.14)
Table 4.3 Effects o f IFNy (100 IU/ml) on XOR activity and cell number xl(f/m l. HB4a 
cells in the log phase o f growth (day 7) were incubated with IFNy for 24h. Cell number 
and XOR activities were assessed as described in Section 3.2.2 & 3.2.7. Results are 
presented as a percentage o f the control which is normalised to 100% (+/- SEM n=5)
The results in Table 4.3 show that the addition of cytokines during the log phase of 
growth has no significant effect on XOR activity or cell number.
4.7 Discussion
The results presented in this chapter describe the detection of XOR activity in two 
particular human and rat epithelial cell lines. The BRLE cell line has much greater
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enzymic activity than the HB4a cell line, which, in common with most human tissues, 
has a low activity. This was expected as both the species and tissue type from which the 
BRLE cells originate have higher XOR activities than those from which the HB4a cells 
originate. The pattern of XOR activity in relation to their growth curves in HB4a cells 
and BRLE cells was interesting. They follow similar patterns with the activity of the 
enzyme rising steeply a few days after confluence and again with decline in cell number. 
The pattern suggests a role for XOR in influencing cell growth and/or apoptosis. Such 
effects could be mediated via the production of ROS, which have been shown, in other 
systems, to influence cell proliferation (Burdon et a l, 1989; 1993; Murrell et a l, 1990; 
Burdon 1995).
Several experiments were carried out to investigate these possibilities. Growth curves 
were established at higher cell densities. These indicated that altering the density of the 
cells had little effect on the pattern of activity, suggesting XOR activity did not depend 
on cell density but may be a feature of the period of time in culture. The lack of activity 
at the beginning of the growth curve was investigated. It was thought that fresh medium 
may affect activity, but this was found not to be the case. The effects of allopurinol were 
studied. Allopurinol did not significantly affect the growth or viability of cells in either 
the log or stationary phases at concentrations used to inhibit the cellular XOR activity in 
the pterin assay, nor did it extend the period of time cells could exist in the stationary 
phase. It must be noted that the NADH oxidase activity of XOR can produce ROS 
(Sanders et a l, 1997) and is not inhibited by allopurinol. It is, accordingly, possible that 
any effects on cell growth could be mediated via the NADH oxidase activity of the 
enzyme. However, to date there is no known specific inhibitor of XOR NADH oxidase 
activity (Harrison, 1997).
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The hormones, progesterone and prolactin, upregulated during pregnancy and involved 
in differentiation and growth of mammary epithelial cells, were shown to have minimal 
effect on XOR activity or cell growth. The inflammatory cytokine, IFNy, which has 
potential cytostatic effects, was then studied. It also appeared to have no effect on cell 
growth or XOR activity when administered in the log phase of growth. This is consistent 
with data obtained by Terada & Arnold (1993), using HUVECs. However, when added 
to the cells in the stationary phase, IFNy elicited a significant increase in XOR activity in 
HB4a cells, but with no corresponding effect on cell growth. The increase in activity is 
investigated further in the next chapter. Overall, these studies show little evidence that 
XOR activity plays a significant role in the regulation of cell growth or differentiation in 
these cell lines.
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5.0 Regulation of XOR Activity by Cytokines in HB4a Cells
5.1 Introduction
Cytokines are small molecular weight proteins which function as intercellular 
messengers. These peptides can either be excreted or expressed on the surface of cells 
(Pober & Cotran 1990). They bind to specific high affinity receptors on the membrane 
surface of target cells to bring about changes in gene expression resulting in numerous 
and diverse physiological responses. Their actions include immune and inflammatory 
effects, as well as cellular proliferation and differentiation (Roitt et al., 1989; Kuby, 
1991). Cytokines generally act in a paracrine or autocrine fashion which is short lived 
and tightly regulated. The dysregulated release of cytokines can cause chronic 
inflammatory syndromes that can be toxic or even life threatening (Larrick & Kunkel, 
1988). The regulation of XOR activity, in HB4a cells, by cytokines, was investigated in 
this chapter.
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5.1.1 Tumour Necrosis Factor alpha (TNFa)
TNFa plays a major role in the inflammatory response. It is one of the first cytokines to 
be produced by activated macrophages in response to injury and is involved in the 
initiation of the acute inflammatory response, causing the secondary wave of cytokine 
secretion. It also plays a key role in the initiation of tissue repair and remodelling 
processes (Roitt et al., 1989; Kunkel etal., 1990; Kuby, 1991).
HB4a cells were treated on day 12, with TNFa at various concentrations, and incubated 
for 24 h under normal conditions. The results are presented in Fig. 5.1.
300 -
1  250 |eo
■s 200 
£
'T  150 £




0 1 10 50 100 150
TNFa (IU/ml)
Fig. 5.1 Effects of 24 h incubation with TNFa, on day 12, on XOR activity in HB4a
cells. XOR activities were monitored as described in Section 3.2.7. Values are
presented as % of the basal activity which is normalised to 100% +/- SEM, n=5.
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TNFa significantly increases XOR activity above basal levels by up to two fold at 50 
IU/ml, as assessed statistically using the students T-test (p < 0.05).
5.1.2 Interleukin 1 beta (IL-lp)
EL-lp is a primary cytokine. It is produced by a variety of cell types in response to injury 
and antigens, and has many properties in common with TNFa, inducing pleiotropic 
effects on target cells (Kuby, 1991).
HB4a cells were treated with IL-ip at a range of concentrations. The results are 
presented in Fig. 5.2.
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Fig. 5.2 Effects of 24 h incubation with IL-lp, on day 12, on XOR activity in HB4a
cells. XOR activities were monitored as described in Section 3.2.7. Values are
presented as % of the basal activity which is normalised to 100% +/- SEM, n=5.
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IL-lp significantly increases XOR activity above basal levels by two fold at 50, 100 and 
150 IU/ml, as assessed statistically using the students T-test (p < 0.05).
5.1.3 Interleukin 6 (IL-6)
IL-6 is also secreted during the initiation of the acute inflammatory response, by 
monocytes, macrophages, Th2 cells and bone stromal cells, and it is important in the 
production of acute phase proteins (Baumann et al., 1989; Kuby, 1991).
The HB4a cells were treated with various doses of IL-6, as seen in Fig 5.3.
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Fig. 5.3 Effects of24h incubation with IL-6, on day 12, on XOR activity in HB4a
cells. XOR activities were monitored as described in Section 3. 2.7. Values are
presented a s% o f the basal activity which is normalised to 100% +/- SEM, n=4.
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EL-6 appears to have little significant effect on XOR activity.
5.1.4 Interferon Gamma (IFNy)
IFNy is an immunoregulatory cytokine secreted by Thl cells, Tc cells and NK cells. Its 
diverse effects include inducing cellular resistance to viruses, MHCn antigen expression 
and effects on cellular growth and differentiation (Roitt et al., 1989; Kuby, 1991; 
Grosser, 1995).
HB4a cells were treated with IFNy at a range of concentrations for 24 h. The results are 
presented in Fig. 5.4.
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Fig. 5.4 Effects of 24 h incubation with IFNy, on day 12, on XOR activity in HB4a
cells. XOR activities were monitored as described in Section 3.2.7. Values are
presented as % of the basal activity which is normalised to 100% +/- SEM, n=4.
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XOR activity is seen to be dramatically increased by the administration of IFNy. 
Maximum activity was 7.8 times higher than basal activity at 100 IU/ml which was 
statistically significant, as assessed using the students T-test (p < 0.05). This is a much 
greater increase than those seen with the previous cytokines.
5.2 The effect of combinations of cytokines on XOR activity in HB4a cells
Cytokines rarely act alone in vivo. TNFa and IL-ip often act synergistically, for 
example promoting the expression of adhesion molecules and other cytokines (Baumann 
et a l, 1989, Pober & Cotran, 1990; Kuby, 1991). TNFa and IFNy are also known to 
act synergistically to increase the expression of adhesion molecules and MHC molecules, 
and together have been implicated in chronic inflammation (Pober & Cotran, 1990; 
Kuby, 1991). Various combinations of cytokines were therefore added to the HB4a cells 




Fig. 5.5 Effects o f 24 h incubation with a combination o f TNFa (50 IU/ml) and IL -lp  
(100 IU/ml), added on day 12, on XOR activity in HB4a cells. XOR activities were 
monitored as described in Section 3.2.7. Values are presented as % o f the basal activity 
which is normalised to 100% +/- SEM, n=4.
The combination of IL-ip and TNFa (Fig. 5.5) gives an additive increase in XOR 
activity but not a synergistic increase.
The combination of the two cytokines thought to be primarily involved in chronic 
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Fig. 5.6 Effects o f 24h incubation with a combination o f TNFa (50 IU/ml) and IFNy 
(100 IU/ml), added on day 12, on XOR activity in HB4a cells. XOR activities were 
monitored as described in Section 3.2.7. Values are presented as % o f the basal activity 
which is normalised to 100% +/- SEM n=2 for TNFa and IFNy and n=6 for
combination.
Fig. 5.6 shows that these two cytokines also gave an additive, but not a synergistic, 
increase in XOR activity.
Finally, a combination of the three cytokines were added to the cultures at the doses that 





Fig. 5.7 Effects o f24h  incubation with IL-lfi (100 IU/ml), TNFa (50 IU/ml) and IFNy 
(100 IU/ml) and a combination o f the three, added on day 12, on XOR activity in 
HB4a cells. XOR activities were monitored as described in Section 3.2.7. Values are 
quoted as a percentage o f the basal activity which has been standardised to 100%, +/-
SEM n=5.
Fig 5.7 shows the effects of adding EFNy, TNFa and EL-1{3, and Fig 5.8 the effects of 
TNFa, EL-lp and EL-6. In both studies the effects appeared to be strictly additive with 





Fig. 5.8 Shows XOR activity in HB4a cells when stimulated for 24h with TNFa (50 
IU/ml), IL-6 (100 IU/ml) and IL -lp  (100 IU/ml) and a combination o f the three, added 
on day 12. XOR activities were monitored as described in Section 3.2.7. Values are 
quoted as a percentage o f the basal activity which has been standardised to 100%,
Average n=2.
5.3 Effects of cytokines on percent oxidase XOR activity in HB4a cells
Cytokines have been reputed to influence dehydrogenase to oxidase conversion of XOR 
in endothelial cells (Friedl et al., 1989) and evidence for such conversion was sought in 
the present studies.
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5.3.1 Addition of dithiothreitol (DTT)
Several groups in the field include concentrations of DTT ranging from 1 mM (Terada 
& Arnold 1993; Paler-Martinez et a l, 1994) to 10 mM DTT (Kurosaki et a l, 1995) in 
their assay buffers. DTT reduces the disulphide bonds in XOR to sulphydryl groups, 
thereby converting reversible oxidase XOR to the dehydrogenase form. Absence of DTT 
in the sample preparation may result in a higher oxidase activity due to reversible D to O 
conversion occurring during experimental procedures.
The inclusion of DTT in the samples therefore allows the measurement of any 
irreversible D to O conversion brought about by the cytokines.
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TNFa (IU/ml) and DTT (ImM)
Fig. 5.9 Shows percentage oxidase XOR activity in HB4a cells when incubated with 
TNFa (50 IU/ml) and DTT (ImM) for 24h, added on day 12. XOR activities were 
monitored as described in Section 3.2.7. Values quoted as a percentage o f the total 
activity, where the basal total XOR activity has been standardised to 100% +/- SEM
n=3.
A comparison was made between the pattern of oxidase activity with (Fig. 5.9) and 
without DTT (Fig. 5 .10), on incubation with TNFa.
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Fig. 5.10 Shows percentage oxidase XOR activity in HB4a cells when incubated with 
TNFa for 24h, added on day 12. XOR activities were monitored as described in 
Section 3.2.7. Values quoted as a percentage o f the total activity, where the basal total 
XOR activity has been standardised to 100% +/- SEM n=3.
As can be seen from Figs. 5.9 and 5.10 DTT has little effect on the oxidase activity 
measured in the samples, showing the reversible D to O conversion in the samples not to 
be significant. The results also indicate that TNFa does not mediate reversible D to O 
conversion.
Dose-response oxidase activity assays were carried out with the other cytokines used 
previously, in the absence of DTT.
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Fig. 5.11 Shows percentage oxidase XOR activity in HB4a cells when incubated with 
IFNy, added on day 12, for 24h. XOR activities were monitored as described in 
Section 3.2.7. Values quoted as a percentage o f the total activity, where the basal total 
XOR activity has been standardised to 100% +/- SEM n=3.
Fig. 5.11 indicates that IFNy appears not to significantly influence the percentage 
oxidase activity.
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Fig. 5.12 Shows percentage oxidase XOR activity in HB4a cells when incubated with 
IL-Ip for 24 h, on day 12. XOR activities were monitored as described in Section
3.2.7. Values quoted as a percentage o f the total activity, where the basal total XOR 
activity has been standardised to 100% +/- SEM n=3.
5.4 The effect of combinations of cytokines on percent oxidase XOR activity in 
HB4a cells
The effect of various combinations of cytokines on oxidase activity was investigated.
The results, shown in Figs. 5.13 and 5.14, give no indication of significant cytokine- 




Fig. 5.13 Illustrates the percentage oxidase activity o f HB4a cells with a combination 
o f TNFa (50 IU/ml) and 1L-1/3 (100 IU/ml), added on day 12, after incubation for 
24h. XOR activities were monitored as described in Section 3.2.7. Values quoted as a 
percentage o f the total activity, where the basal total XOR activity has been 
standardised to 100% +/- SEM n=3.
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control
Fig. 5.14 Illustrates the percentage oxidase activity in HB4a cells with a combination 
o f IFNy (100 IU/ml), TNFa (50 IU/ml) and IL -lp  (100 IU/ml), added on day 12, after 
incubation for 24 h. XOR activities were monitored as described in Section 3.2.7. 
Values quoted as a percentage o f the total activity, where the basal total XOR activity 
has been standardised to 100% +/- SEM n=4.
5.5 Effects of the anti-inflammatory cytokine 1L-13 on XOR activity in HB4a cells
IL-13 is an anti-inflammatory cytokine that is produced by Th cells, and inhibits the 
release and activation of inflammatory cytokines (Kuby, 1991). The XOR activity of 
HB4a cells was measured when the cells were stimulated with IL-13, with and without 
the addition of inflammatory cytokines TNFa or IFNy. The results, shown in Figs. 5.15
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and 5.16, indicate that IL-13 has little effect on XOR activity either alone or in 
combination with inflammatory cytokines. Nor did higher doses alter this conclusion 
(Fig, 5.17).
250 t
control TNF IL-13 TNF +
IL-13
Fig. 5.15 Illustrates XOR activity in HB4a cells incubated for 24 h with IL-13 (5 ng/ml) 
and TNFa (50 IU/ml) , added on day 12. XOR activities were monitored as described 
in Section 3.2.7. Values quoted as a percentage o f the basal activity standardised to
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Fig. 5.16 Illustrates XOR activity in HB4a cells incubated for 24 h with IL-13 (5 ng/ml) 
and IFNy (100 IU/ml), added on day 12. XOR activities were monitored as described 
in Section 3.2.7. Values quoted as a percentage o f the basal activity standardised to
100 % +/- SEM n=7.
Chapter 5 78
800 -j
»  700 '
©
£  600 - e u




|  300 - 
OS 200 -o
*  100 -
0 -
Control IFN IL-13 IL-13 Both Both
lOng 15ng (lOng) (15ng)
Fig. 5.17 Illustrates XOR activity in HB4a cells when incubated with IFNy (100 IU/ml),
IL-13 10 ng/ml or 15 ng/ml or a combination o f IFNy and IL-13, added on day 12, for
24 h. XOR activities were monitored as described in Section 3. 2.7. Values quoted as a
percentage o f the basal activity standardised to 100 %.
Average n=2.
5.6 Discussion
The results presented in this chapter show that the XOR activity in HB4a cells is
significantly increased after 24 h when the cells are stimulated with the inflammatory
cytokines IL-ip, IFNy and TNFa. No significant increase was observed with IL-6. At
optimal doses of TNFa and IL-lp the enzymic activity was induced 200-250% over
basal activity. At the optimum dose, IFNy induced XOR activity by 750-800%; the





observed in non-human cell lines (Dupont et a l, 1992; Falciani et al., 1992). While 
Pfeffer et a l (1994) have reported increases in XOR activity in bovine renal epithelial 
cells with TNFa and IL-lp similar to those seen in this report; the induction of activity 
by IFNy in their studies was markedly less than the 8 fold increase with the HB4a human 
cell line observed here.
The various combinations of the cytokines used to stimulate HB4a cells gave rise to 
increases in XOR activity that were additive, as also found by Pfeffer et al. (1994) with 
the bovine cell line.
The measurement of the percentage oxidase activity of cytokine-induced cells was of 
particular interest because of the capacity of the oxidase form of the enzyme to produce 
ROS. The dehydrogenase to oxidase conversion has been cited as a trigger for 
inflammatory signal transduction (Friedl et a l, 1989; Bulkley et a l, 1993). However, 
activities elicited by the cytokines individually, and in combination, revealed that they 
had no significant regulatory effect on the percentage of oxidase activity, and were 
therefore not involved in a D to O conversion of the enzyme in this system.
XOR is the only enzyme responsible for catalysing the production of urate, which can be 
regarded as an anti-inflammatory agent because of its antioxidant properties. It was, 
accordingly, of interest to establish whether the increase in XOR activity was an anti­
inflammatory response resulting in an increased production of urate. IL-13 was shown 
to have little effect on XOR activity in HB4a cells. These results are similar to those 
seen by Flanders et a l (1997) when using the anti-inflammatory cytokine, transforming 
growth factor-P (TGFp). They showed that neither XOR activity nor mRNA was 
significantly affected by TGFP, and the cytokine was able to diminish XOR activity
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induced by IFNy, thus indicating that the increase in XOR activity induced by the 
inflammatory cytokines was more likely to be involved in inflammatory processes.
Taken as a whole, the results described in this chapter indicate that the significant 
induction of XOR activity in this cell line suggests a role for XOR in the inflammatory 
response which does not involve upregulation of the percentage oxidase activity.
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6.0 Mechanisms of Regulation of XOR Activity in HB4a Cells
6.1 Introduction
It has been established in Chapter 5 that XOR activity is upregulated by certain 
inflammatory cytokines. The upregulation could be possible via de novo protein 
synthesis and/or post-translational activation of a pool of inactive XOR protein. As 
described in the Introduction, significant proportions of inactive XOR comprising of 
demolybdo or desulpho forms of the enzyme occur in other systems. In human milk 
there is evidence of hormonally driven post-translational activation-deactivation cycles, 
involving increases in the activity of the enzyme, but not protein content (Brown et al, 
1995). In this chapter are described investigations carried out to establish the mechanism 
of upregulation of XOR activity by the cytokines.
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6.2 Detection of XOR protein
The XOR protein content of the cell cytosolic fraction of BRLE cells and HB4a cells 
was assessed qualitatively using SDS-PAGE methods and Western blots. Fractions were 









A) 1 2 3 4 B) 1 2 3 4
Fig. 6.1 A) Coomassie stained SDS-PAGE gel, lane 1; high molecular weight markers, 
lane 2; purified HXOR, lane 3; BRLE cells, lane 4; HB4a cells. B) shows a Western 
blot using anti-HXOR antibodies lane 1 markers, lane 2; BXOR, lane 3; BRLE cells,
lane 4; HB4a cells.
Fig. 6.1 shows that XOR protein, the characteristic band at 150 kDa and lower 
proteolysis bands, were detected in both BRLE cells and HB4a cells using the Western 
blot. The amount of protein in both cell lines detected was very low.
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6.2.1 Immunoprecipitation
In order to maximise the detection of the small quantity of XOR protein in the cytosolic 
samples which contained large amounts of total protein, a method of 
immunoprecipitation was employed. The method was as described in Section 3.2.16 
using the same antibodies as in the Western blot. It also provided a second method of 









1 2  3 4
Fig. 6.2 SDS-PAGE of immunoprecipitate from HMXOR solution. Lane 1; 
immunoprecipitated HMXOR, lane 2; high molecular weight markers, lane 3; 
HMXOR and lane 4; immunoprecipitated HMXOR.
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Fig. 6.2 shows that XOR protein can be immunoprecipitated from a solution by anti- 
HXOR antibodies, the band apparent at around 50 kDa is the heavy chain IgG. This 
technique has been used to immunoprecipitate out XOR activity from cell cytosolic 
samples. Control HB4a samples had XOR activities of 0.74 pmol min*1 mg*1 +/- 0.04 
(+/- SEM n=2) and IFNy stimulated HB4a samples had XOR activities of 3.19 pmol 
min*1 mg' 1 +/- 1.22 (+/- SEM n=2) before immunoprecipitation. After
immunoprecipitation XOR activities of these samples were reduced to 0.
Unfortunately in this study the XOR protein from cell samples was not detected on 
SDS-PAGE or Western blots. However, XOR protein has previously been 
immunoprecipitated from an HB4a cell cytosolic sample by my colleague, Dr 
Benboubetra, who used antibodies developed using the same method (Page et al, 
1998).
Both the results seen from the Western blot and from the immunoprecipitation illustrate 
that the antibodies are specific to XOR and can therefore be used in the ELISA.
6.2.2 ELISA
Scale up of the HB4a cultures from 75 cm2 flasks to 300 cm2 flasks enabled the same 
sample to be used for detection of XOR activity, mRNA and protein, thereby minimising 
errors. Measurement of these three parameters was undertaken in order to indicate how 
the XOR activity was upregulated on stimulation with cytokines.
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An ELISA was carried out enabling a quantitative measurement of XOR protein in the 
cell samples. Polyclonal anti-human XOR antibodies were used in the ELISA as 
described in Section 3.2.12.
Control TNFa IFNy
XOR activity (% of 
basal activity)
100  (+/- 0 ) 210 (+/- 30.5) 7 4 4  (+/-175)
XOR protein (ng 
XOR/mg total 
protein)
83.4 (+/- 18.1) 70.5 (+/- 10.3) 274 (+/- 44.3)
Table 6.4 XOR activity and XOR protein o f HB4a cells stimulated with TNFa (50 
IU/ml) and IFNy (100 IU/ml). Results are determined as described in Section 3.2.7. & 
3.2.12. XOR activity is presented as a percentage o f basal activity which is normalised
to 100%, (+/- SEM n=3).
Table 6.4 shows that the XOR activity increases two fold on stimulation with TNFa and 
seven fold with IFNy as previously found (see Chapter 5) confirming that the percentage 
upregulation of XOR activity is not affected by scaling up the culture.
However, the upregulation of XOR protein on stimulation with TNFa is similar to 
control values, and on stimulation with IFNy the protein is upregulated only two fold. 
These are very interesting results as they suggest that the upregulation in activity is only 
partly due to de novo synthesis and the remainder could be due to post-translational 
activation of an inactive pool of protein already present in the cells. The XOR protein
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values obtained for control cells indicate that the HB4a cell line contains XOR of 
specific activity similar to that in human milk. To directly compare the specific activities 
of the human epithelial cell XOR with human milk XOR it was necessary to compare the 
pterin assay used to measure the cell XOR and the urate assay used to measure the milk 
XOR
6.3 Pterin and urate assays
Parallel assays on purified human milk enzyme were carried out, in order to compare the 
kinetic parameters of the substrates, pterin and xanthine.
Fig. 6.3 V versus S plot o f data obtained using 0.25 pM -lOOpM pterin in the pterin 
assay as described in Section 3.2.7. The average rate at JOOpMpterin was 70 nmol 
min1 m g1 isoxanthopterin, whereas at 0.25pM pterin it was 2 nmol min1 m g1
isoxanthopterin.
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Fig. 6.4 V versus S plot o f data obtained when using 2pM -IOOjuM  xanthine in the 
urate assay as described in Section 3.2.8. The average rate at 100pM xanthine was 65 
nmol min1 mg1 urate, whereas at 2pM xanthine it was 12 nmol min1 m g1 urate.
From the data shown in Figs. 6.3 and 6.4, direct linear plots (Enzpak 3) gave the Km of 
pterin as 0.888 pM and as 7.83 pmol min^mg'1 .Corresponding values for xanthine 
was Km 7.22 pM and Fmax of 71.6 pmol min^mg'1 . These data show that calculations of 
specific activities determined using the pterin assay are approximately 8 times lower than 
those calculated using the urate assay.
The specific XOR activity of the human cell line, when conversion is taken into account, 
is 94.9 nmol min'1 mg'1. This value is comparable with that of human milk XOR, 62 +/- 
22 nmol min'1 mg'1 (+/-SEM n = ll) and much lower than values found for bovine milk 
or rat liver enzymes (3000-5000 nmol min'1 mg'1) (Bray, 1975)
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6.4 The effects of cycloheximide on XOR upregulation by cytokines
A further experiment was undertaken to establish whether the upregulation of XOR 
activity on the addition of cytokines resulted from de novo protein synthesis or from 
activation of protein already present. The protein synthesis inhibitor cycloheximide was 
added to the cultures, and XOR activity was measured. Activity of cycloheximide is 
limited to eukaryotic cells and cytosolic ribosomes, where it inhibits the peptidyl 
transferase activity of the 60S ribosomal subunit.
HB4a cultures were treated with cycloheximide 30 min before the addition of cytokines. 
The cells were then harvested and assayed in the normal way after 24 h incubation.
cycloheximidecontrol
Fig. 6.6 XOR activity o f HB4a cells after addition of TNFa (50 IU/ml) and 
cycloheximide (20fig/ml) and a combination o f the two, added on day 12. Activities 
were determined as described in Section 3.2.7. Results are presented as pmoles min1
m g1 n=2 +/- SEM.
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Fig. 6.6 shows that cycloheximide has a significant effect on the upregulation of XOR 
















Fig. 6.7 X07? activity of HB4a cells after addition o f IFNy (100 
IU/ml) and cycloheximide (20pg/ml) and a combination of the two, added on day 12. 
Activities were determined as described in Section 3.2.7. Results are presented as
pmoles min1 m g1 n=5 +/- SEM.
Fig. 6.7 shows again that the addition of cycloheximide results in the reduction of the 
cytokine-mediated increase in XOR activity. However, in this case the combination of 
cycloheximide and EFNy gives a slightly higher activity than treatment with
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cycloheximide alone. The remainder may be due to the post-translationally activated 
XOR
These results suggest that the majority of the XOR increase induced by cytokines is due 
to de novo protein synthesis, either of XOR itself or a regulatory protein.
6.5 The effect of sodium molybdate on XOR upregulation
Post-translational activation of XOR protein has been observed in the mouse cell line, 
L929, following addition of sodium molybdate (Falciani et al., 1994). The possibility 
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Fig. 6.9 XOR activity of HB4a cells after addition of sodium molybdate (lOmM).
Activities determined as described in Section 3.2.7. Results are presented as pmoles
min1 mg1 n=4 +/- SEM.
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Fig 6.9 shows that the addition of sodium molybdate to HB4a cells does not upregulate 
XOR activity. Sodium molybdate was administered to the cultures for 48 h, and the 
XOR activity measured. Activity of the treated cells (0.3 pmol min*1 mg'1) was similar to 
that found with control cells (0.29 pmol min'1 mg'1 (data from one experiment)). Sodium 
molybdate was also added to the cultures at a concentration of 20mM for 24 h, this led 
to a decrease in the viability of the cells and XOR activities could not be measured.
These results indicate that sodium molybdate has little effect on XOR activity in this cell 
line.
6.6 Discussion
This chapter describes the detection of XOR protein in HB4a cells and BRLE cells by 
Western blotting. Quantitative detection of XOR protein in HB4a cells revealed the 
specific activity of HB4a cells to be very low, similar to that seen with the human milk 
enzyme. The low specific activity of the HMXOR has been shown to result from a high 
content of naturally occurring inactive forms, particularly the demolybdo enzyme 
(Godber et al., 1997). It seemed likely that the XOR in HB4a cells could have a similar 
composition of inactive forms, providing a potential for activation in response to 
physiological requirements. Possible mechanisms of post-translational activation in 
HB4a cells were investigated. In view of the findings by Falciani et a l (1994) that XOR 
enzymic activity of the mouse cell line, L929, was only expressed following addition of 
sodium molybdate, addition of the latter to HB4a cell cultures was investigated, but 
found to have little effect on XOR activity. This result is consistent with the proposal by
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Falciani et a l (1994) that upregulation of activity in the L929 cells reflects a cell line 
specific deficiency in molybdenum incorporation, as in their hands no other cell line 
showed a similar increase in response to sodium molybdate.
Evidence for post-translational activation of XOR in HB4a cells was obtained in the case 
of the inflammatory cytokines IFNy and TNFa. ELISA showed that the IFNy-induced 
7-8 fold upregulation of enzymic activity was matched by only 2-3 fold increase in XOR 
protein. This result corresponded to mRNA studies (Dr F. Selase) indicating a 2-3 fold 
increase in mRNA in IFNy treated HB4a cells (Page et a l, 1998). The increase in 
activity of TNFa stimulated cells seems to be entirely due to post-translational 
activation of the enzyme. This apparent post-translational activation was further 
investigated by the treatment of cultures with cycloheximide. While the results point to 
involvement of protein synthesis in cytokine-mediated upregulation of XOR activity, the 
protein concerned could be either XOR itself or a protein needed to upregulate the 
enzyme.
The apparent 2-3 fold post-translational activation of XOR by inflammatory cytokines in 
HB4a cells could be explained by desulpho-sulpho conversion. Incorporation of sulphur 
catalysed by an unspecified enzyme has been proposed as a post-translational activation 
mechanism for diet-induced activation of XOR in rat and chicken liver (Itoh et a l, 1978; 
Furth Walker & Amy, 1987), and chemically-driven desulpho-sulpho conversions can be 
readily effected in vitro (Wahl & Rajagopalan, 1982).
The high proportion of demolybdo enzyme in HMXOR, and the similarities discussed 
earlier with the HB4a enzyme, suggest that an enzyme-catalysed mechanism of 
incorporation of molybdenum or its cofactor could be possible. However, to date there 
is no precedent for this mechanism. Nevertheless, the results presented in this chapter do
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support the concept that human XOR of low specific activity may be subject to various 
forms of upregulation in a physiological context (Harrison, 1997).
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7.0 immunolocalisation of XOR in Epithelial Cells
7.1 Introduction
In spite of the many techniques that have been used to establish the distribution of XOR 
in a variety of tissue types, there are few published investigations of its precise 
subcellular localisation. The enzyme is generally understood to be cytosolic (Jarasch et 
a l, 1981; Ichikawa et a l, 1992), although, Bruder et a l (1982) detected XOR protein 
both in the cytoplasm and tightly associated with membrane surfaces in mammary 
epithelial and capillary endothelial cells. Moreover, Angermuller et a l (1987) reported 
peroxisomal as well as cytoplasmic localisation for XOR within rat and bovine liver 
cells.
The subcellular localisation of the human enzyme is of particular interest in view of its 
anomalous characteristics and ambiguous physiological role. In the present work 
confocal microscopy was used in a study of human and rat epithelial cells.
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7.2 Distribution of XOR in permeabilised HB4a cells
HB4a monolayers were grown on chamber slides and permeabiiised cells were subjected 
to immunolocalisation as described in Section 3.2.19.
The results are presented in Fig. 7.1.
XOR appears to be distributed throughout the cytoplasm, with more intense 
fluorescence around the perinuclear region in some instances.
7.3 Distribution of XOR in unpermeabilised HB4a cells
HB4a monolayers were grown on chamber slides and unpermeabilised cells were 
subjected to immunolocalisation as described in Section 3.2.19.
The results are presented in Fig. 7.2.
Immunolocalisation in the unpermeabilised cells clearly shows the presence of XOR on 
the surface of cells, with distribution being localised asymmetrically to specific areas of 
the cell surface.
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Fig 7.1 Distribution of XOR in permeabilised HB4a cells.
Immunofluorescent (A,C,F) and DIC (B,D,G) with overlay (E,H) images are shown. 
Magnification x 630 (A,B) and x 400 (C-H), bar 20um.
For experimental detail see Section 3.2.19.
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Fig. 7.2 Distribution of XOR in unpermeabilised HB4a cells. Immunofluorescent (A,D,F) and DIC (B,E,G) 
with overlay (C), images are shown. Magnification x 400 (A-C,F,G), bar 20um, x 640 (D,E)
For experimental details see Section 3.2.19.
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7.3.1 Controls
To ensure that the surface XOR had not come from extraneous sources, a number of 
control experiments were undertaken. The cells were tested to ensure that they were 
indeed unpermeabilised. Two methods were used. Firstly, the cells were incubated with 
anti-TGN antibody (anti-TGN 38), specific for intracellular golgi compartments (Fig. 
7.3). Secondly, the monolayer was washed with trypan blue, a dye that can only enter 
permeabilised cells (results not shown). These results confirm that the cells are 
unpermeabilised.
To ensure that there was no non-specific binding to the monolayer, the cells were 
incubated with secondary antibody only (Fig. 7.3).
Growth medium and FCS were tested for XOR activity using the pterin assay and found 
not to contain active XOR, although this did not preclude the presence of inactive XOR 
protein.
To ensure that the growth medium or blocking serum did not contain trace amounts of 
XOR, heparin-agarose beads were incubated with these solutions and also with BXOR 
as a positive control. Immunolocalisation studies were carried out on the beads as 
described in Section 3 and the results are presented in Fig. 7.4. Images A and B show 
that XOR binds to heparin beads, and images C-F show that there is no XOR protein 
detected by immunofluorescence in the medium or goat serum.
Cells were also grown in medium which had previously been passed down a heparin 
agarose column (preabsorbed medium). These were compared with cells that had been 
grown in normal medium and found to have identical fluorescence. The results are 
presented in Fig. 7.5
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Fig. 7.3 Distribution of TGN-38 in permeabilised (A,B) and unpermeabilised (C,D) HB4a cells. 
Permeabilised HB4a cells incubated with 2nd FITC antibody alone (E,F) .
Immunofluorescent (A,C,E) and DIC (B,D,F) images are shown. Magnification x 400 (A-F), bar 20um 




Fig. 7.4 Control experiments using heparin-agarose beads for 24 h.
Immunofluorescent (A,C,E) and DIC (B,D,F) images are shown.
Beads incubated with BXOR (A,B), medium (C,D) and goat serum (E,F). Magnification x 100. 






Fig 7.5 Distribution of XOR in unpermeabilised HB4a cells incubated 
with preabsorbed medium (A,B) and normal medium (C,D). 
Immunofluorescent (A,C) and DIC (B,D) images are shown. 
Magnification x 400. For experimental details see Section 3.2.19
B
Fig 7.11 Distribution of XOR (green) and TGN-38 (red) in permeabilised 
HB4a cells (A,B)
Immunofluorescent (A) and DIC (B) images are shown.
Magnification x 630. For experimental details see Section 3.2.19
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7.4 Investigations into the subcellular localisation of XOR
The protein synthesis inhibitor, cycloheximide, was used to try to establish whether the 
perinuclear XOR observed in permeabilised cells was associated with the endoplasmic- 
reticulum permanently, or as the protein was being processed.
Firstly, it was necessary to establish when all the de novo XOR would be cleared from 
the cell. This was done by treating HB4a cultures with cycloheximide for various 
periods before harvesting and assaying for XOR activity, as described in Section 3.2.7.
control 4 hours 24 hours 48 hours
Fig. 7.6 XOR activity of HB4a samples 4, 24 and 48 h after addition of cycloheximide
(20pg/ml), on day 12. Activities determined as described in Section 3.2.7. Results are
presented as pmoles min1 m g1 n=3 +/- SEM.
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Fig. 7.6 shows that the XOR activity is reduced by 50% after 24 h and around 75% by 
48 h. There is a small increase in XOR activity after 4 h, which may indicate the 
presence of an XOR repressor protein, although this increase was not shown to be 
significant
Permeabilised (Fig. 7.7) and unpermeabilised (Fig. 7.8) HB4a cell monolayers were then 
treated with cycloheximide for 24 h prior to immunolocalisation, as described in Section 
3. The images show that there is slightly less XOR protein in the permeabilised cells but 
the pattern of localisation is not affected. The pattern and intensity of fluorescence in the 
unpermeabilised cells are similar to that of controls.
HB4a cells were also incubated with cycloheximide for 48 h and, as seen in the previous 
images, the pattern of XOR distribution remains the same, although, the intensity of 
fluorescence in both the permeabilised (Fig. 7.9) and unpermeabilised cells (Fig. 7.10) is 
lower than that seen in the controls.
A further method was employed to try to establish whether the XOR protein was inside 
the transgolgi network or truly perinuclear. An antibody to the transgolgi network (anti- 
TGN 38) was used in conjunction with anti-XOR antibodies (Fig. 7.11, p. 101).
The images show that XOR and TGN 38 are closely linked in their localisation. Further 
co-localisation investigations need to be carried out to clarify the distribution of XOR 
protein.
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Fig. 7.7 Distribution of XOR in permeabilised HB4a cells, control (A-C) and treated 
with cycloheximide (20ug/ml) for 24 h (D-I).
Immunofluorescent (A,D,G) and DIC (B,E,H) and overlay (C,F,I) images are shown. 
Magnification x 400. bar 20um. For experimental details see Section 3.2.19.
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Fig. 7.8 Distribution of XOR in unpermeabilised HB4a cells, control (A-C) and treated 
with cycloheximide (20ug/ml) for 24 h (D-l).
Immunofluorescent (A,D,G) and DIC (B,E,H) and overlay (C,F,I) images are shown. 
Magnification x 400. bar 20um. For experimental details see Section 3.2.19.
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Fig. 7.9 Distribution of XOR in permeabilised HB4a cells, control (A-C) and treated 
with cycloheximide (20ug/ml) for 48 h (D-I).
Immunofluorescent (A,D,G) and DIC (B,E,H) and overlay (C,F,I) images are shown. 
Magnification x 400. bar 20um. For experimental details see Section 3.2.19.
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Fig. 7.10 Distribution of XOR in unpermeabilised HB4a cells, control (A-C) and treated 
with cycloheximide (20ug/ml) for 48 h (D-I).
Immunofluorescent (A,D,G) and DIC (B,E,H) and overlay (C,F,I) images are shown. 
Magnification x 400. bar 20um. For experimental details see Section 3.2.19.
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7.5 Intracellular and surface localisation of XOR after cytokine treatment
It was of interest to examine the localisation of XOR protein in the epithelial cells after 
cytokine treatment.
Fig. 7.12 shows permeabilised HB4a cells treated with TNFa or IFNy. The images show 
that TNFa stimulated cells (D-F) appear to have a similar intensity of fluorescence to 
that of controls. However, IFNy stimulated cells (G-I) show a more intense 
fluorescence, approximately double that seen in the control cells (A-C). This is as 
expected from the ELISA results. Fig. 7.13 shows unpermeabilised HB4a cells similarly 
treated with TNFa or IFNy. The intensity of fluorescence in both TNFa (D-F) and IFNy 
(G-I) stimulated cells seems to be higher than that seen in control cells (A-C).
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Fig. 7.12 Distribution of XOR in permeabilised HB4a cells, control (A-C) and treated 
with TNFoc(50 IU/ml) (D-F) or IFNy(100 IU/ml) (G-I) for 24 h (D-I). 
Immunofluorescent (A,D,G) and DIC (B,E,H) and overlay (C,F,I) images are shown. 
Magnification x 400, bar 20um. For experimental details see Section 3.2.19.
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Fig.7.13 Distribution of XOR in unpermeabilised HB4a cells, control (A,C) 
and treated with TNRx(50 IU/ml) and IFNy(100 IU/ml) (G-I) for 24 h. 
Immunoflourescent (A,D,G) DIC (B,E,H,) and overlay (C,F,I) images are shown. 
Magnification x 400, bar 20um. For experimental details see Section 3.2.19.
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7.6 Distribution of XOR on the HB4a cell surface after treatment with 
heparitinase
The presence of XOR protein on the surface of the HB4a cells was further investigated 
using heparitinase. This would provide an indication of how the XOR was attached to 
the cell surface, as heparitinase cleaves heparin-like glycosaminoglycans from the cell 
surface. Cell monolayers were incubated with heparitinase (1 U/ml) for 2 h at 37°C, then 
washed with PBS three times, prior to immunolocalisation.
The results are presented in Fig. 7.14. The images show that heparitinase has little effect 
on the intensity of the fluorescence compared with control cells.
7.7 The distribution of ROS in HB4a cells
The distribution of ROS inside the cell was of interest in relation to the localisation of 
XOR protein, and could give some indication of whether the protein was active, and of 
its possible role in the cell. This was investigated using dihydrorhodamine-1,2,3 which is 
oxidised to fluorescent rhodamine-1,2,3 on reaction with ROS (Rothe et a l, 1988; 
Henderson & Chappie, 1993). As there are many sources of ROS in the cell, allopurinol 
was added as a control. The results are presented in Fig. 7.15.
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(A) (B)
Fig. 7.15 The detection o f ROS within permeabilised HB4a cells. (A) shows cells 
incubated with dihydrorhodamine-1,2,3 (24pM) for 45 min. (B) shows cells incubated 
with allopurinol (50pm) for 24 h, prior to incubation with dihydrorhodamine-1,2,3 
(24pM) for 45 min. Magnification x 400. Other experimental details are described in
Section 3.2.19.
As the images show, the fluorescence in the cells with allopurinol is slightly more 
intense, suggesting that the XOR in the cells contributes very little towards the total 
ROS produced within a cell.
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G H
Fig.7.14 Distribution of XOR in unpermeabilised HB4a cells, control (A-C) 
and treated with heparitinase (1 IU/ml) (D-I). Immunofluorescent (A,D,G) 
and DIC (B,E,H) and overlay (C,F,I) images are shown.
Magnification x 400, bar 20um. For experimental detail see Section 3.2.19.
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7.8 Localisation of XOR in BRLE cells
The localisation of XOR in BRLE cells was investigated.
The results are presented for permeabilised cells in Fig. 7.16 and unpermeabilised cells in 
Fig. 7.17. The images show XOR on the cell surface, and that permeabilised and 
unpermeabilised cells have similar distribution patterns to that seen in the HB4a cells. 
However, the DIC images of unpermeabilised BRLE cells appear to show some 
disrupted cells, and further studies should be carried out to optimise conditions for 
immunolocalisation in these cells, minimising cellular damage.
Chapter 7
Fig.7.16 Distribution of XOR in permeabilised BRLE cells. 
Immunofluorescent (A,C) and DIC (B,D) images are shown.
Magnification x 400, bar 20um. For experimnetal details see Section 3.2.19
Chapter 7
Fig. 7.17 Distribution of XOR in unpermeabilised BRLE cells. 
Immunofluorescent (A,C) and DIC (B,D) images are shown.
Magnification x 400, bar 20um. For experimental details see Section 3.2.19.
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7.9 Cell surface XOR activity
The demonstration of XOR on the surface of the cells led to investigations into whether 
the enzyme protein was active. HB4a monolayers were incubated with heparin in order 
to detach XOR from the cell surface. The total XOR. activity was measured using the 
pterin assay (Fig. 7.18). This was also carried out with heparinase, as heparitinase was 
limited by supply (Fig. 7.19).
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Fig. 7.18 XOR activity in HB4a cells incubated with heparin (JOmg/ml) at 4°C for 10 














Fig. 7.19 XOR activity o f HB4a cells incubated with heparinase (2 IU/ml) at 3TC for 
2h. Activities were determined as described in Section 3.2.7. +/- SEM n=2.
Fig. 7.18 shows that incubation with heparin does not appear to remove any 
extracellular XOR. Fig. 7.19 shows that the difference between control and heparinase 
incubated cells was not significant.
A preliminary attempt was also made to detect NADH oxidase activity on the surface of 
the cells. The depletion of NADH in supernatant over HB4a cell monolayers was 
measured at time points over 6 h. As cells contain many enzymes with NADH oxidase 
activity, controls consisting of monolayers with substrate and anti-XOR antibodies were 
measured at the same time.
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Fig. 7.20 Depletion o f NADH (500pM) at 30° C, measured at 340 nm, in fixed 
monolayers o f HB4a cells alone (Sample) and with anti-XOR antibodies (Control).
Data from one experiment.
Fig. 7.20 demonstrates the difficulty in measuring extracellular XOR activity. There 
appears to be more NADH depletion where anti-XOR antibodies are present, indicating 
that the controls are not working, or that the amount of NADH oxidase activity 
produced by XOR is negligible.
7.10 Discussion
This chapter describes the subcellular localisation of XOR in HB4a cells and BRLE 
cells. The XOR in permeabilised HB4a cells appears to be distributed throughout the 
cytosol with more intense fluorescence around the perinuclear region. This perinuclear 
localisation of the enzyme has not been reported previously and is clearly relevant to the 
potential role of XOR-derived ROS in activation of nuclear transcription factors such as
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NF-AB (Pahl & Baeuerle, 1994). In attempts to investigate the precise localisation, the 
cells were incubated with cycloheximide. The addition of cycloheximide to the 
monolayers reduced fluorescent intensity as expected, but did nothing to further clarify 
the subcellular localisation of XOR protein. Co-localisation studies with TGN-38 
suggest that XOR protein is within the golgi apparatus. The introduction of 
cycloheximide into this co-localisation system would be of interest. The distribution of 
ROS in the cell was also investigated with the prior addition of allopurinol, but no 
discernible pattern was seen. It should be noted that the ROS produced by the NADH 
oxidase activity of the enzyme would not have been inhibited by allopurinol.
XOR protein was detected on the surface of unpermeabilised HB4a cells. While 
extracellular localisation of the enzyme has previously been briefly reported on 
endothelial cells (Bulkley, 1991; Schiller et al., 1991) the present studies represent the 
first detailed investigations into the localisation of XOR on any cell type. Several 
methods were employed to eliminate the possibility that the surface XOR was derived 
from exogenous sources. Growth media did not contain XOR activity as determined by 
the pterin assay, although this did not exclude the possibility of small amounts of XOR 
being present. Concentration of possible low amounts XOR in the media was attempted 
using a heparin column. No activity was detected on elution of the column (results not 
shown), nor was there any difference in fluorescent intensity in cells grown with or 
without the preabsorbed media. The XOR may have originated from lysed neighbouring 
cells, but this is unlikely in that cells were in the log phase of growth and more than 98% 
viable. Moreover, the majority of non-viable cells would have been removed during the 
procedure for immunolocalisation.
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If the extracellular XOR is an endogenous enzyme then the mechanisms of its secretion 
must be explained. The classical secretion of proteins is from the endoplasmic reticulum 
via the golgi apparatus to the plasma membrane: a process controlled by means of a 
cleavable signal peptide (Rapoport, 1992). Human XOR has no signal peptide and is not 
known to be glycosylated (Ichida et a l, 1993; Xu et a l, 1994); a consequence of the 
classical secretory pathway. However, an increasing number of proteins are being shown 
to be secreted without glycosylation or signal peptides (Kuchler, 1993), and it is possible 
that XOR is processed via this non-classical pathway. The relatively high affinity of 
XOR for heparin (Fukushima et a l, 1994) is interesting in view of a suggestion that 
muscle L-14 lectin, exported by a non-classical pathway, could thereby be separated 
from glycoconjugates (with which it interacts) until after its secretion (Cooper & 
Barondes, 1990). Similar considerations could apply to XOR, which may bind to surface 
glycosaminoglycans following secretion (Radi et a l, 1996). Binding of extraneous 
HXOR to porcine endothelial cells has been found by Adachi et a l (1993) to be 
inhibitable by addition of heparin or pre-treatment of the cells with heparitinase or 
heparinase. Heparin was used here to try to detach endogenous surface XOR from the 
HB4a cell, as were heparinase and heparitinase. However, none of these experiments 
was conclusive in determining whether the XOR was bound to glycosaminoglycans or 
whether the protein was in an active form.
The distribution and quantity of XOR in HB4a cells after cytokine treatment was further 
investigated. The intensity of fluorescence increased on treatment with IFNy and TNFa 
by around 2 fold, as expected from ELISA results, which indicated a 2-3 fold increase in 
XOR protein. While this was clear with the unpermeabilised cells, the intensity was not 
as much as expected with the permeabilised cells, especially on stimulation with TNFa.
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This may be due to their stage of growth. As previously seen in Chapter 4, upregulation 
of XOR activity does not occur until the stationary phase of growth. Stationary phase 
monolayers were too crowded to enable clear study of XOR distribution using this 
technique and, a compromise between stage of growth and clarity had to be achieved. 
The distribution of XOR between the surface and the cytosol appears not to be altered 
by stimulation with inflammatory cytokines, but there are indications that XOR protein 
appears initially on the surface of the cell when stimulated with cytokines. It would be 
interesting to carry out a time course to discover at which stage and where, the XOR 
appeared in the cell.
The results presented in this chapter demonstrate the presence of both cytosolic and 
surface XOR in BRLE cells. However, the cells appear to be disrupted and further 
investigation is required to find a less aggressive method of immunolocalisation.
The images suggest a diffuse cytosolic, and more localised perinuclear distribution for 
intracellular XOR in HB4a cells, and an asymmetrical distribution of XOR on the cell 
surface which strongly suggests a role for the enzyme in cell-cell interactions. However, 
the exact localisation of the perinuclear XOR has yet to be determined, as does the 
nature of the extracellular XOR.
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8.0 Discussion
The physiological role of XOR in milk has long been contentious, and the low specific 
activity of the human enzyme for conventional reducing substrates has raised further 
intriguing questions. BMXOR is known to contain approximately 60% inactive enzyme, 
whereas the human XOR is thought to be up to 98% inactive. Such a high proportion of 
inactive enzyme suggests a potential for post-translational activation of XOR by 
pathological or physiological stimuli. Indeed, possible post-translational activation- 
deactivation cycles have been seen in HMXOR (Brown et al., 1995). Regulation of 
XOR enzymic activity by inflammatory mediators has been noted in various non-human 
cell types (see Introduction), and initial studies in our laboratory have shown that XOR 
activity in the human mammary epithelial cell line, HB4a, is elevated in response to IFNy 
(Powell, 1995). The known localisation of XOR to mammary epithelial cells, and their 
involvement in production and secretion of milk proteins, as well as the ability of 
epithelial cells to regulate and respond to various immune and inflammatory mediators, 
has made these cells an interesting system for further investigation into the nature of 
HXOR regulation. In this thesis HB4a cells, and buffalo rat liver epithelial cells (BRLE) 
were studied to explore alternative patho/physiological roles for the enzyme.
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In the present work, XOR activity could be detected in both HB4a and BRLE cells, 
although levels were some 70 fold lower in the human cell line. Determination of XOR 
by ELISA showed that XOR in HB4a cells has very low specific activity, comparable to 
that shown by HMXOR (Chapter 6). The low specific activity of purified HMXOR can 
be attributed to a low Mo content (Godber et a l, 1997), and it seems that, as HMXOR 
is derived from mammary epithelium, a similar situation may prevail in the HB4a cells. 
Falciani et a l, (1994) reported that inactive XOR in the mouse fibroblastic cell line, 
L929, was activated on addition of Mo salts. They concluded that the activation is cell 
line specific, and results from impaired synthesis of Mo cofactor in the enzyme. 
However, an attempt to upregulate HB4a XOR activity in this way met with no success. 
Some information on Mo cofactor biosynthesis and metabolism has come from human 
patients suffering from a rare genetic disease known as ‘combined deficiency of sulphite 
and xanthine oxidase* (Rajagapolan & Johnson, 1992). Investigations using mutant 
strains of prokaryotes (Rajagapolan & Johnson, 1992), indicated that several genes are 
involved in the biosynthetic pathway of Mo pterin cofactor, with the final step in Mo 
pterin biosynthesis being similar to that in humans, involving a precursor and converting 
factor either of which could be deficient in the disease. Although not proven, it seems 
likely that the low specific activity of XOR in HB4a cells can be attributed to low Mo 
content, probably together with low Mo cofactor content. The reasons could be 
complex and may be due to one or many deficiencies in biosynthesis or metabolism of 
the Mo pterin cofactor.
The pattern of XOR activity in relation to cell growth was particularly interesting, 
showing a rapid increase in activity just before confluence and another rise when the
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growth appears to be stationary, suggesting an involvement in the regulation of cell 
growth and/or differentiation. It is tempting to assign a role for XOR-derived ROS in 
these processes. ROS are known to regulate genes involved in cell growth, such as c- 
fos, c-jun and c-myc and the possible involvement of XOR was investigated using 
allopurinol, a specific XOR inhibitor. It was found, however, that allopurinol had no 
effect on cell growth or viability, in contrast to reports by Burdon & Gill (1993), who, 
using HeLa cells, found a decrease in cell growth after addition of oxypurinol. 
Allopurinol has been reported to act as an unspecific antioxidant (Moorhouse et al, 
1986) but this can be taken into account by using low concentrations (Terada et al., 
1991; Klein et a l, 1995). Allopurinol is known (Sanders et a l, 1997) not to inhibit the 
NADH oxidase activity of XOR which also produces ROS. It is difficult however, to 
demonstrate the involvement of this activity for which there is no known specific 
inhibitor (Harrison, 1997).
As HB4a cells are mammary epithelial cells, the effects of lactogenic hormones on their 
growth and XOR activity were investigated. Prolactin and hydrocortisone have been 
found to be essential for induction of morphogenesis, while progesterone can have 
opposing effects. At physiological levels it induces cellular proliferation, whereas at 
supraphysiological levels it inhibits proliferation (Darcy et a l, 1995a;b). Kurosaki et a l 
(1996) found that XOR activity was induced by both dexamethasone and prolactin in 
mouse mammary epithelial cells (HC11), and a combination of these hormones resulted 
in a synergistic increase in activity. Hayden et a l, (1991) also observed an increase in 
XOR that was 10 times higher in mid-lactation than in mid-gestation, where XOR was 
induced during periods of rapid mammary cell proliferation. In contrast to these results, 
lactogenic hormones did not appear to have a significant effect on HB4a cellular
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proliferation or XOR activity. This could be due to the immortalised nature of the cell 
line. Studies using lactating cells or a primary cell line would be of interest.
Possible cytostatic effects of IFNy were investigated, as it is a potent antiproliferative 
agent in both normal and transformed cells (Gresser, 1985; Friesel et a l , 1987). This is 
thought to mediate its antiviral effects. However, IFNy had no discernible effect on 
HB4a cells in the log. phase of growth. XOR activity in stationary phase cells was 
significantly increased by 7-8 fold, although there was no corresponding alteration in cell 
number compared to controls.
The lack of effect on cell growth by several agents known to effect XOR activity 
suggest that the characteristic pattern of enzymic activity seen during the cell cycle, is 
not related to cell growth or differentiation.
An alternative hypothesis could be that XOR acts as a catalyst for the hydroxylation of 
purines which are upregulated just before confluence, because of their faster turnover as 
the cells rapidly divide. The second upregulation, as the cells reach the end of stationary 
phase, is more difficult to explain, but may involve removing purines from dying cells. 
Investigations into the true specific XOR activity (using ELISA) in relation to cell 
growth, and the availability of purines during the cycle, may help elucidate this issue.
The regulation of XOR by inflammatory cytokines in the HB4a cell line was 
investigated. It has been established in this study that XOR activity in HB4a cells is 
upregulated 2-3 fold by the inflammatory cytokines, TNFa and IL-1(3, and 7-8 fold by 
IFNy. This is in agreement with initial studies carried out by Powell (1995). Pfeffer et a l 
(1994) investigated the effects of cytokines on bovine renal epithelial cells and found a 
similar pattern of XOR regulation with TNFa and flL-1. The effects of IFNy, however
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were much smaller than reported here, with a maximum value of 150% of control. They 
also reported increases in XOR activity with IL-6 and dexamethasone, which were not 
found in the case of the human cell line in the present study. Such tissue specificity is not 
unexpected, as cytokines exert their effects by specific binding to high affinity receptors 
on target tissues. This may account for the lack of response in HB4a cells when treated 
with IL-6, as mammary cells are known themselves to produce IL-6 (Basolo et a l, 
1993; 1994), which may fully occupy the receptor sites and inhibit further response.
The specific and marked stimulation of XOR activity by IFNy was of particular interest. 
IFNy is produced by Thl cells relatively late in the immune response, and exerts 
pleiotropic effects on a variety of cell types, including antiviral and cytostatic effects. It 
also activates other immune responses including increased class 2 MHC molecules and 
cytokine expression, as well as chemotactic, microbicidal and pyrogenic effects (Kuby 
1994; Vilcek 1994). Increased XOR activity in response to IFNy has been reported to 
occur in rat lung microvascular cells (Dupont et a l, 1991), while IFNy and IFNy 
inducers increase XOR activity in rodent liver (Ghezzi et a l, 1985; Adamson & Billings 
1995). The upregulation of XOR, by these inflammatory cytokines, in the human 
mammary epithelial cell line, strongly suggests a role for the enzyme in the immune 
response. In the case of the human enzyme investigated in the present work, this 
suggestion is reinforced by the reported characterisation of the human XOR gene (Xu et 
al, 1996) and the detection of an IL-6 site and potential IFNy, TNF and IL-1 responsive 
elements.
The mechanism of regulation of XOR activity by the cytokines was investigated. Dupont 
et a l (1991) and Pfeffer et a l (1994) reported that the increases in XOR activity in their 
respective cell lines were due to transcriptional activation of the XOR gene, supported
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by measurement of mRNA. This is not unexpected, as cytokines generally act by altering 
the gene expression within cells.
The XOR protein in the HB4a cell line was found to be upregulated, but not by the same 
order of magnitude as the increase in activity. Measurement of mRNA (carried out by 
Dr F. Selase) was in agreement with this finding (Page et a l, 1998). This suggested a 
post-translational increase in activity, by around 2-3 fold in the case of IFNy stimulated 
cells, and even higher with TNFa stimulated cells.
As previously mentioned, most sources of the enzyme contain significant amounts of 
inactive forms, and the HB4a enzyme with its low specific activity may have a similar 
composition to that of HMXOR. Desulpho-sulpho conversion, resulting in enzyme 
activation can be effected both by direct chemical sulphide incorporation and by an 
unspecified enzyme catalysed conversion of this type (Coughlan, 1981; Nishino et a l, 
1983; Furth Walker & Amy, 1987). This may be the mechanism in the case of cytokine- 
induced activation of XOR, and could explain the apparent presence of another protein 
mediator suggested by the effects of cycloheximide (Chapter 6). However, the low 
concentration of Mo site activity makes direct proof of this problematic. The high 
proportion of ,demolybdo enzyme makes the concept of a regulatory enzyme-catalysed 
incorporation of Mo also attractive. However, there is no precedent for this mechanism. 
Other post-translational activations of XOR include D to O conversion. The widespread 
hypothesis explaining IRI focuses on D to O conversion mediated via proteolysis 
(Granger et a l, 1986), and the ability of the resulting O form to generate ROS. This 
mechanism has been suggested as a trigger for signal transduction during inflammation, 
as Friedl et a l (1989) reported that inflammatory mediators, including TNFa, initiated a 
rapid conversion from type D to irreversible type O, in rat pulmonary artery endothelial
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cells, as did Adamson & Billings (1995) in mouse hepatocytes. In contrast, results 
obtained by Terao et a l (1992), using IFNy, showed no evidence of a similar cytokine- 
mediated conversion. It was accordingly of interest to examine this possibility in relation 
to IL-ip, TNFa and IFNy in the HB4a cell line, especially in view of the proposed 
contribution of XOR-derived ROS to inflammatory signalling. However, the percentage 
of O form showed no evidence of a D to O conversion brought about by the 
inflammatory cytokines. However, ROS generated by the NADH oxidase activity of the 
enzyme would not require a D to O conversion (Sanders et a l, 1997), and it may be that 
this ability has a physiological role in cytokine activation.
In vivo, cytokines are rarely expressed alone, and exhibit both synergy and redundancy 
in their combined actions. IL-1 and TNFa commonly act in synergy to produce the 
secondary wave of cytokine expression in response to activated macrophages. 
Neutrophils are thus primed to respond to further inflammatory stimuli, and the 
expression of adhesion molecules I-CAM and E-selectin is upregulated. Together with 
IL-6 they initiate the acute phase response. IFNy and TNFa are also reported to have 
synergistic actions, causing a dramatic increase in class 1 MHC molecules and adhesion 
molecules. These two cytokines have been implicated as damaging factors in chronic 
inflammatory disorders such as rheumatoid arthritis, and IFNy is also a primary 
inflammatory mediator in delayed type hypersensitivity. Pfeffer et a l (1994) described 
additive increases in XOR activity when TNFa and IFNy or IL-1 (3 and IL-6 were 
combined, which led them to suggest a role for XOR in the acute phase response. In the 
human cell line studied here, various combinations of inflammatory cytokines, at their
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optimal doses, also gave additive increases in XOR activities, supporting the general 
conclusions of Pfeffer and co-workers.
The ability of XOR to catalyse the production of urate should not be overlooked in the 
context of inflammation. Urate has been suggested by Pfeffer et a l (1994) to play an 
anti-inflammatory role in its capacity as an antioxidant. In the present work, the anti­
inflammatory cytokine IL-13 was used to stimulate the cultures. It was found that XOR 
activity was not significantly affected, suggesting that the production of urate was not 
involved in the anti-inflammatory response. Reports by Flanders et a l, (1997) that the 
anti-inflammatory cytokine, TGF(3, is capable of inhibiting XOR activities induced by 
inflammatory cytokines, support the view that XOR is not involved in anti-inflammatory 
events.
The subcellular localisation of XOR is clearly relevant to its function, and was 
investigated in both the HB4a and BRLE cell lines. XOR is generally assumed to be 
cytosolic, which was confirmed in this thesis. More intense fluorescence was found 
around the perinuclear region; a localisation that has not been previously reported, and 
that has interesting implications for the role of XOR, which will be in a prime position 
for activation ofNF-^B via ROS.
Attempts were made to define further the localisation of the perinuclear enzyme. The 
perinuclear membrane is closely associated with the endoplasmic reticulum (ER), and it 
was thought that the protein may be in the process of moving through the ER in the 
course of biosynthesis. Cycloheximide was used to try to establish whether this was the 
case, but results were inconclusive. Co-localisation of XOR with TGN-38 appeared to
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indicate that the enzyme is located within the Golgi apparatus. This, however, is a 
preliminary experiment and merits further investigation.
The pattern of fluorescence observed on the monolayers, with some cells having intense 
fluorescence and others much less, suggests that XOR may be expressed differently in 
cells at different stages of growth, or it may be an artefact of the method. It would be 
interesting to synchronise the stage of growth of the cells to determine whether the 
fluorescence became uniform.
XOR was clearly detected on the surface of both cell lines and this appears to be the first 
report of surface XOR on epithelial cells. Various controls were undertaken to ensure 
that the XOR was not derived from exogenous sources. The XOR appears to be 
asymmetrically localised, providing further intriguing evidence for an alternative role for 
the enzyme, perhaps in intercellular signalling or adhesion.
Several years ago Bulkley and co-workers (Bulkley, 1991; Schiller et a l 1991) reported, 
in abstract form, the localisation of XOR to the outside of microvascular endothelial 
cells. It was only after the publication of our data (Rouquette et al. 1998) that this group 
published a full paper describing their findings (Vickers et a l, 1998). They confirmed 
detection of XOR on the surface of endothelial cells, but did not comment on detailed 
distribution.
Possible mechanisms of secretion of XOR need to be discussed. XOR has none of the 
necessary attributes of a protein that follows the classical secretory pathway, from the 
ER to the Golgi apparatus. The enzyme, for example, has no signal sequence (Ichida et 
a l, 1993; Xu et a l, 1994). An increasing number of proteins are now believed to follow 
a non-classical pathway. For instance, a muscle lectin L-14, which is secreted via the 
non-classical pathway, interacts with GAGs, and is therefore separated from interaction
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with them until after its secretion (Cooper & Barondes, 1990). This could be a relevant 
consideration for XOR, as it has also been shown to interact with GAGs (Adachi et al., 
1993; Radi etal., 1996). Further investigation into the proposed mechanism of secretion 
of XOR is needed and this would help clarify the origins and role of the extracellular 
XOR.
Several attempts were made to investigate the properties of the extracellular XOR, 
although none of the experiments was conclusive in discovering whether the XOR was 
active or able to bind to GAGs. Active XOR on the surface of cells could be involved in 
signalling or antimicrobial defence, via direct production of ROS or acting as 
chemotactic agents for neutrophils. This location is particularly well suited for epithelial 
cells, which frequently come into contact with antigens in their capacity as an interface 
between the body and external environment.
In view of the potential inflammatory actions of XOR, the extra- and intra-cellular 
localisation of XOR was investigated after stimulation with inflammatory cytokines. The 
fluorescence levels on the surface of the HB4a cells, increased by approximately 2-3 fold 
on stimulation with TNFa and IFNy. This magnitude of increase was expected from 
ELISA results. However, the cytoplasmic fluorescence was lower than expected, 
probably due to the stage of growth of the cells. The results from TNFa stimulated cells 
indicate that surface XOR seemed to appear prior to the cytoplasmic XOR. A time 
course would be interesting, and could show if translocation of XOR from the surface to 
the nucleus or vice-versa, is occurring.
The production of ROS is central to the hypothesis of XOR as a second messenger in 
inflammation. An attempt was made to localise ROS production in the cells using
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dihydrorhodamine, however, results were inconclusive and the quantity of ROS 
produced by other mediators in the cell was a problem.
The production of ROS by XOR is central to many theories regarding its alternative 
roles. Nevertheless, little is known about the human enzyme’s ability to produce ROS in 
vivo, as most specific inhibitors act at the Mo site, leaving NADH oxidase activity intact. 
The discovery of an NADH oxidase inhibitor specific to XOR would be of great use in 
defining alternative roles for XOR (Harrison, 1997). Measurement of the production of 
ROS by HB4a cells, both intracellularly and extracellularly, could then establish whether 
the quantities produced are relevant to involvement in the immune response as 
secondary messengers.
Recently the ability of XOR to convert nitrate to nitrite at the Mo centre in oxygen 
limited environments, and its ability to catalyse the production of NO have been 
investigated, and it would be of interest to discover the characteristics of this activity in 
the system discussed here.
The apparent posttranslational activation of pools of inactive XOR merits further 
investigation. A detailed study of the activity and regulation of cell surface and 
perinuclear XOR would be of particular interest.
The implications of the findings of this thesis are wide ranging. The involvement of XOR 
in inflammation has been demonstrated. Pools of inactive protein have the potential to be 
posttranslationally activated by up to 7 fold during inflammatory events. This strongly 
suggests that XOR has an alternative or additional role, other than purely ‘house 
keeping’ purine catabolism. The consequences of this upregulation of activity, 
particularly by the cytokines involved in the initiation of the immune response, could
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implicate XOR as an initial mediator in the inflammatory response, due to its ability to 
increase ROS production and therefore amplify the response further through activation 
of transcription factors such as NFAB or AP-1. This would result in an increased 
production of cytokines and adhesion molecules, thereby resolving a pathogenic event 
more quickly. Alternatively, in the case of inflammatory disorders such as rheumatoid 
arthritis and delayed type hypersensitivity, XOR may be implicated in the persistence of 
deleterious effects. The significant effect of IFNy in activating XOR strongly suggests a 
role for the enzyme in the late or viral immune response. In its capacity to hydroxylate 
purines, XOR may assist IFNy to induce cytostasis, as purines would be removed from 
the cell more rapidly. However, the actions of IFNy are diverse and many are still under 
investigation, making it difficult to assign a role for XOR via the effects of IFNy .
The exciting discovery of XOR protein on the surface of cells, and its increase in 
response to cytokines, could be of primary importance in the ability of the enzyme to 
attract neutrophils, by the production of ROS, to the site of inflammation. This protein, 
should it prove to be active, could also participate in intercellular signalling, as 
suggested by its asymmetrical localisation, and apparent involvement in the growth 
cycle. Much more investigation is required into this intriguing aspect of the enzyme. 
XOR with the ability to produce ROS on the surface of epithelial cells may provide a 
protective ‘superoxide zone’ around the cells lining lumens which are exposed to a 
multitude of pathogens. It may also participate in keeping the protein rich environment 
of the mammary alveoli free of microbial infection, this also could be a relevant function 
for milk XOR in the vulnerable neonate gut.
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The implications of the regulation of human XOR by inflammatory cytokines are 
fascinating, and the work described in this thesis provides a sound basis for further 
investigation into the potential role of XOR as a mediator in inflammatory events.
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A b str a c t
Xanthine oxidoreductase (XOR) in human mammary epithelial cells was shown to have low true specific activity, similar 
to that in breast milk. Enzymic activity was increased in response to inflammatory cytokines; increases of 2-2.5-fold being 
seen with TNF-a and IL-1/3 and of approximately 8-fold with IFN-y. No significant increase was seen with IL-6. A 
combination of IFN-y and TNF-a, or of these two cytokines plus IL-1/3, led to responses representing the sum of those 
obtained by using the individual cytokines. The 8-fold increase in enzymic activity, stimulated by IFN-y, corresponded to 
only a 2-3-fold increase in specific mRNA, suggesting the possibility of post-translational activation; a possibility strongly 
supported by the corresponding 2-3-fold rise in XOR protein, as determined by ELISA. In no case was cytokine-induced 
activation accompanied by changes in the oxidase-dehydrogenase ratio of XOR. These data strongly support a role for 
XOR in the inflammatory response of the human mammary epithelial cell, and provide further evidence of post-translational 
activation of a low activity form of human XOR, similar to that previously observed in vivo for the breast milk enzyme. 
© 1998 Elsevier Science B.V. All rights reserved.
K eywords: Xanthine oxidoreductase; Cytokines; Epithelium; (Hum an)
1. Introduction
Xanthine oxidoreductase (XOR) is a widely dis­
tributed molybdenum-containing flavoenzyme that 
plays a key role in purine catabolism, catalysing the 
hydroxylation of hypoxanthine and xanthine to xan­
thine and uric acid, respectively [1]. It exists in two 
separate but interconvertible forms, xanthine dehy-
A bbreviations: X O R , xanthine oxidoreductase; F B S, foetal 
b ovine serum
Corresponding author. Fax: + 4 4 -1 2 2 5 -8 2 6 7 7 9 ; E-mail:
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drogenase (EC 1.1.1.204) and xanthine oxidase (EC 
1.1.3.22). The dehydrogenase form preferentially re­
duces NAD, in contrast to the oxidase form, which 
does not reduce NAD, preferring molecular oxygen. 
Reduction o f oxygen leads to superoxide anion and 
hydrogen peroxide, and it is the potential to generate 
these reactive oxygen species that has led to 
widespread interest in the enzyme as a pathogenic 
factor in a wide variety of clinical disorders, espe­
cially ischaemia-reperfusion injury [2-5].
XOR is present at high levels in bovine milk, from 
which it was first purified over 60 years ago, and 
which remains the major source of this well-studied
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enzyme [6]. In milk, XOR is associated with the milk 
fat globule membrane, derived from the mammary 
epithelial cell [7], which, together with other epithe­
lial and capillary endothelial cells, shows the highest 
concentrations of XOR [8,9]. Human XOR is of 
especial interest and, surprisingly, appears to differ 
from other mammalian forms of the enzyme, at least 
in milk. XOR purified from breast milk has very low 
activity towards ‘conventional’ reducing substrates, 
such as hypoxanthine and xanthine, compared with 
the bovine milk or rat liver enzymes; a property 
attributable to a largely inactive molybdenum centre 
[10,11].
The physiological function of XOR in milk has 
long been contentious and an anti-microbial role, 
involving generation of reactive oxygen species in 
the neo-natal gut, has been proposed [12,13]. These 
questions are now made more intriguing in view of 
the low specific activity of the purified human en­
zyme. A low basal activity suggests the possibility of 
activation in response to physiological stimuli, which, 
for an enzyme generating reactive oxygen species is 
of particular interest. Indeed, in the case of the 
human milk enzyme, we have found evidence of 
post-translational activation-deactivation cycles in 
vivo, whereby activity to hypoxanthine varied many- 
I fold while enzyme protein remained essentially con- 
\ stant [14]. These variations, possibly hormonally 
; driven [14], may well reflect corresponding changes 
I in the true specific activity of XOR in the secretory 
(epithelial cells, where an anti-microbial role of the 
; enzyme is equally feasible. If this is the case, then 
( epithelial cell XOR might be expected to be involved 
lin the inflammatory process. With this in mind, we 
ihave made use of HB4a, a relevant cell line, to 
j investigate the nature of human mammary epithelial 
’cell XOR and its responses to inflammatory cy- 
jtokines.
2. Materials and methods
2.1. Materials
RPMI 1640 culture medium was obtained from 
ICN, Costa Mesa, USA. Penicillin (5000 U/ml), 
streptomycin (5000 fig/ml), 200 mM glutamine and
foetal bovine serum (FBS) were from Life Technolo­
gies, Paisley, Scotland. Human recombinant tumour 
necrosis factor-a (TNF-a), interleukin-1/3 (IL-1/3) 
and interleukin-6 (IL-6) were purchased from Sigma, 
Poole, Dorset, UK and human recombinant inter­
feron-y (IFN-y) from Calbiochem, Nottingham, UK. 
Human /3-actin oligonucleotide probe was from 
Cambridge Biosciences, Cambridge, UK. Blotting 
membranes (Hybond-N), [a-32P]UTP and [y-32P] 
ATP were from Amersham International, Amersham, 
UK, and X-ray sensitive film was from Genetic 
Research Instrumentation, Dunmow, Essex, UK. 
Oligo (dT)25 linked to magnetic beads was from 
Dynal, Wirral, UK. All other reagents, unless other­
wise stated, were from Sigma.
2.2. Cells and cell culture
HB4a is a human mammary epithelial cell line, 
conditionally immortalised by transfection with SV40 
virus [15] and kindly donated to us by Dr. T. Ka- 
malati and Professor B. Gusterson of the Institute for 
Cancer Research, Royal Cancer Hospital, Sutton, UK. 
HB4a cells were routinely grown in 75 cm2 uncoated 
polystyrene culture flasks, seeded with approx. 0.3 X 
105 cells/ml in Growth medium. Growth medium 
consisted of RPMI 1640 medium (15 ml), supple­
mented with 10% (v/v) foetal bovine semm (FBS), 3 
mM L-glutamine, penicillin (100 U/ml), strepto­
mycin (100 /ig/ml), insulin (5 /x,g/ml), hydrocorti­
sone (5 /xg/ml) and cholera toxin (100 ng/ml). The 
cultures were incubated at 37°C in an atmosphere of 
5% C02/95% air and medium was changed every 
3-4 days. Cells grew to confluence, forming a strict 
monolayer, showing a characteristic ‘crazy paving’ 
appearance and stained strongly positive (see Section 
2.3) for the epithelial cell marker, cytokeratin [16].
Cells were subcultured at, or shortly after, conflu­
ence. The monolayer was washed twice with sterile 
PBS, prewarmed to 37°C, and detached from the 
flask by incubation, at 37°C, with PBS, containing 
0.05% (w/v) trypsin and 0.02% (w/v) EDTA. After 
5-10 min, greater than 90% of the cells were de­
tached, as assessed by light microscopy. An equal 
volume of Growth medium was added to the cells, 
which were then centrifuged, at 100 X g for 5 min, 
and resuspended in Growth medium. An aliquot of 
the cell suspension was counted in a haemocytome- 
ter, using a 1:1 dilution with 0.04% (w/v) trypan
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blue to ascertain cell viability. The cells were then 
seeded, at the required density, in Growth medium, in 
75-cm2 flasks.
Cell stocks were routinely preserved in liquid ni­
trogen. Confluent cells, from one 75-cm2 flask, were 
trypsinised and pelleted as described above, before 
being resuspended in 50% (v/v) FBS, 40% (v/v) 
Growth medium and 10% (v/v) DMSO, in a total 
volume of 1 ml, in cryogenic vials. Vials were main­
tained, for 24 h, in the vapour above liquid nitrogen, 
before being immersed in the latter and stored. Frozen 
stocks were defrosted in a waterbath, at 37°C, before 
being rapidly decanted into Growth medium (20 ml), 
centrifuged as above and reseeded in Growth medium 
at the appropriate density.
2.3. Immunodetection of cytokeratin in HB4a cells
HB4a cells were allowed to grow to confluence in 
24-well plates, for 48 h, before being washed twice in 
prewarmed (37°C) PBS and treated, for 15 min, with 
5% (v/v) acetic acid/70% (v/v) ethanol, at — 20°C, 
to fix and permeabilise them. The cells were then 
washed three times with PBS, and blocked by incuba­
tion with PBS, containing 3% FBS (PBS/FBS, 300 
/xl/well), for 30 min at 37°C. Mouse monoclonal 
anti-pancytokeratin antibody (Sigma), diluted (1:300) 
in PBS /FBS, was added to the cells and allowed to 
incubate at 37°C for 2 h. The cells were washed twice 
with PBS/FBS before incubation, for 1-3 h at 37°C, 
with FlTC-conjugated goat anti-mouse IgG (Sigma) 
diluted (1:128) in PBS/FBS. Finally, the cells were 
washed three times with PBS and mounted under a 
13-mm coverslip, using Vectashield (Vector Labora­
tories, Peterborough, UK, 15 /u,l), as a protective 
mountant. Controls, from which either primary or 
second antibody were omitted, were prepared in par­
allel. Cells were observed by using a Nikon Diaphot 
microscope equipped for phase contrast and epi-fluo- 
rescence.
2.4. Determination of XOR enzymic activity
Cells were washed, removed by trypsinisation, 
counted and pelleted, as described above for routine 
subculture. The cell pellet was resuspended in Stabili­
sation buffer (1.2 ml) [50 mM potassium phosphate 
buffer, pH 7.4, containing 0.1 mM EDTA, 0.1 mM
PMSF, pepstatin A (1 jug/ml), leupeptin (1 jtig/ml), 
antipain (1 /ig/ml) and aprotinin (1 fig/ml)] and 
transferred to an eppendorf tube, maintained at 4°C. 
The cells were then sonicated for 20 s, at setting 7.5, 
using a 3 mm probe in an MSE, 150 W Ultrasonic 
Disintegrator Mk2 and finally centrifuged, at 100,000 
X  g for 25 min, at 4°C to yield a cytosolic fraction. 
XOR enzymic activity, in the cytosolic fraction, was 
determined fluorimetrically, essentially according to 
the general procedure described by Beckman et al. 
[17].
Cell extract (0.5 ml) was added to assay buffer 
(0.48 ml) (50 mM potassium phosphate, pH 7.4, 
containing 0.1 mM EDTA) in a 1-ml quartz cuvette 
at room temperature. A fluorimeter (Perkin-Elmer 
LS-5B Luminescence Spectrometer) was set at an 
excitation wavelength of 345 nm and an emission 
wavelength of 390 nm with slit width of 5 nm. The 
cuvette was introduced and, after stabilisation of the 
baseline, 1 mM pterin was added to a final concentra­
tion of 10 ilM. The increase in fluorescence was 
recorded, over several minutes, to obtain oxidase 
activity of XOR.
Total (oxidase plus dehydrogenase) activity was 
determined by subsequent addition of 1 mM Methy­
lene Blue, also to a final concentration of 10 fiM. 
The reaction was stopped by addition (50 /il) of a 
1-mM stock solution of allopurinol, and the increase 
in fluorescence was calibrated by addition of a range 
of pmolar concentrations of isoxanthopterin as an 
internal standard. Reaction rates were then calculated 
as pmoles isoxanthopterin min-1 mg-1 total protein. 
Total protein content of the cytosolic fraction was 
determined by the method of Bradford [18]. Levels of 
XOR in the 12-day-old cultures used in cytokine 
studies varied between 0.4-0.8 pmol min-1 mg-1.
All assays were performed in duplicate. Observ­
able rates could always be inhibited by 50 / j l M  
allopurinol or 50 i^M amflutizole, two distinct and 
specific inhibitors. The observed rates were linear 
with respect to the volume of cell extract in the assay, 
and did not decrease within the time scale of the 
assay.
In order to check whether the assay was affected 
by the presence of endogenous small metabolites, 
such as purines or NAD, the following comparison 
was made. A sample of cell extract was divided into 
two portions, one of which was assayed directly as
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described above. The remaining portion was gel- 
filtered through Sephadex G25 before assay. No sig­
nificant difference ( p  >  0.05, n =  4) was observed 
between activities determined with or without gel 
filtration, which was, accordingly not routinely em­
ployed. Comparability between the above fluorimet- 
ric assay and the more commonly used, but less 
sensitive urate assay for XOR is known to depend on 
the source of enzyme [17]. In our hands, parallel 
assays on purified samples of human milk XOR 
established that the specific activity determined by 
the fluorimetric assay was 4-5-fold  less than the 
urate assay.
2.5. Northern analysis
RNA was extracted from cytokine-stimulated and 
control H B 4a cells by acid guanidinium  
thiocyanate-phenol-chloroform  extraction [19]. 
mRNA was isolated by using oligo (dT) linked to 
magnetic beads, electrophoresed through a 2.2 M 
form aldehyde/1 % agarose gel and transferred to a 
nylon filter by capillary action overnight, using 20 X 
SSPE buffer (3 M sodium chloride, 0.2 M sodium 
hydrogen phosphate, 0.02 M EDTA). Membranes 
were crosslinked by illumination with a hand-held 
UV lamp for 15 min. Prehybridisation was at 65°C 
for 2 h in 5 X SSPE, 50% formamide, 5 X Denhardf s 
solution [0.1% (w /v )  Ficoll, polyvinylpyrrolidone 
and BSA] and 0.5% (w /v )  SDS. A radiolabelled 
cRNA probe was prepared from a cloned fragment of 
human XOR cDNA (kindly provided by Dr. J.R. 
Hoidal, University of Utah) by using T7 RNA poly­
merase and [a - 2P] UTP (66 GBq, sp.act. 110 
TBq/m m ol) and a portion (0.02 MBq) was added to 
the prehybridised filters. Hybridisation was carried 
out overnight at 50°C in the same solution that was 
used for pre-hybridisation. Filters were washed in 
2 X SSPE, 0.1% SDS twice for 15 min at 55°C, 
air-dried and autoradiographed. Human /3-actin 
oligonucleotide probe was used as a control in paral­
lel with these experiments, but labelled with [y-32P] 
ATP using T4 polynucleotide kinase. The intensity of 
the resultant bands was quantified by using Molecu­
lar analyst software 2000 (Biorad. Image Analysis 
Systems, Hercules, LA, USA).
Preliminary experiments established that cytokine- 
induced increases in specific mRNA were first de­
tectable after 6-h exposure and reached maximal 
values after 24 h. Subsequent determinations of 
mRNA were therefore made after 24-h exposure to 
the relevant cytokine.
2.6. Generation and affinity-purification o f anti- 
(human XOR) antibodies
Rabbits were immunised initially with Alum adju­
vant (Pierce, Rockford, IL, USA, 400 jul) containing 
purified human XOR (200 pg)  [11]. A similar injec­
tion was given 2 weeks later, followed by further 
immunisations in PBS after 4 and 5 weeks. One week 
after the final injection, rabbits were sacrificed and 
serum (approx. 100 ml/rabbit) was collected. The 
rabbit antiserum (5 ml) was continuously cycled, for 
24 h at 4°C, over a column (8 ml) of human XOR 
coupled to cyanogen bromide-activated Sepharose 4B 
(4 -7  mg purified X O R /m l gel, coupled according to
M.Wt. kDa
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 < ----  97
 <  66
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Fig. 1. SD S-P A G E  o f  im munoprecipitate from H B 4a ce lls . H B 4a  
cells w ere extracted, and the extracts w ere incubated w ith affin­
ity-purified rabbit anti-(human X O R ) antibodies bound to protein 
A -Sepharose gel as described in Section 2. The gel w as sepa­
rated, subjected to SD S-P A G E , and stained with C oom assie  B lue  
(Section  2). The rabbit antibodies were sim ilarly subjected to 
SD S-P A G E  and stained. Lanes are as follow s: (1 )  Im m unoprecip­
itate. (2 ) A ffin ity-purified  rabbit anti-(human X O R ) antibodies.
(3 ) M olecular w eight markers.
1 2 3
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Pharmacia, Uppsala, Sweden). The column was 
washed with PBS until no further absorbance was 
detected at 280 nm, when anti-XOR antibodies were 
eluted with PBS, containing 4 M urea. The eluate 
was dialysed against PBS, divided into aliquots, and 
stored at — 20°C.
The specificity of the affinity-purified anti-(human 
XOR) antibodies for XOR in HB4a cell extracts and 
consequent suitability for ELISAs was established by 
their use in immunoprecipitation of XOR from HB4a 
cell extracts (see below for procedure). Incubation of 
HB4a cell extracts with the gel-bound specific anti­
bodies removed 100% of XOR enzymic activity. The 
SDS-PAGE pattern of the immunoprecipitate is shown 
in Fig. 1 (lane 1) in which the 145 kDa, 135 kDa and 
90 kDa bands corresponding to XOR and its prote­
olytic products [10] are clearly seen, together with the 
50 kDa and 25 kDa bands corresponding to the heavy 
and light chains, respectively, of rabbit IgG.
2.7. ELISA fo r  human XOR
Human XOR in cell extracts was assayed, by a 
sandwich ELISA, essentially as previously described 
for bovine XOR [20]. Affinity-purified rabbit anti- 
(human XOR) antibodies were biotinylated [21] to 
the level of 6-9 mol biotin/mol antibody. Non-bio- 
tinylated affinity-purified rabbit anti-(human XOR) 
antibodies [100 /id, 8 /ig/ml in coating buffer (50 
mM Na2 C03/NaHC03, pH 9.6)] were added to 
each well of a 96-well microtitre plate (Becton Dick­
inson Labware, Plymouth, UK) and allowed to stand 
overnight at 4°C. The wells were washed with PBS, 
containing 0.05% (v/v) Tween 20 (PBS-Tween), and 
incubated with 1% (w/v) casein in PBS-Tween 
(PBS-Tween-casein) for 2 h at 37°C. Serial two-fold 
dilutions of a standard solution of purified human 
XOR (340 ng/ml in PBS-Tween-casein) were added 
to successive wells and incubated for 1-2 h at 37°C 
before washing with PBS-Tween and incubation, for 
2 h at 37°C, with biotinylated affinity-purified anti- 
(human XOR) antibodies (100 / j l \ ,  7 /-cg/ml in PBS- 
Tween-casein). The wells were again washed 3 times 
with PBS-Tween and streptavidin-horseradish perox­
idase conjugate (Sigma, 100 p \, 2.5 /zg/ml in PBS- 
Tween-casein) was added to each well. The plates 
were allowed to stand for 20 min at room tempera­
ture, washed 3 times with PBS-Tween, and twice
with PBS and incubated with peroxidase substrate 
(100 /H/well). Peroxidase substrate solution con­
tained 3,3',5,5'-tetramethylbenzidine in DMSO (0.25 
ml, 10 mg/ml) in 0.1 M sodium acetate buffer, pH
6.0, (24.75 ml), containing 30% hydrogen peroxide 
(3 p \). Colour was allowed to develop before stop­
ping the reaction by addition of 1 M H2S04 (50 
fi 1/well) and measuring absorbance at 450 nm. A 
plot of absorbance against dilution of stock human 
XOR gave a standard curve, the use of which allowed 
levels of enzyme as low as 0.5 ng/ml to be detected 
consistently.
2.8. Immunoprecipitation o f XOR from  HB4a cells
Affinity-purified rabbit anti-(human XOR) anti­
bodies (500 p g ) in PBS (1 ml) were incubated with 
Protein A-Sepharose CL-4B gel (600 p\) overnight at 
4°C. The gel was washed with PBS to remove un­
bound protein and incubated overnight at 4°C with 
the high-speed supernatant from sonicated HB4a cells 
(see determination of XOR enzymic activity), before 
separation and washing as above. The gel was then 
incubated with an equal volume of an aqueous solu­
tion, containing 6 M urea, 10% (w/v) SDS and 0.1% 
(w/v) Bromophenol Blue, for 30 min at room tem­
perature, to release antibody-antigen complexes from 
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Fig. 2. Growth pattern o f  H B 4a human m am m ary ep ithelial cells  
in culture. H B4a cells w ere seeded  and a llow ed  to grow  in 
75-cm 2 culture flasks, as described in Section  2. C ell number ( O
 O )  and total (oxidase plus dehydrogenase) X O R  en zym ic
activity ( • --------- • )  were determ ined as described  in S ection  2.
Error bars represent ±  S.E .M . ( n =  5 ).
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Fig. 3. D o se -re sp o n se  profiles o f  increases in XO R m R N A  and 
XO R en zym ic activity induced in H B4a cells by IF N -y . (A ) 
m RNA: IF N -y  w as added to 12-day-old cultures o f  H B4a cells, 
which w ere harvested after 24 h, and their extracts assayed for 
XO R m R N A , as described in Section 2. The intensities o f  the 
bands w ere quantified (Section  2) and expressed relative to that 
obtained in the absence o f  IF N -y . /3-Actin m R N A  is shown for 
each sam ple as control. (B ) X O R  enzym ic activity: duplicate 
extracts o f  IF N -y  treated HB4a cells , corresponding to those 
used for (A ), w ere assayed for total XO R enzym ic activity as 
described in Section 2. A ctiv ities are expressed as percentages o f  
controls in the absence o f  IF N -y . V alues are m eans ± S .E .M . 
( /» =  5).
3000 X g for 5 min, leaving a solution that was 
subjected to SDS-PAGE with Coomassie Blue stain­
ing [22].
2.9. Statistical analysis
The significance of differences between experi­
mental values and controls was assessed by Analysis 
of Variance (Microsoft Excel, version 5).
3. Results
3.1. XOR activity in HB4a cells
Cells seeded in 75 cm2 flasks, as described in 
Section 2.2, grew to confluence after 9 days in 
culture. They remained as a monolayer until days 
16-18, when they began to detach from the surface 
of the flask. The cells had a doubling time of approx­
imately 36 h and achieved a maximum density of 
about 28 X  106 cells/75 cm2 flask. As can be seen 
in Fig. 2, specific XOR enzymic activity lagged 
behind cell count, remaining essentially undetectable 
until after day 3, when it rose sharply, attaining 
plateau values shortly before confluence. These 
plateau values were maintained for approximately 10 
days. Interestingly, a further rise in enzymic activity 
was consistently observed, starting approximately at 
day 15, when cells are beginning to detach from the 
plastic and die. The levels achieved on days 12 and 
18 were 0.57 + 0.09 and 0.99 ±0.10 pmol min-1 
mg~l total protein respectively (mean ±  S.E.M., n =
5). On the basis of ELISA determinations of XOR 
protein, the specific activity of XOR in HB4a cells 
was 45 + 5.0 nmol min-1 mg-1 (mean + S.E.M., 
n =  4).
800
f 
1  600 o
g.
j*  400
(n - t3 )
200 (»-5)
(n=18)
control IL-6 TNFct IL-13 IFNy
Treatm ent
Fig. 4. Increases in the X O R  enzym ic activity o f  H B 4a cells in 
response to optim al levels o f  cytokines. IL-1/3 (1 5 0  I U /m l) ,  
IL-6 (1 0  I U /m l) ,  TNF-ar (5 0  I U /m l)  and IF N -y  (1 0 0  I U /m l)  
were added to 12-day-old cultures o f  H B4a ce lls , w hich  w ere  
harvested after 24  h and their extracts assayed for total X O R  
enzym ic activity as described in Section 2. A ctiv ities are e x ­
pressed as percentages o f  controls in the absence o f  cytokines. 
Values are m ea n s± S .E .M . * D enotes significantly different from  
control ( p  <  0 .04).
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3.2. Effect o f  added molybdate on XOR activity in 
HB4a cells
In view of the findings of Falciani et al. [23] of 
defective molybdenum incorporation in their mouse 
L929 fibroblastic cell line (see Section 4), sodium 
molybdate was added to cells grown for 12 days in 
culture. Final concentrations of 20 mM, incubated for 
24 h or of 10 mM, incubated for 48 h proved to be 
cytotoxic. Cells remained viable when incubated for 
24 h with 10 mM sodium molybdate. Under these 
conditions, no significant increase ( p  >  0.05) in XOR 
activity compared with controls was observed.
3.3. Stimulation o f total XOR enzymic activity in 
HB4a cells by inflammatory cytokines
IFN-y, IL-1/3 and TNF-a, when added to 12 
day-old cultures of HB4a cells, all led to increases in 
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Fig. 6. E ffects o f  IF N -y , T N F -a  and IL-1/3 on the percentage 
oxidase activity o f  H B 4a cells . Varying levels o f  cytokines w ere 
added to ce ll cultures as described in the legend to Fig. 4 , and the 
cell extracts were assayed for oxidase and total X O R  enzym ic  
activity as described in Section  2. V alues are m eans ± S .E .M .  
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Fig. 5. Increases in X O R  en zym ic activity o f  H B 4a ce lls  in 
response to com binations o f  cytokines. (A ) IF N -y  and T N F -a . 
V alues are m eans ± S .E .M . (B ) IF N -y , T N F -a  and IL -1/3. V al­
ues are m eans ± S .E .M . ( n =  5). C ytokines were added individu­
ally or in com bination to ce ll cultures, and total X O R  activity  
was determ ined and expressed  as described in the legend to Fig. 
4.
In no case was an effect seen at 6 h. The increase in 
XOR activity caused by IFN-y peaked at 24 h, 
declining by 48 h, whereas increases in response to 
IL-1 /3 and TNF-a rose slightly between 24 h and 48 
h before declining (data not shown).
Enzymic activity, determined after 24 h incubation 
with each cytokine, was dose-responsive, as shown 
for IFN-y in Fig. 3, which also shows the corre­
sponding Northern blots and quantification of relative 
XOR mRNA levels. Maximum values for each cy­
tokine are shown in Fig. 4. IFN-y stimulated by far 
the greatest increase, with a mean value of almost 
eight-fold.
Combination of IFN-y and TNF-a (Fig. 5A) or of 
these two cytokines plus IL-1/3 (Fig. 5B) led to 
increases that corresponded to the sum of those shown 
by the relevant cytokines individually.
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3.4. Effects o f  cytokines on percentage o f oxidase 
activity o f  XOR in HB4a cells
In view of suggestions (see Section 4) that inflam­
matory cytokines activate XOR by initiating dehydro- 
genase-to-oxidase conversion, evidence of such ef­
fects was sought in the present system.
The oxidase content of XOR in HB4a cells was 
approximately 40% prior to addition of cytokines. 
Dose-response profiles for IFN-y, TNF-a and IL-1 /3 
are shown in Fig. 6, in which it can be seen that in no 
case was a significant increase in the percentage of 
oxidase activity observed.
3.5. Comparison o f the effects o f IFN-y on XOR 
enzymic activity, mRNA and protein
In order to compare the responses of specific 
mRNA and enzyme protein with the increases in 
enzymic activity induced by IFN-y, large-scale cul­
tures of HB4a cells were set up in 300 cm2 flasks. 
IFN-y (100 IU/ml) was added to the cultures on day 
12 and allowed to incubate for 24 h, as for the other 
experiments. The cytosolic fractions from the cells 
were divided into portions, duplicates of which were 




XOR mRNA XOR pro tein
Fig. 7. Com parison o f  the effects o f  IF N -y  on X O R  enzym ic  
activity, m R N A  and protein. IF N -y  was added to large-scale 
cultures o f  HB4a cells (Section  3) and assayed for enzym e 
activity, m R N A  and, by ELISA, for XOR protein as described in 
Section  2. The resulting values are expressed relative to those 
from parallel control cultures, without IF N -y  and defined as 
100%. V alues are means ±  S.E.M . * D enotes significantly differ­











relative to control cultures (without IFN-y and de­
fined as 100%) are displayed in Fig. 7.
4. Discussion
Even at peak values, the XOR enzymic activity in 
HB4a mammary epithelial cells is very low compared 
with that in non-human cells [24-28]; being, in gen­
eral, some two orders of magnitude lower. Im­
munofluorescence comparison of HB4a and buffalo 
rat liver epithelial cells suggested [26] that, despite 
the very much higher XOR enzymic activity of the 
rat cells, the content of XOR protein in the two cell 
types was similar, implying a low true specific activ­
ity of the human enzyme. Indeed, ELISA data in the 
present study allow calculation of the specific activity 
of XOR in unstimulated HB4a cells to be 160-200 
nmol min-1 mg-1 [converted to urate assay equiva­
lent (see Section 2)]; a value comparable with those 
[62 ± 22 (mean ± S.E.M., n = l l )  nmol min-1 
mg-1] obtained by us (Wade, V., Padgett, T and 
Harrison, R., unpublished) for purified human milk 
XOR, and very much lower than the accepted values 
[1] for bovine milk or rat liver enzymes (3000-5000 
nmol min-1 mg - ! ).
Falciani et al. [23] reported that mouse L929 fi­
broblastic cells, which contain low, but detectable 
levels of XOR mRNA, show no enzymic activity 
unless millimolar concentrations of molybdenum are 
added to the medium. This effect was not observed in 
several other mouse and human cell lines tested, and 
the authors attributed their results to a defect in 
molybdenum incorporation specific to the L929 cell 
line. In order to eliminate the possibility that a similar 
situation prevails in HB4a cells, these were incubated 
with 10 mM molybdate. However, we did not ob­
serve any increase in activity.
The low specific activity of XOR in HB4a cells 
suggests that, as found for the breast milk enzyme in 
vivo [14], human mammary epithelial cell XOR might 
be subject to activation in response to specific stim­
uli. Moreover, the ability of XOR to generate reactive 
oxygen species and the involvement of the latter in 
inflammation, prompted a study of the effects of 
inflammatory cytokines on the enzyme. IL-1/3, TNF- 
a and IFN-y caused significant increases in XOR 
enzymic activity of HB4a cells after 24 h, when
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added individually and at optimum doses. However, 
whereas the mean activities resulting from incubation 
with IL-1 /3 and TNF-a ranged between 200-250% 
of control, IFN-y was found to stimulate very much 
higher increases of 750-800% (Fig. 4).
Pfeffer et al. [25] investigated the effects of cy­
tokines on bovine renal epithelial cells and found 
increases in XOR activity that, in the case of IL-1 
and TNF-a, were broadly similar to those reported 
here for human cells. The effects of IFN-y were, 
however, very much lower in their system, represent­
ing a maximum value of only 150% control. In 
contrast to the present data, they observed a small 
increase in XOR activity in response to IL-6. In the 
case of bovine epithelial cells, the effects of combina­
tions of cytokines were shown to be additive; a result 
also obtained in the present study (Fig. 5). Additive 
and potentiative effects of these cytokines are fre­
quently reported in other systems [29-32], and their 
association with XOR suggests a role for the enzyme 
in inflammation and the acute phase response. In the 
case of the human enzyme, studied in the present 
work, this suggestion is strongly reinforced by the 
recently reported characterisation of the human XOR 
gene [33] and the detection, in the 5'-flanking region, 
of an IL-6 site and of potential TNF, IFN-y and IL-1 
responsive elements.
The specific and marked stimulation of XOR en­
zymic activity by IFN-y is of particular interest. 
Interferons have a pleiotropic effect on a range of cell 
types, inhibiting the proliferation of both normal and 
tumour cells, and amplifying immune and inflamma­
tory responses [34-36]. Interferons and interferon 
inducers have been shown to induce XOR enzymic 
activity in rodent liver [37-39], while IFN-y upregu- 
lates this activity in rat pulmonary endothelial cells 
[24] and, as discussed above, to a lesser extent in 
bovine renal epithelial cells [25].
In the case of rat lung microvascular endothelial 
cells, Dupont et al. [24] reported a five-fold increase 
in XOR activity and a corresponding seven-fold in­
crease in specific mRNA after 24-h exposure to 
optimal doses of rat IFN-y. XOR protein was not 
measured. In the present study, a large-scale culture 
of HB4a cells was used to measure XOR enzymic 
activity, mRNA and XOR protein increases in re­
sponse to an optimal dose of IFN-y. In marked and 
significant contrast to rat endothelial cells, a large
increase in XOR enzymic activity (in the human case, 
approximately 8-fold) was not accompanied by an 
equivalent rise in mRNA. mRNA in HB4a cells only 
rose by 2-3 fold (Fig. 3), suggesting the possibility 
of post-translational activation; a suggestion strongly 
supported by ELISA determinations of XOR protein, 
increases in which closely matched those for mRNA 
(Fig. 7).
The XOR activity increases discussed above refer 
to total activity, i.e., dehydrogenase plus oxidase. The 
widespread interest in XOR as a causative agent in 
ischaemia-reperfusion injury [2-5] centres on its abil­
ity to undergo dehydrogenase to oxidase conversion 
in response to proteolysis [40], based on the general 
understanding that only the oxidase form of the en­
zyme is capable of generating reactive oxygen species. 
Dehydrogenase to oxidase conversion has also been 
cited as a trigger for inflammatory signal transduction 
[41], based on the demonstration that TNF-a stimu­
lates conversion in rat pulmonary artery endothelial 
cells [42]. It was, accordingly, of interest to examine 
the effects of IL-1/3, TNF-a and IFN-y on the 
percentage oxidase content of XOR in the HB4a 
human epithelial cells. In fact, no significant change 
from control values was observed in any case (Fig.
6), showing that, at least in these human cells, this 
particular form of post-translational activation is un­
likely to be a factor.
Other forms of post-translational activation of XOR 
might be relevant in the human mammary epithelial 
cell. XOR, from most sources, contains significant 
proportions (up to 50%) of ‘inactive’ enzyme. Such 
‘inactive’ enzyme is commonly made up of two 
forms, demolybdo- and desulpho-enzymes, which 
lack, respectively, molybdenum or an essential Mo = 
S grouping (replaced by Mo = O). Xanthine and 
hypoxanthine, in common with most reducing sub­
strates (including pterin), donate their electrons to the 
Mo site and are, accordingly, not oxidised by these 
enzyme forms. The presence of naturally occurring 
‘inactive’ forms of XOR offers the potential for 
activation of the enzyme in response to specific 
physiological requirements, and the human enzyme 
may be particularly well suited to such activation
[43]. Human milk XOR, which has been purified and 
characterised in some detail [10,11], contains an ex­
ceptionally low content of molybdenum-containing 
enzyme, of which a high proportion is desulpho form
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[44]. The similarly low true specific activity of the 
human mammary cell enzyme may well reflect a 
similar composition. Desulpho-sulpho conversion, 
resulting in enzyme activation, can be effected by 
means of sulphide incorporation in vitro [45]. An 
unspecified enzyme-catalysed conversion of this type 
has been proposed as the basis for diet-induced acti­
vation of XOR in chicken [46] and rat [47] livers, in 
both of which cases, the increase in enzymic activity 
apparently exceeds that in enzyme protein. Indeed, 
such a mechanism has been proposed as a general 
means of regulation of relevant enzymes [48-50], 
and may well be operating in the case of cytokine-in­
duced activation of XOR in our human mammary 
epithelial cells. However, in view of the extremely 
low concentration of molybdenum site activity, direct 
proof of this is far from straightforward. As a conse­
quence of the high content of demolybdo enzyme in 
human milk XOR, and of its apparent similarities 
with the HB4a cell enzyme, it is tempting to consider 
also a form of post-translational activation involving 
enzyme-catalysed incorporation of molybdenum 
and/or its cofactor. There is, however, no precedent 
for such a mechanism that would seem to be an 
unnecessarily cumbersome means of regulation.
In summary, XOR in human mammary epithelial 
cells has low specific activity to ‘conventional’ re­
ducing substrates, similar to that in human milk. 
Activity is strongly upregulated by cytokines, sug­
gesting a role for the enzyme in the inflammatory 
response of these cells. The strongest response, to 
IFN-y, involved a 2-3-fold increase in XOR mRNA 
matched by a corresponding increase in XOR protein, 
but greatly exceeded by a 7-8-fold rise in enzymic 
activity. This apparent post-translational activation, 
which did not involve changes in oxidase-dehydro- 
genase ratios, parallels similar, possibly hormonally 
driven, effects seen in the breast milk enzyme in vivo 
[14] and supports the idea [43] that human XOR of 
low specific activity may be subject to various forms 
of upregulation in fulfilling a physiological role.
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Abstract Subcellular localisation of xanthine oxidoreductase 
(XOR) was determined by indirect immunofluorescence using 
confocal microscopy in human endothelial and epithelial cell lines 
and in primary cultures of human umbilical vein endothelial cells. 
XOR was diffusely distributed throughout the cytoplasm but with 
higher intensity in the perinuclear region. In non-permeabilised 
cells, XOR was clearly seen to be asymmetrically located on the 
outer surfaces, showing, in many cases, a higher intensity on 
those faces apposed by closely neighbouring cells. Such specific 
distribution suggests a functional role for the enzyme in cell-cell 
interactions, possibly involving signalling via reactive oxygen 
species
© 1998 Federation of European Biochemical Societies.
Key words: Xanthine oxidoreductase; Immunolocalization; 
Endothelial; Epithelial; Human
1. Introduction
Xanthine oxidoreductase (XOR) is a molybdenum-contain­
ing flavoenzyme that catalyses the hydroxylation of hypoxan­
thine to xanthine and of xanthine to uric acid in the latter 
stages of purine catabolism [1]. In mammals, it occurs in two 
interconvertible forms, xanthine dehydrogenase (EC 1.1.1.204) 
and xanthine oxidase (EC 1.1.3.22). Both forms of the enzyme 
can reduce molecular oxygen, although only the dehydrogen­
ase form can reduce NAD, which it prefers as an electron 
acceptor. Reduction of oxygen leads to superoxide anion 
and hydrogen peroxide and it is the potential to generate these 
reactive oxygen species that has led to widespread interest in 
the enzyme as a pathogenic agent in many forms of ischae- 
mia-reperfusion injury [2]. More recently, reactive oxygen spe­
cies are being increasingly cited as intermediates in normal 
signal transduction pathways [3,4].
XOR is widely distributed, being particularly rich in mam­
mary epithelial cells and in capillary endothelium in a range of 
tissues [5,6]. While the enzyme is generally understood to be 
cytosolic, there have been very few published investigations of 
its precise subcellular localisation. Jarasch et al. [5] used both 
light and electron microscopic immunohistochemicai proce­
dures to show that XOR is located throughout the cytoplasm 
of bovine capillary endothelial cells. This was also found to be
■"Corresponding author. Fax: (44) (1225) 826779.
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Abbreviations: X O R , xanthine oxidoreductase: FCS, foetal calf 
serum; H U V E C , human umbilical vein endothelial cell; D IC , 
differential interference contrast
the case in rat liver endothelial cells [7,8]. In contrast, using 
immunoelectron microscopy, Ichikawa et al. [9] concluded 
that the enzyme was exclusively cytosolic with no significant 
association with intracellular organelles, including endoplas­
mic reticulum, Golgi apparatus, lysosomes or peroxisomes.
The apparent confusion over the subcellular location of 
XOR prompted us to investigate the situation in human cells. 
The human enzyme is of especial interest, particularly in view 
of questions regarding its anomalous characteristics and phys­
iological role [10]. We have, accordingly, made use of confocal 
microscopy in immunolocalisation of the enzyme in human 
endothelial and epithelial cells in culture. We show here that 
XOR is present not only in the cytoplasm but also on the 
outer surface of all three cell types studied. Moreover, the 
extracellular enzyme shows a strongly polarised distribution, 
being in many cases concentrated on those surfaces closely 
apposed by neighbouring cells.
2. Materials and methods
2.1. M aterials
RPM I 1640 culture medium was obtained from IC N , Costa Mesa, 
CA, USA. Penicillin, streptomycin and foetal calf serum (FCS) were 
from Life Technologies, Paisley, U K . Rabbit anti-TG N 46 antibody  
was a kind gift from Dr. George Banting (Department o f  Biochemis­
try, University o f  Bristol, UK ). Rabbit anti-(bovine milk X O R ) was 
from Chemicon International, Harrow, U K . All other reagents, unless 
otherwise stated, were from Sigma, Poole, U K .
2.2. Cell culture
EA-hy-926, a permanent endothelial cell line [11], was a gift from  
Dr. Andrew George, Imperial College School o f M edicine, Hammer­
smith Hospital, London. The cells were routinely grown in an atmos­
phere o f  5% C 0 2/95% air in 75-cm2 flasks at 37°C, as previously 
described [12]. Growth medium, RPM I 1640, containing 10% (v/v) 
FCS and penicillin/streptomycin [12], was changed every 3 -4  days. 
The cells grew to form a confluent m onolayer after approximately 
7 days, exhibiting typical endothelial cell characteristics and were 
shown, by immunofluorescence (results not shown), to  be positive 
for factor VIII, as reported by Edgell et al. [11].
HB4a is a human mammary epithelial cell line, conditionally im­
mortalised by transfection with SV40 virus [13] and kindly donated to 
us by Dr T. Kamalati and Professor B. Gusterson o f  the Institute for 
Cancer Research, Royal Cancer Hospital, Sutton, U K . HB4a cells 
were routinely grown at 37°C in 75-cm2 culture flasks, in an atmos­
phere o f  5% C 0 2/95% air as previously described [14]. Growth me­
dium, RPM I 1640 containing 10% (v/v) FCS and other supplements
[14], was changed every 3-4  days. Cells grew to confluence, forming a 
strict m onolayer after 9 days, showing a characteristic ‘crazy paving’ 
appearance and stained strongly positive (results not shown) for the 
epithelial cell marker, cytokeratin [14].
Human umbilical vein endothelial cells (H UVECs) were obtained 
from human umbilical veins (kindly donated by the nursing staff o f  
the Princess Anne Wing, Royal United Hospitals, Bath) and cultured 
essentially as described by Jaffe et al. [15].
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( ells were seeded (approx. 2 x  10 eells/ml) in I'our-clnimbered glass 
slides (Nunc Inc.. Naperville. IL. IS A ), incubated lor 24 h al 37°C 
and washed twice with pre-warmed PBS before fixing for 20 min al 
room temperature with 4" . (w/v) formaldehyde in PBS.
( ells were permeabilised by incubation with 0 1 '.. (w/v) saponin in 
PBS for 45 min. then incubated with rabbit polyclonal anti-( human 
XOR) antibodies in PBS (0.02 mg/ml), containing 0.1".. (w/v) saponin. 
5" ■ (v/v) normal goal serum and (w/v) BSA. for 2 h at room 
temperature. The cells were washed three times with 0.1"/.. (w/v) sap­
onin in PBS before incubation, for 2 h al room temperature, with 
secondary antibody [FITC-conjugated goat anti-rabbit IgG (0.025 mg/ 
ml. Jackson Immunoresearch Labs. Inc.. West Grove. PA. USA)], 
diluted 1:100 in the same diluant as for the primary antibodies. The 
cells were then washed three times with PBS containing 0.1% (w/v) 
saponin, before removing the chambers from the slides prior to con­
focal microscopy.
Unpermeabilised cells were obtained and treated as above, except 
that saponin was omitted throughout.
The permeabilised or unpermeabilised nature o f the cells was con- 
lirmed by immunolabelling with rabbit anti-TGN 46 antibody, which 
is specific for the trans-Golgi network (results not shown) [16].
Images were collected on a confocal laser-scanning microscope 
(LSM 510. with either X40 1.30 NA or x 6 3  1.40 NA apochromatic 
objective; Carl Zeiss. Welwyn Garden. UK). The 488 lines o f  an 
argon laser were used for excitation o f FITC.
2.4. Assay fo r  XOR enzymic activity
Cell extracts were prepared and assayed for total (oxidase plus 
dehydrogenase) activity as previously described [14], using a sensitive 
fiuorimetric procedure [17], EA-hy-926 and HB4a cells contained 1-2 
pmol isoxanthopterin/min/mg. Activity o f HUVECs was below the 
lower limit o f sensitivity o f  the assay (0.1 pmol isoxanthopterin/min/ 
mg).
2.5 . Heparin-Sepharose treatment o f  growth medium
A column (3.5 c m X l.5  cm) o f  heparin-Sepharose (Sigma) was 
washed with appropriate growth medium (30 ml) lacking FCS. 
Growth medium (100 ml) containing FCS (10"..) was then passed 
through the column and collected in a sterile container. The column 
was washed with 25 mM sodium phosphate buffer. pH 7.4, until A-jsit 
reached a baseline level, and then with the same buffer containing 1 M 
NaCI. Protein-containing fraction (/UsU) was assayed for XOR enzy­
mic activity as described above.
2.6 . Generation and affinity purification o f  rabbit polyclonal 
unti-(human XOR)  antibodies
Antibodies were generated and affinity-purified as previously de­
scribed [14], Their specificity has been previously established by im- 
munoprecipitation o f XOR from HB4a cell extracts [14], Incubation 
o f HB4a cell extracts with the gel-bound specific antibodies removed 
100 " .. o f  XOR enzymic activity, while SDS-PAGE o f the immunopre- 
cipitate showed only the characteristic band o f XOR. apart from 
bands attributable to the antibodies themselves [14],
3 .  R e s u l t s
T hree hu m an  cell types, includ ing  en d oth elia l (E A -h y -9 2 6 )  
and ep ithelia l (H B 4 a ) cell lines and prim ary en d oth elia l ( H U -  
VEC ) cells in cu lture, w ere stud ied  using affin ity-purified  rab­
bit an ti-(hu m an  X O R )  a n tib od ies (see S ection  2). In all cases, 
im m u n oloca lisa tion  o f  X O R  in perm eabilised cells sh ow ed  the  
enzym e to  be d iffusely d istributed  through ou t the cy top lasm , 
althou gh  fluorescence in the perinuclear region w as m ore in­
tense (F ig . 1). Im m u n oloca lisa tion  o f  X O R  in u n p erm eabi­
lised cells c learly  sh o w ed  the presence o f  the en zym e on the  
outer cell surface, the d istrib u tion  being loca lised  to specific  
areas o f  the cell (Fig.  2). In several cases. X O R  appeared  to  be 
con cen trated  on  those  parts o f  the surface that a p p osed  or  
w ere ex ten d in g  tow ard s n eigh b ouring  cells (F ig . 2C . arrow s).




Fig. 1. Distribution o f  XOR in permeabilised EA-hy-926 cells (A. 
B). HB4a cells (C, D) and HUVECs (E, F). For experimental de­
tails see Section 2. Immunofluorescent (A. C, E) and differential in­
terference contrast (DIC) (B. D. F) images are shown. Magnifica­
tion X630 (A, B). X400 (C -F); bar. 20 pm.
X O R )  an tib od y  gave the sam e results as those  described  
a b o v e  (resu lts n ot show n).
B ecause o f  the possib ility  that X O R  on  the surface o f  our  
cells in cu lture orig inated  in the grow th  m edium  (w h ich  c o n ­
tains FC S) the latter w as assayed  for X O R . E nzym ic activ ity  
cou ld  not be detected  by the sensitive fiuorim etric procedure  
(see Section  2). In view  o f  the high affin ity o f  hum an X O R  for  
heparin  [18.19], w e sou gh t to  co n cen tra te  any sm all am ou n ts  
o f  X O R  in the grow th m ed ium  by p assage d ow n  a co lu m n  o f  
hep arin -S ep h arose (see S ection  2). In n on e  o f  six  batches o f  
serum  w as X O R  activ ity  d etectab le  by fluorescence assay  
w hen the heparin  co lu m n  w as su b seq u en tly  eluted  wi th 1 M 
N aC I. co n d itio n s k now n to e lu te  the hum an en zym e [19], T w o  
further con tro l experim ents addressed  this issue. In the first o f  
these, parallel cu ltures o f  E A -h y -9 2 6  or  H B 4a cells w ere 
grow n in 75-cm 1’ flasks in the co rresp on d in g  grow th  m edium  
that had. or had not been p assed  d o w n  a hep arin -S ep h arose  
co lu m n  (see Section  2). In each  case, cells w ere then seeded  
o n to  d u p lica te  w ells o f  glass slides as usual and subjected  to
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Fig. 2. Distribution o f  XOR in unpermeabilised EA-hy-926 cells (A -C ), HB4a cells (D -F ) and HUVECs (G -I). For experimental details see 
Section 2. Immunofiuorescent (A, D. G) and DIC (B. E, H) images are overlaid (C, F, 1) to emphasise the polarised distribution. Arrows (C) 
show examples where fluorescence is concentrated on surfaces that appose those o f neighbouring cells. Magnification X400; bar, 20 pm.
immunolabelling. No difference was apparent in the distribu­
tion or intensity o f the fluorescence patterns between unper­
meabilised cells grown in heparin-treated and untreated me­
dium, nor was there any significant difference in total XOR 
activity in the cells, as assayed fluorimetrically. Results for 
EA-hy-926 cells are shown in Fig. 3C -F . in which the polar­
ised distribution o f the enzyme is again clearly seen. In the 
second control experiment, heparin-Sepharose beads (300 pi) 
were washed twice with PBS before incubation overnight, with 
continuous gentle agitation, either with growth medium (con­
taining FCS), PBS or with PBS containing bovine X OR (10 
pg/ml). Subsequent labelling with anti-X OR antibody showed 
clear immunofluorescence on the surface o f the beads in the
latter but not the form er case (Fig. 3). Similar incubation of 
heparin beads with norm al goat serum, used as a blocking 
agent in immunolabelling, also failed to lead to im m unofluo­
rescence on the surface o f the beads.
4 . D iscussion
While reactive oxygen species are increasingly being consid­
ered as agents o f signal transduction [3,4], their source is sel­
dom clear, and X OR, with its capacity for generation of 
superoxide anion and hydrogen peroxide, is in many cases 
an attractive candidate [10]. The subcellular localisation of 
the enzyme is clearly relevant to its function and it is with




Fig. 3. Control experiments showing that cell surface XOR is not 
derived from growth medium. Heparin beads were incubated for 24 
h with growth medium (A) or with PBS containing bovine XOR  
(B) (see Section 3). C, D and E, F show EA-hy-926 cells grown in 
medium (containing FCS). that has (E. F) or has not (C. D) been 
preabsorbed on a heparin-Sepharose column (see Section 2). Immu­
nofluorescence (A -C , E) and DIC (D . F) images were obtained as 
described in Section 2. Magnification X 100; bar. 50 pm (A, B); 
X400: bar. 20 pm (C -F).
this in mind that we examined the former in cultured hum an 
cells.
XOR is generally assumed to be a cytoplasmic enzyme, 
although its precise localisation is unclear, having been de­
scribed as being both peroxisomal [7.8] and exclusively cyto­
solic [9], In the permeabilised cells o f the present study. XOR 
was seen to be generally distributed throughout the cytoplasm 
but with more intense staining in the perinuclear region. This 
latter localisation has not. to our knowledge, been suggested 
previously and has interesting implications concerning possi­
ble functions o f the cytoplasmic enzyme. A perinuclear loca­
tion would, for example, accord with a role for XOR as a
source o f reactive oxygen species that activate nuclear tran­
scription factors, such as N F -kB [20],
XOR was clearly detected on the outer surface of unper- 
meabilised cells of all three hum an cell types studied. While 
extracellular localisation o f XOR has previously been pro­
posed in bovine aortic endothelial cells [21,22]. our presently 
reported findings constitute the first detailed evidence o f such 
a localisation in any cell type. In view o f the potential im por­
tance o f these results, it was necessary to eliminate the possi­
bility that surface enzyme is derived from exogenous sources, 
such as, for example FCS in the growth media. G row th media 
did not contain levels o f XOR above the limit o f sensitivity o f 
the fluorimetric assay. This, in itself, does not necessarily pre­
clude the presence o f lower levels o f enzyme. However, XOR 
was not detected in the growth media following attem pted 
concentration o f the enzyme by chrom atography on hepa­
rin-Sepharose. nor were any differences in immunolabelling 
detected when any o f the three cell types was grown in pre­
absorbed medium. M oreover, grow th medium for all three 
cells failed to show fluorescence labelling o f heparin-Sephar­
ose beads when incubated with the latter. Similar results were 
obtained with goat serum, routinely used as a blocking agent 
in immunolabelling. Finally, it is highly unlikely that cell sur­
face X OR originated in lysed neighbouring cells, which are at 
low density early in their grow th cycle and are essentially 
100% viable.
If we accept that the extracellular X OR is indeed an endog­
enous enzyme, then the mechanisms o f its secretion come into 
question. The classical secretory pathw ay o f protein biosyn­
thesis involves transfer from the endoplasm ic reticulum 
through the Golgi apparatus to the plasma m em brane and 
depends upon the presence o f a cleavable signal peptide [23], 
H um an X OR has no signal peptide [24,25] and is not known 
to be glycosylated, a consequence o f the classical secretory 
pathway. However, increasing num bers o f polypeptides with 
these characteristics, that are nevertheless secreted from both 
prokaryotic and eukaryotic cells, are being discovered [26] and 
it may well be that X OR is another such protein using a non- 
classical secretory pathway. In view o f the relatively high af­
finity of XOR for heparin [18,19], it is interesting to note an 
earlier suggestion [27] tha t muscle L-14 lectin, exported by a 
non-classical pathway, would thus be separated from glyco- 
conjugates, with which it interacted, until after its secretion. 
Similar considerations could apply to  X OR. which may be 
expected to bind to cell surface glycosylaminoglycans follow­
ing secretion. It is notew orthy that incubation of EA-hy-926 
cells with heparin, followed by washing, failed to significantly 
diminish the intensity o f staining (results not shown), suggest­
ing that other glycosylaminoglycans may be involved.
O ur results clearly show that XOR is not only present on 
the outer surface of cultured hum an endothelial and epithelial 
cells, but is asymmetrically distributed, in many cases appear­
ing to be localised to surfaces apposed to those o f closely 
neighbouring cells. This extracellular localisation and partic­
ularly its polarised nature strongly suggest a role for XOR in 
cell-cell interactions, possibly involving signalling via reactive 
oxygen species. We believe this to be an entirely novel concept 
worthy o f detailed further investigations. Such investigations 
are, however, beyond the scope o f the present study.
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R e f e r e n c e s
1Potential Inhibition of BXOR by Chinese Herbal Tea 
1 Introduction
Type O XOR has the ability to produce superoxide (0 {) and hydrogen peroxide (H2O2) 
which, via Fenton and iron-mediated Haber-Weiss reactions, can generate the very 
reactive hydroxyl radical (OH). Alternatively XOR can produce ROS via an NADH 
oxidase activity (Sanders et a l , 1997) which occurs both in the D and O form of the 
enzyme.
1.1 Atopic eczema
Atopic eczema is a condition where the patient typically presents with itching and 
lichenified skin and chronic dermatitis that is exacerbated around the joints (Bos et a l, 
1994). These symptoms are caused when an inappropriate immune response to normally 
innocuous antigens occurs, and, in common with hayfever and asthma, corresponds to a 
hypersensitivity type 1 reaction (Kuby, 1991). An antigen cross links IgE sensitised mast 
cells resulting in the degranulation of the mast cell and an acute inflammatory reaction. 
The mast cells are thought to have two types of IgE receptors on their surface, a high 
affinity receptor and a low affinity CD 23 receptor. CD 23 has been implicated in the
2pathogenesis of eczema, in which the number of CD 23 molecules on monocytes and 
other cells is increased, as is the production of superoxide and nitric oxide (Leslie et a l, 
1994; Latchman et a l, 1995).
Two cytokines are predominantly involved in the type 1 hypersensitivity reaction, IL-4 
and IFNy. IL-4 is released by the Th2 subset of T cells and induces the class switch of 
IgM to IgE. It also regulates the clonal expansion of IgE committed B cells. IFNy is 
released by Thl cells, and, because it reduces IgE production, has been used in the 
treatment of eczema. However, IFNy is also reputed to be involved in subsequent tissue 
damage by increasing ICAM production and therefore the attraction to, and 
accumulation of; inflammatory cells at the site. Successful treatment of eczema has been 
shown by Grewe et a l (1994) to reduce IFNy mRNA and ICAM production.
The involvement of IFNy in atopic eczema is particularly interesting in relation to XOR, 
as IFNy has been shown (Page et a l, 1998) to upregulate XOR de novo protein 
synthesis by two fold and activity by 7 fold in human epithelial cells.
1.2 Chinese herbal tea
Chinese herbal tea has been used as a traditional remedy for eczema for many years, and 
clinical trials have shown it to be effective in producing remission of disease activity, 
although the beneficial effect has been claimed to be temporary (Sheenan et a l, 1994). 
The tea consists of 11 plant components, some of which are thought to have anti­
inflammatory or sedative effects (Harper, 1994). However, the active ingredients, the 
method by which the symptoms of eczema are alleviated and the potential toxicological 
effects that may occur are still under investigation to ensure quality assured and safe
3medicine. Chinese herbal tea has been shown to produce immunological changes such as 
a decrease in serum IgE complexes and decreased IL-4 induced expression of CD 23 
(Latchman et a l, 1996).
In the present work a luminometer was used to measure superoxide produced via the 
NADH oxidase activity of XOR, and potential inhibition of such production, by a 
Chinese herbal tea (CHT) produced by Phytopharm. Barley cup (BC) was used as a 
comparitor.
42  M a t e r i a l s
2.1 Instruments
Centrifugation was carried out in a Beckman TL-100 bench top Ultracentrifuge, and a 
MSE Centaur 2 benchtop centrifuge.
Sonication was done using an MSE 150 Watt Ultrasonic Disintigrator Mk2.
Fluorescent enzyme assays were carried out on a Perkin-Elmer LS-5B Luminescence 
Spectrometer. Absorbance spectra were determined using a CE 272 linear readout 
ultraviolet spectrophotometer
Protein assays were read on a Multiskan MCC, Labsystems plate reader. Luminescence 
was measured using an Anthos Lucy 1 microplate luminometer, Anthos labtec 
instruments Ges.m.b.H, Salzburg, Austria.
Chinese herbal tea and its separate components and barley cup were kindly donated by 
Phytopharm. All other chemicals were obtained from Sigma Poole, Dorset.
2.2 Cell culture
Dublecco’s Modified Eagle Medium M l99, penicillin 5000 U/ml, streptomycin 5000 
pg/ml, 200mM glutamine and foetal bovine serum were obtained from Life technologies, 
Paisley, Scotland. RPMI 1640 was obtained from ICN, Costa Mesa, USA. Tumour 
necrosis factor alpha, interleukin-1 beta and interleukin-6 were obtained from Sigma, 
Poole, Dorset. Interferon gamma was obtained from Calbiochem. Interleukin-13 was
5kindly donated by the pharmacy department of the University of Bath. Plasticware was 
obtained from Falcon, Becton Dickinson, or WLS. Lab-Tek 4 well chamber slide system 
was obtained from Lab-Tek, Nalge Nunc International, Naperville, Illinois, USA.
Cell culture was carried out in a class n  microflow culture hood.
2.2.1 Cells
Conditionally immortalised human mammary luminal epithelial cells (HB4a), were the 
kind donation of Dr Kalamati of The Royal Cancer Hospital, Sutton UK. The cells were 
obtained originally from a reduction mammoplastie, and transfected with SV40 (Stamps 
etal., 1994).
Buffalo rat liver epithelial cells (BRLEs) were the kind donation of Dr T. Edwards, 
University of Bath. These cells are considered to be immortalised (Coon, 1968).
3  M e th o d s
3.1 Routine maintenance of cell cultures
HB4a cells were grown as a monolayer in 75 cm2 tissue culture flasks. The cells were 
maintained in RMPI 1640 (w/o glutamine), supplemented with 10% foetal bovine serum 
(FBS) (v/v), 3 mM L-glutamine, penicillin (100 IU/ml), streptomycin (100 pg/ml) 
insulin, (5 jig/ml), hydrocortisone (5 (ig/ml) and cholera toxin (100 ng/ml). The cells 
were incubated at 37°C humidified with 5% CO2 95% air (v/v).
6The BRLE cells grow as a monolayer in 25 cm2 flasks and were maintained in DMEM 
(w/o glutamine), 10% FBS (v/v), 2mM glutamine, penicillin (100 IU/ml) and 
streptomycin (100 pg/ml).
The cells were provided with 0.2ml of media per cm2, this was discarded after 3 to 4 
days, and replaced with fresh prewarmed media.
3.2 Subculturing cells
HB4a and BRLE cells were subcultured at, or shortly after confluence. The monolayers 
were washed twice with sterile phosphate buffered saline (PBS), and detached from the 
flask by trypsinisation, using 0.05% (w/v) trypsin 0.02% (w/v) EDTA solution in PBS. 
The flask was then incubated at 37°C for 5-10 minutes until the cells detached from the 
surface. The reaction was stopped by the addition of an equal volume of medium.
An aliquot of the cell suspension was counted and assessed for viability in a 
haemocytometer using the trypan blue exclusion method. The suspension was diluted 
1:1 with trypan blue [0.04% (w/v)].
New tissue culture flasks were then seeded with 0.3 x 105 cells/ml.
3.3 Cryopreservation of cells
Cell stocks were preserved by freezing in liquid nitrogen. One flask of confluent cells 
was trypsinised as detailed above, and a cell pellet obtained by centrifugation at lOOg for 
5 min in a sterile tube. The supernatant was discarded and the pellet resuspended in 50% 
(v/v) FBS. The cells were then transferred to a sterile cryogenic tube with 40% (v/v)
7medium and 10% (v/v) DMSO. The tube was placed in cold N2 vapour for 24 h, then 
transferred to a liquid N2 container.
Frozen cells were defrosted by immersion in a 37°C water bath. The cell suspension was 
washed by centrifugation (lOOg for 5 min) in fresh medium, and the cell pellet 
resuspended in fresh medium in a new culture flask.
3.4 Cell growth and XOR activity curve
The growth activity curve is routinely used to estimate when the cells should be 
harvested for assay (Fig. 3.4). Cells seeded at 0.3 xl06/ml are assayed or cytokines 
added after 12 days, to standardise basal activity.
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Fig. 3.4 Cell growth and XOR activity curve
83.5 Cell harvesting for pterin assay
Cells were harvested by trypsinisation for the assay, as described in Section 3.2. The 
cells were counted and a cell pellet was obtained by centrifugation (lOOg for 5 min). 
This pellet was resuspended in cell buffer ((1.2 ml) 50 mM potassium phosphate, pH 7.4 
containing O.lmM EDTA, O.lmM PMSF, pepstatin A (1 |ig/ml), leupeptin (lpg/ml), 
antipain (lpg/ml) and aproteinin (lpg/ml)).
The suspension was then transferred to an eppendorf in a cool box to maintain the 
temperature at 4°C whilst sonication took place using a 3mm probe for 20 s on power 
setting 6 microns. The sample was then ultracentrifuged at 500 OOOg for 10 min at 4°C, 
or at 100 OOOg for 25 min, to give a crude cytosolic fraction.
The samples were assayed for XOR activity on the same day as harvesting.
3.6 Pterin assay
The fluorimetric enzyme activity assay was carried out using the method of Beckman et 
a l (1989). The reducing substrate was 10 pM pterin and the oxidising substrate was 
atmospheric oxygen or 10 pM methylene blue. The assay measures the rate of 
production of the fluorescent product isoxanthopterin from the oxidation of pterin, as 
catalysed by XOR at the molybdenum active site. To assess the activity of the oxidase 
form, pterin alone was added to the sample and to measure total activity (dehydrogenase 
and oxidase) both pterin and methylene blue were added.
9The fluorimeter was set with an excitation wave length of 345nm and an emission wave 
length of 390nm, with slit width of 5nm. All reactants were brought to room 
temperature, and a stable base line was obtained using buffer, 480pl, (50 mM potassium 
phosphate pH 7.4 containing O.lmM EDTA) and cell supernatant, 500pl, in a glass 
cuvette. The reaction rate was measured after addition of methylene blue and pterin 
using x5 scale at 0.5 cm/min. The reaction was inhibited by the addition of 50 \xM 
allopurinol.
Sequential additions of 10 pM isoxanthopterin were added to provide calibration and an 
internal standard accounting for variations caused by fluorescence quenching and 
scattering. The reaction rate was then calculated as pmoles isoxanthopterin min'1 mg"1 
total protein.
In order to compare Km and Fmax values to those obtained using the urate assay, (Section 
3.7), the assay was carried out as above, but using lOpl of a 1:100 dilution of purified 
human milk XOR enzyme (2.84 mg/ml), essentially obtained as described by Abadeh et 
al. (1992). The volume was made up to 1 ml using 50 mM potassium phosphate, pH
7.4, containing 0. lmM EDTA. Concentrations of pterin ranging from 0.25pM - lOOpM 
were used to establish the Km and Vmax for pterin.
3.7 Urate assay
A spectrophotometric method was used to measure the activity of the human milk 
enzyme. The assay mixture consisted of concentrations of xanthine ranging from 2- 
lOOpM and 500pM NAD+ in 50mM bicine buffer pH 8.3. Purified human milk enzyme 
(lOpl, 2.24 mg/ml) was added to a 1ml cuvette and the rate of uric acid production
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measured at 295 nm at room temperature. Specific activities were calculated using an 
extinction coefficient of 9600 M 1 cm'1, and Km and Vmax for xanthine were established.
3.8 NADH oxidase activity assay
A spectrophotometric assay was used to determine the NADH oxidase activity of 
BXOR. The depletion of NADH was measured at 340nm at 25 °C. The final 
concentration of enzyme was 40pg/ml and of NADH was 200pM, diluted with PBS, pH
7.4, in a 1 ml acrylic cuvette. Various concentrations of CHT or BC diluted in PBS were 
used to assess their ability to inhibit the activity of BXOR. Specific activities were 
calculated using an extinction coefficient of 6220 M l cm*1.
3.9 Chemiluminescent superoxide assay
An Anthos Lucy 1 Luminometer was used to measure superoxide production by the 
NADH oxidase activity of BXOR at 37°C. The substrates were lucigenin (10,10 
dimethyl 9,9 ‘bisacridinium nitrate) 200 pM and NADH 200 pM, diluted in PBS pH 7.4. 
The assay is based on the reaction of lucigenin with 0 2- . Lucigenin is oxidised by O2-' to 
yield two molecules of methylacridinium, one of which is in the excited state and emits 
light on relaxation, with peak light emission at 500nm.
The substrates were injected into an opaque 96 well plate with wells containing 
concentrations of BXOR ranging from 0.25 mg/ml to 8 pg/ml diluted in PBS and 
concentrations of CHT or BC ranging from 50 mg/ml to 2 mg/ml dissolved in PBS. The 
final volume in each well was 250 pi, with samples in triplicate. The light emitted was
11
measured at approximately 12 sec intervals for 30 readings per well, and the integral 
data reduction method was used.
Xanthine was also used as a substrate at 200 pM diluted in PBS pH 7.4.
3.10 Protein estimations
Total protein content of the crude cytosolic fraction was estimated using the method of 
Bradford (1976). The standard used was lmg/ml bovine serum albumin, with a standard 
curve ranging from 2-10pg of standard protein diluted with assay buffer to give lOOpl 
total volume. 1ml of BIO-RAD solution was then added and left to develop for 15 min. 
The absorbance of each sample was then measured at 595nm.
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4 Results
4.1 Inhibition of NADH oxidase activity by CHT and BC
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Fig. 4.1 Luminescence created by NADH oxidase activity o f BXOR (0.02mg/ml) with 
and without CHT at concentrations o f 50-2.5 mg/ml. The assay was carried out as 
described in Section 3.9. Values are shown as +/- SEM n=3
Fig.4.1 shows that the BXOR produced a peak value of approximately 1.2 units of light 
indicating the maximum production of superoxide by NADH oxidase activity of the 
enzyme. CHT and PBS were used as controls with no enzyme and gave base line values,
13
as expected. The CHT with BXOR also gave base line values for superoxide production, 
indicating a potential inhibitory mechanism.
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Fig. 4.2 Luminescence created by NADH oxidase activity o f BXOR (0.02 mg/ml) with 
and without BC at concentrations o f 50-2.5 mg/ml. The assay was carried out as 
described in Section 3.9. Values are shown as +/- SEM n=3
The graph shows that BC alone gives base line values, as does BC with XOR at a 
concentration of 50 mg/ml. However, lower concentrations of BC give peak values of 
0.1 and 0.3 units of light, still much lower than that of BXOR, but above base line, and 
certainly higher than values in the presence of similar concentrations of CHT.
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Fig. 4.3 Luminescence created by NADH oxidase activity o f BXOR (0.04mg/ml) with 
and without CHT or BC at concentrations o f 0.01 g/ml. The assay was carried out as 
described in Section 3.9. Values are shown as +/- SEM n=3
Fig. 4.3 shows that 0.01 g/ml CHT totally inhibits superoxide production by 0.04mg/ml 
BXOR. In contrast to 0.01 g/ml BC which shows inhibition of only approximately 50%.
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4.2 Inhibition of NADH oxidase activity by CHT components
CHT is composed of a variety of plant ingredients. Eleven of these components were 
supplied by Phytopharm for testing as inhibitors of NADH oxidase activity. The 
components were dissolved in PBS, and the experiment was undertaken as previously 
described in Section 3.9.
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Fig. 4.4 Luminescence created by NADH oxidase activity o f BXOR (0.04mg/ml) with 
and without CHT components at concentrations o f 0.02 g/ml The assay was carried 
out as described in Section 3.9. Values are shown as +/- SEM n=3
Fig 4.4 shows that the components of the CHT have different levels of effects on the 
NADH oxidase activity of BXOR. PAE and LOP are the most effective, bringing the
16
luminescence down to base line levels. DIC and SAP have much less effect. The 
components alone gave base line values (results not shown).
4.3 Inhibition of the xanthine oxidase activity of BXOR by CHT and BC
To establish whether superoxide production by BXOR in the presence of xanthine can 
also be inhibited by the CHT, the effects on type O BXOR derived superoxide were 















Fig. 4.5 Luminescence created by xanthine activity o f BXOR (0.02mg/ml) with and 
without CHT or BC at concentrations o f 0.01 g/ml. The assay was carried out as 
described in Section 3.9. Values are shown as +/- SEM n=3
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The graph presented in Fig. 4.5 illustrates that the superoxide produced by the ‘O’ form 
activity of BXOR peaks at around 2 units which is higher than that seen with NADH 
oxidase. The addition of CHT or BC to the enzyme reduces the value to around base 
line levels, indicating that the inhibitory effect on superoxide production previously 
observed is not specific to the NADH oxidase activity of BXOR.
4.4 Inhibitory effects of CHT or BC on spectrophotometric assays of xanthine or 
NADH oxidation
The effects of CHT or BC on NADH depletion were studied in order to determine 
whether the apparent inhibition of superoxide production measured by the luminometer 







Fig. 4.6 NADH oxidase activity o f BXOR (0. Olmg/ml) with and without CHT or BC 
(0.04g/ml). The assay was carried out as described in Section 3.8. Values are shown as
+/- SEM n=3
The graph shows that CHT or BC have little effect on NADH depletion catalysed by 
BXOR
A similar experiment was carried out using xanthine as the substrate. The results are 





Fig. 4.7 Xanthine oxidase activity o f BXOR (1 mg/ml) with and without CHT or BC 
0.02g/ml. The assay was carried out as described in Section 3.7. Values are shown as +
/- SEM n=3
The graph shows that CHT or BC have little effect on xanthine depletion catalysed by 
BXOR
4.5 The inhibitory effects of CHT and BC on pterin assays
To further investigate the effects of CHT or BC on the activity of BXOR at the Mo 
centre, various concentrations of CHT or BC were dissolved in pterin assay buffer and 
incubated with the enzyme for 10 min prior to addition of the substrates.
Fig. 4.8 shows the percentage XOR activity with the concentration of CHT ranging 
from 1 mg/ml to 100 mg/ml.
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Fig. 4.8 Activities o f BXOR (0.01 mg/ml), measured using the pterin assay (as described 
in Section 3.6) when incubated for 10 min with various concentrations o f CHT or BC.
XOR activity is expressed as a percentage o f control activity (in the absence o f 
inhibitors) normalised to 100%. Values are shown as +/- SEM n=3 for 10 mg/ml and
n=4 for 1 mg/ml.
The CHT or BC at 1 mg/ml or 10 mg/ml seem to have no significant effect on BXOR 
activity as determined by the pterin assay. At a concentration of 4 mg/ml both CHT and 
BC seem to increase activity. However, the results are from one experiment only and are 
probably not significant. At a concentration of 100 mg/ml CHT or BC seem to decrease 
activity, but again these are results from one experiment and require further 
investigation.
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4.6 The effect of CHT and BC on HB4a XOR activity and cell growth
HB4a cells were incubated for 24 h or 48 h with CHT or BC dissolved in growth 
medium, controls were cultures with fresh growth media added. The cytosolic cell 
activity was assessed using the pterin assay, cell number was also determined. Results 
are presented in Figs. 4.9. to 4.11.
120
control CHT BC
Fig. 4.9 HB4a XOR activity after 24 h incubation with 1 mg/ml CHT or BC, added on
day 12. XOR activity was determined as described in Section 3.6 and is expressed as a
percentage of control activity normalised to 100%. Values are shown as +/- SEM n=3.
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Fig. 4.10 HB4a XOR activity after 24 h incubation with 2 mg/ml CHT or BC, added on 
day 12. XOR activity was determined as described in Section 3.6 and is expressed as a 
percentage o f control activity normalised to 100%. Values are shown as +/- SEM n=6.
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Fig. 4.11 HB4a XOR activity and cell number (x JO5 /m)I after 48 h incubation with 
1 mg/ml CHT or BC, added on day 12. Activity determined as described in Section 3.6 
and expressed as a percentage o f control activity normalised to 100%. Values are
shown as +/ - SEM n=3.
Figs.4.9 to 4.11 demonstrate that CHT or BC have little effect on XOR activity in HB4a 
cells or the cell number compared with controls.
4.6.1 The effect of CHT and BC on BRLE XOR activity and cell growth
The effect of CHT and BC on BRLE cells was investigated. The BRLE cultures were 
incubated with CHT or BC 1 mg/ml dissolved in growth medium, XOR activity was 
assessed using the pterin assay, cell number was also determined, as described in 
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Fig. 4.12 BRLE XOR activity and cell number (x 10? /ml) after 24 h incubation with 
1 mg/ml CHT or BC, added on day 11. XOR activity determined using the pterin assay 
as described in Section 3.6 and is expressed as a percentage o f control activity 
normalised to 100%. Values are shown as +/- SEM n=4.
Fig. 4.12 shows that CHT and BC has little effect on the XOR activity of BRLE cells or 
the cell number, compared with controls.
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5  D i s c u s s io n
This chapter describes the investigation of the effects of Chinese herbal tea and barley 
cup on NADH oxidase activity of BXOR. The results presented here suggest that both 
compounds have a negative effect on superoxide production which is more pronounced 
with CHT. The components of CHT were tested individually on the NADH oxidase 
activity, and it was found that the levels of inhibition varied. Two components brought 
the luminescence down to base line, while a number of others had little or no effect. It 
was necessary to establish whether the apparent inhibitory effect resulted from a 
neutralisation of the already formed ROS, or a direct inhibitory effect on their 
production by the enzyme. Luminescence assays showed that CHT inhibited both 
NADH oxidase and xanthine oxidoreductase activities of BXOR, as assessed by ROS 
production. There was, however, little effect on NADH depletion or on urate or 
isoxanthopterin production in the relevant assays, suggesting that the CHT is scavenging 
the ROS produced by XOR, and is not specifically inhibiting the activity of the enzyme. 
BC was used as a comparitor, and was found in general, to behave like CHT but very 
much less effectively, as judged from the higher concentrations required.
The antioxidant effects of CHT may be similar to those seen in green and black tea 
(Camellia Sinesis), where the main antioxidants are thought to be tea polyphenols or 
catechins. These have been demonstrated to specifically inhibit the type O production of 
ROS by XOR (Aucamp et al., 1997). However, more detailed chemical analysis on the 
CHT constituents needs to be carried out. It would also be of use if they could be
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purified to remove the colouration of the CHT and its constituents, which interferes with 
the assays at high concentrations.
The effects of CHT and BC on living cells was also investigated. Neither compound 
appeared to have a significant effect on cell number or XOR activity. In the context of 
medical applications of CHT, this is encouraging as there is no evidence of cytotoxic 
effects in these systems. The efficacy of the CHT in treating eczema has been attributed 
to its direct immunomodulatory effects (Latchman et aL, 1996), however the antioxidant 
properties of CHT demonstrated in my results may well augment its alleviation of the 
symptoms, by reducing the amount of damage to cells by monocytes and macrophages; 
but direct effects on XOR appear to be unlikely.
27
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